https://www.amgen.com/ 2025-08-06 always https://www.amgen.com/fighting-the-worlds-toughest-diseases 2025-03-31 daily 0.5 https://www.amgen.com/india 2025-03-31 daily 0.5 https://www.amgen.com/manufacturing-expansion 2025-05-05 daily 0.5 https://www.amgen.com/stories 2025-09-23 monthly 1.0 https://www.amgen.com/science 2024-12-06 monthly 0.5 https://www.amgen.com/teneobio 2023-04-26 monthly 0.5 https://www.amgen.com/knowkras 2024-02-13 monthly 0.5 https://www.amgen.com/cardiovascular 2024-10-31 monthly 0.5 https://www.amgen.com/annualmeeting 2022-05-20 monthly 0.5 https://www.amgen.com/executivecompensation 2024-04-17 monthly 0.5 https://www.amgen.com/exec-compensation-form 2024-02-06 always https://www.amgen.com/newsroom 2025-08-07 monthly 0.5 https://www.amgen.com/partners 2022-01-05 monthly 0.5 https://www.amgen.com/bcr 2021-07-27 monthly 0.5 https://www.amgen.com/horizon-notification 2024-01-26 monthly 0.5 https://www.amgen.com/ukrainian-refugee-clinical-trial-information 2024-01-26 monthly 0.5 https://www.amgen.com/about 2026-03-06 daily 0.5 https://www.amgen.com/community-guidelines 2022-03-04 daily 0.5 https://www.amgen.com/amgen-worldwide 2022-05-06 daily 0.5 https://www.amgen.com/contact-us 2022-09-13 monthly 0.5 https://www.amgen.com/products 2026-01-08 monthly 0.5 https://www.amgen.com/obesity 2026-01-23 monthly 0.5 https://www.amgen.com/targeting-cd19-autoimmune 2025-10-23 monthly 0.5 https://www.amgen.com/privacy-statement 2022-12-06 monthly 0.5 https://www.amgen.com/responsibility 2025-12-19 monthly 0.5 https://www.amgen.com/sitemap 2021-04-30 monthly 0.5 https://www.amgen.com/chemocentryx-notification 2024-01-26 monthly 0.5 https://www.amgen.com/dp 2021-06-17 monthly 0.5 https://www.amgen.com/healthdataprivacypolicy 2024-02-02 monthly 0.5 https://www.amgen.com/terms-of-use 2024-04-11 monthly 0.5 https://www.amgen.com/tepezza-side-effects-and-safety-information 2025-05-09 monthly 0.5 https://www.amgen.com/error-page 2021-03-15 monthly 0.5 https://www.amgen.com/page-not-found 2021-12-13 monthly 0.5 https://www.amgen.com/search-results 2021-05-20 monthly 0.5 https://www.amgen.com/tavneos-prescribers 2026-02-03 monthly 0.5 https://www.amgen.com/tavneos-update 2026-02-05 daily 1.0 https://www.amgen.com/india/privacy-statement 2024-08-08 monthly 0.5 https://www.amgen.com/india/terms-of-use 2024-08-08 monthly 0.5 https://www.amgen.com/science/biosimilars 2024-06-11 monthly 0.5 https://www.amgen.com/science/clinical-trials 2024-05-29 monthly 0.5 https://www.amgen.com/science/manufacturing 2021-03-18 monthly 0.5 https://www.amgen.com/science/research-and-development-strategy 2025-04-14 monthly 0.5 https://www.amgen.com/science/scientific-advisory-boards 2021-10-21 monthly 0.5 https://www.amgen.com/science/scientific-community-initiatives 2021-10-08 daily 0.5 https://www.amgen.com/science/biosimilars 2025-10-15 monthly 0.5 https://www.amgen.com/cardiovascular/cardiovascular-ambition-stories 2024-10-31 monthly 0.5 https://www.amgen.com/newsroom/press-releases 2026-03-28 monthly 0.5 https://www.amgen.com/newsroom/company-statements 2025-08-07 monthly 0.5 https://www.amgen.com/newsroom/image-library 2025-08-07 daily 0.5 https://www.amgen.com/partners/academic-collaborations 2021-04-26 monthly 0.5 https://www.amgen.com/partners/wholesalers 2022-03-17 monthly 0.5 https://www.amgen.com/partners/suppliers 2025-10-31 monthly 0.5 https://www.amgen.com/horizon-notification/horizon-therapeutics-terms-of-use 2024-01-26 monthly 0.5 https://www.amgen.com/about/amgen-history 2022-05-09 monthly 0.5 https://www.amgen.com/about/awards-and-accolades 2025-03-27 monthly 0.5 https://www.amgen.com/about/how-we-operate 2022-03-18 monthly 0.5 https://www.amgen.com/about/leadership 2021-04-26 monthly 0.5 https://www.amgen.com/about/mission-and-values 2021-04-26 monthly 0.5 https://www.amgen.com/about/therapy-areas 2025-05-07 monthly 0.5 https://www.amgen.com/contact-us/locations 2021-04-30 monthly 0.5 https://www.amgen.com/contact-us/product-inquiries 2022-09-13 monthly 0.5 https://www.amgen.com/contact-us/contact-us-feedback 2021-04-26 monthly 0.5 https://www.amgen.com/products/counterfeit-drug-statement 2021-04-26 monthly 0.5 https://www.amgen.com/products/global-patient-safety 2022-12-06 monthly 0.5 https://www.amgen.com/products/safety-data-sheets 2021-12-17 monthly 0.5 https://www.amgen.com/obesity/voices-from-the-patient-community 2026-03-03 monthly 0.5 https://www.amgen.com/responsibility/2024-sustainability-highlights-report 2025-05-14 monthly 0.5 https://www.amgen.com/responsibility/corporate-sustainability-strategy 2025-05-12 monthly 0.5 https://www.amgen.com/responsibility/healthy-people 2025-12-19 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet 2024-05-14 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen 2025-12-19 monthly 0.5 https://www.amgen.com/responsibility/reporting-and-metrics 2025-05-12 monthly 0.5 https://www.amgen.com/chemocentryx-notification/chemocentryx-privacy 2024-01-26 monthly 0.5 https://www.amgen.com/chemocentryx-notification/chemocentryx-terms-of-use 2024-01-26 monthly 0.5 https://www.amgen.com/dp/schedule 2026-02-17 monthly 0.5 https://www.amgen.com/stories/categories/patients 2022-03-17 monthly 1.0 https://www.amgen.com/stories/categories/responsibility 2021-03-13 monthly 1.0 https://www.amgen.com/stories/categories/leadership 2021-03-13 monthly 1.0 https://www.amgen.com/stories/categories/science-and-innovation 2021-03-13 monthly 1.0 https://www.amgen.com/stories/categories/people-and-culture 2021-03-13 monthly 1.0 https://www.amgen.com/science/clinical-trials/about-clinical-trials 2024-03-06 monthly 0.5 https://www.amgen.com/science/clinical-trials/clinical-data-transparency-practices 2022-04-06 monthly 0.5 https://www.amgen.com/science/clinical-trials/clinical-out-of-hours-support-program 2022-12-20 monthly 0.5 https://www.amgen.com/science/clinical-trials/clinical-trial-representation 2026-03-02 monthly 0.5 https://www.amgen.com/science/clinical-trials/information-for-healthcare-professionals 2021-10-21 monthly 0.5 https://www.amgen.com/science/manufacturing/innovation 2021-03-18 daily 0.5 https://www.amgen.com/science/manufacturing/quality 2021-03-18 daily 0.5 https://www.amgen.com/science/manufacturing/reliability 2021-03-18 daily 0.5 https://www.amgen.com/science/research-and-development-strategy/human-and-disease-biology 2025-04-14 monthly 0.5 https://www.amgen.com/science/research-and-development-strategy/novel-targets-and-modalities 2025-04-14 monthly 0.5 https://www.amgen.com/science/research-and-development-strategy/clinical-trial-optimization 2025-04-14 monthly 0.5 https://www.amgen.com/science/research-and-development-strategy/ai-in-research-and-development 2025-04-14 monthly 0.5 https://www.amgen.com/science/scientific-community-initiatives/educational-outreach-program 2020-12-07 daily 0.5 https://www.amgen.com/science/scientific-community-initiatives/postdoctoral-fellows 2024-04-02 daily 0.5 https://www.amgen.com/science/scientific-community-initiatives/scientific-conferences-program 2020-12-07 daily 0.5 https://www.amgen.com/science/scientific-community-initiatives/start-up-network-program 2020-12-07 daily 0.5 https://www.amgen.com/science/biosimilars/rigorous-development-and-regulatory-pathways 2025-05-27 always https://www.amgen.com/science/biosimilars/biosimilars-for-patients 2025-06-12 monthly 0.5 https://www.amgen.com/science/biosimilars/biosimilars-for-healthcare-providers 2025-06-06 monthly 0.5 https://www.amgen.com/science/biosimilars/value-of-biosimilars-and-amgens-commitment 2025-06-12 monthly 0.5 https://www.amgen.com/science/biosimilars/our-leadership-in-biosimilars 2025-05-27 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-update-on-patent-litigation-related-to-fresenius-denosumab-biosimilar-products 2025-03-10 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-update-on-patent-litigation-related-to-celltrion-denosumab-biosimilar-products 2025-01-24 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-provides-statement-on-maritide-phase-1-data 2024-11-13 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-irs-notice-related-to-horizon-acquisition 2024-07-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-update-on-patent-litigation-related-to-sandoz-denosumab-biosimilar-products 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/update-on-change-healthcare-cyberattack 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/lumakras-dose-comparison-study-results 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-fda-odac-meeting 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/statement-on-fourier-analysis-published-in-bmj-open 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/statement-on-drug-pricing-provisions-included-in-inflation-reduction-act 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-russia-ukraine 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-supports-industry-efforts-to-address-global-access-to-covid-19-vaccines 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/10-25-17-amgen-provides-update-on-status-of-puerto-rico-operations 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-comments-for-icers-2020-value-assessment-framework 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-comments-on-icers-proposed-changes-to-the-2020-value-assessment-framework 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-comments-on-icers-proposed-methods-adaptations-for-assessments-of-potential-cures 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-comments-on-pcsk9-patent-litigation-in-germany 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-comments-on-the-supreme-court-of-japan-ruling-on-pcsk9-patent-infringement-litigation 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-final-summary-comments-re-icer-car-t-assesssment 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-introduces-new-value-based-pharmacy-benefits-insurance-provision-for-u-s--staff-members 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-proudly-supports-phrmas-new-principles-on-clinical-trial-diversity 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-provides-update-on-status-of-puerto-rico-operations 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-reaches-settlement-agreement-to-resolve-allegations-related-to-patient-assistance-programs 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-reaches-settlement-with-coherus-in-trade-secrets-case-regarding-pegfilgrastim 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-reponse-to-hta-program-draft-evidence-report-on-the-treatment-of-chronic-migraines 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-in-support-of-the-2018-aha-acc-cholesterol-clinical-practice-guidelines 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-in-support-of-the-2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icer-plaque-psoriasis-draft-evidence-report 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icer-rheumatoid-arthritis-draft-evidence-report 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icers-call-for-comments-on-its-value-assessment-framework 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icers-draft-evidence-report-and-voting-questions 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icers-draft-scoping-document-on-car-t-therapy-for-b-cell-cancers 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icers-draft-scoping-document-on-cgrp-preventive-therapy-for-migraine 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icers--on-cgrp-inhibitors-as-preventive-treatments 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icers-proposed-adaptation-of-the-icer-value-framework 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icers-updated-value-assessment-framework 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-icer-updated-value-assessment-framework 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-response-to-the-icer-draft-report-on-anabolic-therapies-for-osteoporosis 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgens-comments-on-icers-price-increase-draft-protocol 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgens-comments-on-icer-value-based-price-of-a-cure---methods 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgens-position-on-orphan-drugs-and-icers-orphan-drug-assessment 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgens-response-to-icers-draft-scoping-document-on-targeted-immunomodulators-for-plaque-psoriasis 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgens-statement-on-cost-effectiveness-of-kyprolis-compared-to-velcade 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-and-response-to-icer-revised-value-framework 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-appeals-court-decision-on-pcsk9-antibody-patents 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-complete-response-letter-from-the-us-fda-for-abp-980 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-pricing 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-the-clinical-and-economic-value-of-blincyto 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-statement-on-the-economic-benefit-of-xgeva 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/amgen-update-regarding-covid-19 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/helping-patients-understand-the-price-of-their-medicines 2024-06-12 monthly 0.5 https://www.amgen.com/newsroom/company-statements/oklahoma-health-care-authority-and-amgen-enter-into-value-based-contract-for-enbrel 2024-06-12 monthly 0.5 https://www.amgen.com/partners/academic-collaborations/new-requests 2023-01-18 monthly 0.5 https://www.amgen.com/partners/academic-collaborations/requests-for-refill-or-amendment 2023-01-18 monthly 0.5 https://www.amgen.com/partners/academic-collaborations/scientific-report-or-notice-of-invention 2023-01-18 monthly 0.5 https://www.amgen.com/partners/academic-collaborations/submission-failed 2021-01-28 daily 0.5 https://www.amgen.com/partners/suppliers/supplier-procurement-guidelines 2025-10-31 monthly 0.5 https://www.amgen.com/partners/suppliers/supplier-code-of-conduct 2025-10-31 monthly 0.5 https://www.amgen.com/partners/suppliers/conflict-minerals-policy 2025-10-31 monthly 0.5 https://www.amgen.com/partners/suppliers/supplier-invoice-guidelines 2025-10-31 monthly 0.5 https://www.amgen.com/partners/suppliers/supplier-shipping-and-receiving 2025-10-31 monthly 0.5 https://www.amgen.com/partners/suppliers/supplier-contact-information 2025-10-31 monthly 0.5 https://www.amgen.com/partners/suppliers/existing-supplier-on-boarding 2025-10-31 monthly 0.5 https://www.amgen.com/partners/suppliers/supplier-terms-and-conditions 2025-10-31 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance 2024-01-16 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures 2023-04-27 monthly 0.5 https://www.amgen.com/about/leadership/senior-management 2021-01-21 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards 2022-10-27 daily 0.5 https://www.amgen.com/about/therapy-areas/bone-health 2025-05-07 monthly 0.5 https://www.amgen.com/about/therapy-areas/cardiovascular 2025-05-07 monthly 0.5 https://www.amgen.com/about/therapy-areas/inflammation 2025-05-07 monthly 0.5 https://www.amgen.com/about/therapy-areas/oncology 2025-05-07 monthly 0.5 https://www.amgen.com/about/therapy-areas/rare-disease 2025-05-07 monthly 0.5 https://www.amgen.com/products/global-patient-safety/who-we-are 2020-12-07 monthly 0.5 https://www.amgen.com/products/global-patient-safety/our-commitment 2022-04-27 monthly 0.5 https://www.amgen.com/products/global-patient-safety/what-we-do 2020-12-07 monthly 0.5 https://www.amgen.com/products/global-patient-safety/adverse-event-reporting 2023-09-20 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment 2025-12-15 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines 2025-10-16 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/health-equity 2025-07-26 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/environmental-sustainability 2024-05-14 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/responsible-sourcing 2025-10-31 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/our-workforce 2025-12-19 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/business-ethics-and-compliance 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/ethical-research 2024-05-14 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/cybersecurity-and-data-privacy 2022-04-27 monthly 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/cdp 2022-04-27 monthly 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/patents-for-our-five-top-selling-products 2023-09-21 monthly 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports 2024-05-14 monthly 0.5 https://www.amgen.com/stories/2026/02/highlights-from-amgens-2025-fourth-quarter-and-full-year-earnings-report 2026-02-03 daily 0.5 https://www.amgen.com/stories/2026/02/how-patients-and-supportive-care-partners-work-together-to-turn-their-world-right-side-up-after-a-cancer-diagnosis 2026-02-02 daily 0.5 https://www.amgen.com/stories/2026/02/when-advocacy-meets-science-in-the-care-of-people-living-with-gmg 2026-02-25 daily 0.5 https://www.amgen.com/stories/2026/03/2025-letter-to-shareholders 2026-03-31 daily 0.5 https://www.amgen.com/stories/2026/03/amgen-helps-bring-youth-soccer-clinic-to-greater-los-angeles-with-skills-drills-and-fun-amid-run-up-to-2026-world-cup 2026-03-18 daily 0.5 https://www.amgen.com/stories/2026/03/amgen-named-one-of-the-2026-worlds-most-ethical-companies-by-ethisphere 2026-03-25 daily 0.5 https://www.amgen.com/stories/2026/03/amgen-named-to-forbes-2026-list-of-americas-best-large-employers 2026-03-09 daily 0.5 https://www.amgen.com/stories/2026/03/the-genetic-puzzle-of-heart-disease-inside-amgens-commitment-to-lpa 2026-03-23 daily 0.5 https://www.amgen.com/stories/2026/04/turning-up-the-volume-on-igg4-rd-awareness-and-diagnosis 2026-04-02 daily 0.5 https://www.amgen.com/stories/2025/01/cracking-cholesterol---biology-driven-breakthrough-wins-rathmann-award 2025-01-21 daily 0.5 https://www.amgen.com/stories/2025/01/north-carolina-ribbon-cutting-marks-important-milestone-in-expansion-to-meet-growing-demand-for-amgen-medicines 2025-01-24 daily 0.5 https://www.amgen.com/stories/2025/01/advancement-in-combination-biomarker-driven-therapy-for-adult-patients-with-chemorefractory-kras-g12c-mutated-metastatic-colorectal-cancer 2025-01-17 daily 0.5 https://www.amgen.com/stories/2025/01/amgen-and-the-amgen-foundation-commit-10-million-dollars-to-support-southern-california-communities-impacted-by-wildfires 2025-01-13 daily 0.5 https://www.amgen.com/stories/2025/02/breaking-barriers---from-farm-to-pharma 2025-02-11 daily 0.5 https://www.amgen.com/stories/2025/02/empowering-change---addressing-cardiovascular-risk-in-underserved-communities-through-clinical-research 2025-02-27 daily 0.5 https://www.amgen.com/stories/2025/02/fortune-ranks-amgen-among-top-biotech-firms-on-2025-list-of-worlds-most-admired-companies 2025-02-26 daily 0.5 https://www.amgen.com/stories/2025/02/highlights-from-amgens-2024-fourth-quarter-and-full-year-earnings-report 2025-08-04 daily 0.5 https://www.amgen.com/stories/2025/02/united-by-unique---putting-people-at-the-heart-of-cancer-care 2025-02-04 daily 0.5 https://www.amgen.com/stories/2025/03/amgen-and-amgen-foundation-donation-dollars-on-the-ground-with-direct-relief-in-wake-of-southern-california-fires 2025-03-13 daily 0.5 https://www.amgen.com/stories/2025/03/shining-a-light-on-multiple-myeloma---insights-from-an-expert 2025-03-11 daily 0.5 https://www.amgen.com/stories/2025/04/45-years-of-amgen 2025-04-07 daily 0.5 https://www.amgen.com/stories/2025/04/2024-letter-to-shareholders 2025-03-28 daily 0.5 https://www.amgen.com/stories/2025/04/can-southern-californias-conejo-valley-become-biotech-valley---amgen-convenes-local-life-sciences-community 2025-04-01 daily 0.5 https://www.amgen.com/stories/2025/04/driving-drug-design-using-dna-encoded-libraries 2025-04-24 daily 0.5 https://www.amgen.com/stories/2025/04/first-fda-approval-of-its-kind-for-people-living-with-igg4-related-disease 2025-04-03 daily 0.5 https://www.amgen.com/stories/2025/04/follow-the-data 2025-04-17 daily 0.5 https://www.amgen.com/stories/2025/04/unlocking-disease---amgens-omics-approach-advances-targeted-treatments 2025-08-13 daily 0.5 https://www.amgen.com/stories/2025/05/forbes-names-amgen-one-of-americas-best-large-employers 2025-05-12 daily 0.5 https://www.amgen.com/stories/2025/05/highlights-from-amgens-2025-first-quarter-earnings-report 2025-08-04 daily 0.5 https://www.amgen.com/stories/2025/05/inside-amgens-center-for-observational-research-revolutionizing-drug-development-for-real-world-impact 2025-05-21 daily 0.5 https://www.amgen.com/stories/2025/05/on-the-global-stage-amgens-top-voices-drive-conversations-on-ai-and-innovation 2025-05-22 daily 0.5 https://www.amgen.com/stories/2025/05/im-worth-the-hassle-how-one-woman-with-vasculitis-takes-charge-of-her-care 2025-05-15 daily 0.5 https://www.amgen.com/stories/2025/05/moms--and-kids--thrive-at-amgen 2025-05-08 daily 0.5 https://www.amgen.com/stories/2025/05/one-patients-gout-story-shines-in-striking-new-murals 2025-05-22 daily 0.5 https://www.amgen.com/stories/2025/05/robots-of-amgen 2025-05-15 daily 0.5 https://www.amgen.com/stories/2025/06/amgens-science-first-culture-encourages-award-winning-talent 2025-06-04 daily 0.5 https://www.amgen.com/stories/2025/06/football-legend-barry-sanders-spotlights-ldl-c-and-heart-attack-risk-in-new-film 2025-06-26 daily 0.5 https://www.amgen.com/stories/2025/06/implementation-science---the-missing-link-in-cardiovascular-care 2025-06-02 daily 0.5 https://www.amgen.com/stories/2025/06/inside-amgens-phase-3-maritime-program---advancing-the-future-of-obesity-care 2025-09-03 daily 0.5 https://www.amgen.com/stories/2025/06/a-fathers-strength-amid-disaster 2025-06-12 daily 0.5 https://www.amgen.com/stories/2025/06/amgen-named-among-worlds-greenest-companies-by-newsweek 2025-06-09 daily 0.5 https://www.amgen.com/stories/2025/06/meet-the-woman-leading-the-obesity-and-related-conditions-team-at-amgen 2025-06-05 daily 0.5 https://www.amgen.com/stories/2025/07/inspired-by-nature-how-amgen-designs-the-future-of-medicine 2025-07-16 daily 0.5 https://www.amgen.com/stories/2025/08/meet-one-amgen-scientist-who-helped-crack-the-undruggable-kras-code 2025-08-28 daily 0.5 https://www.amgen.com/stories/2025/08/cracking-kras 2025-08-28 daily 0.5 https://www.amgen.com/stories/2025/08/from-blocking-to-locking---rethinking-how-amgen-intervenes-in-disease 2025-08-21 daily 0.5 https://www.amgen.com/stories/2025/08/generative-ai-tools-support-amgens-mission-to-serve-patients 2025-08-07 daily 0.5 https://www.amgen.com/stories/2025/08/highlights-from-amgens-2025-second-quarter-earnings-report 2025-08-05 daily 0.5 https://www.amgen.com/stories/2025/08/missing-coordinates---americas-cardiology-deserts 2025-08-06 daily 0.5 https://www.amgen.com/stories/2025/09/amgen-employees-making-a-difference-on-land-and-sea---20-years-of-coastal-cleanup 2025-09-29 daily 0.5 https://www.amgen.com/stories/2025/09/amgen-once-again-recognized-as-top-pharma-company-by-us-patients 2025-09-05 daily 0.5 https://www.amgen.com/stories/2025/09/championing-change-amgens-commitment-to-blood-cancer-care-in-hispanic-communities 2025-09-17 daily 0.5 https://www.amgen.com/stories/2025/09/decoding-the-genetics-of-obesity 2025-09-03 daily 0.5 https://www.amgen.com/stories/2025/09/induced-proximity---turning-molecular-matchmakers-into-medicines 2025-09-23 daily 0.5 https://www.amgen.com/stories/2025/09/paying-tribute-to-one-of-amgens-own-on-9-11 2025-09-11 daily 0.5 https://www.amgen.com/stories/2025/09/remembering-dr--david-baltimore---nobel-laureate-and-former-amgen-board-member 2025-09-08 daily 0.5 https://www.amgen.com/stories/2025/10/aanikas-journey---life-after-a-severe-asthma-diagnosis 2025-10-13 daily 0.5 https://www.amgen.com/stories/2025/10/a-bold-goal-for-stronger-bones-preventing-3-million-fractures-by-2033 2025-10-16 daily 0.5 https://www.amgen.com/stories/2025/10/amgen-breaks-ground-on-600-million-dollar-center-for-science-and-innovation-in-thousand-oaks 2025-10-31 daily 0.5 https://www.amgen.com/stories/2025/10/honoring-peggy-emily-razaqi-shares-a-personal-story-for-breast-cancer-awareness-month 2025-10-29 daily 0.5 https://www.amgen.com/stories/2025/10/from-breakthrough-science-to-real-world-impact-amgens-legacy-in-cardiovascular-disease-care 2025-10-01 daily 0.5 https://www.amgen.com/stories/2025/11/amgen-at-the-milken-future-of-health-summit-2025 2025-11-24 daily 0.5 https://www.amgen.com/stories/2025/11/amgen-foundation-doubles-down-on-giving-tuesday 2025-11-11 daily 0.5 https://www.amgen.com/stories/2025/11/delivering-excellence-celebrating-quality-safety-compliance-month-at-amgen 2025-11-12 daily 0.5 https://www.amgen.com/stories/2025/11/highlights-from-amgens-2025-third-quarter-earnings-report 2025-11-04 daily 0.5 https://www.amgen.com/stories/2025/11/how-amgen-uses-ai-to-support-patient-access-and-reimbursement 2025-11-13 daily 0.5 https://www.amgen.com/stories/2025/11/the-role-of-the-airway-epithelium-in-chronic-rhinosinusitis-with-nasal-polyps 2025-11-18 daily 0.5 https://www.amgen.com/stories/2025/11/amgen-foundation-renews-commitment-to-signature-amgen-scholars-program 2025-11-03 daily 0.5 https://www.amgen.com/stories/2025/12/amgen-named-official-biotech-partner-by-los-angeles-sports-and-entertainment-commission-ahead-of-fifa-world-cup-2026 2025-12-04 daily 0.5 https://www.amgen.com/stories/2025/12/2025-at-amgen-investing-expanding-and-serving-more-patients 2026-03-23 daily 0.5 https://www.amgen.com/stories/2025/12/bio-meets-tech-how-amgen-is-designing-the-medicines-of-tomorrow 2025-12-02 daily 0.5 https://www.amgen.com/stories/2024/01/amgen-staff-helping-shatter-scientist-stereotypes 2024-02-21 daily 0.5 https://www.amgen.com/stories/2024/01/amgen-staff-member-works-his-24th-rose-parade-while-amgen-sponsors-its-first-float 2024-02-21 daily 0.5 https://www.amgen.com/stories/2024/01/a-patients-journey-empowering-others---inspired-by-dr-kings-vision-of-service 2024-01-12 daily 0.5 https://www.amgen.com/stories/2024/02/amgen-goes-oh-io-with-opening-of-newest-manufacturing-facility 2024-02-28 daily 0.5 https://www.amgen.com/stories/2024/02/how-amgen-is-working-to-close-the-care-gap-this-world-cancer-day 2024-10-28 daily 0.5 https://www.amgen.com/stories/2024/02/how-gender-impacts-care-four-takeaways-from-the-washington-post-womens-heart-health-event 2025-07-18 daily 0.5 https://www.amgen.com/stories/2024/02/moving-at-the-speed-of-trust 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/02/personal-perspectives-prioritizing-cardiovascular-health-this-american-heart-month 2024-10-28 daily 0.5 https://www.amgen.com/stories/2024/03/at-amgen-inclusion-isnt-a-concept-its-in-our-culture 2024-03-08 daily 0.5 https://www.amgen.com/stories/2024/03/building-trust-with-the-black-community 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/03/jean-charles-soria-elected-to-aacr-board-of-directors 2024-04-16 daily 0.5 https://www.amgen.com/stories/2024/03/mastering-the-art-of-cooking-and-life-without-sight 2024-09-11 daily 0.5 https://www.amgen.com/stories/2024/03/that-ref-on-amgen-court-he-also-refs-college-hoops-and-once-did-a-game-featuring-an-nba-star 2024-03-27 daily 0.5 https://www.amgen.com/stories/2024/03/three-amgen-leaders-honored-for-exceptional-leadership-and-mentorship 2024-03-20 daily 0.5 https://www.amgen.com/stories/2024/03/very-exciting-future-for-cancer-research-bradway-says-at-business-of-biotech-conference 2024-03-11 daily 0.5 https://www.amgen.com/stories/2024/04/2023-letter-to-shareholders 2024-04-10 daily 0.5 https://www.amgen.com/stories/2024/04/first-cancer-diagnosis-led-to-a-dark-place---aiding-another-helped-lift-him-out-of-it 2024-04-16 daily 0.5 https://www.amgen.com/stories/2024/04/getting-older-and-still-standing-tall 2024-09-05 daily 0.5 https://www.amgen.com/stories/2024/04/how-amgens-real-world-evidence-is-changing-the-future-of-patient-care-in-psoriatic-disease 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/04/how-the-lattice-consortium-is-igniting-action-and-innovation-in-cardiovascular-care 2024-10-29 daily 0.5 https://www.amgen.com/stories/2024/04/navigating-the-landscape-of-precision-medicine-in-gastric-cancer 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/05/scientists-of-the-future-with-the-very-viral-alexis-nikole-nelson 2024-05-29 daily 0.5 https://www.amgen.com/stories/2024/05/from-the-office-to-the-lab-amgen-uses-ai-tools-to-unlock-innovation 2025-03-06 daily 0.5 https://www.amgen.com/stories/2024/05/amgens-global-impact---a-commitment-to-bettering-the-world 2024-05-17 daily 0.5 https://www.amgen.com/stories/2024/05/expanding-innovation-in-bite-technology-for-patients-with-extensive-stage-small-cell-lung-cancer 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/05/trusting-your-gut---one-womans-two-decade-long-anca-associated-vasculitis-journey-of-persistence-and-tenacity 2024-05-16 daily 0.5 https://www.amgen.com/stories/2024/05/actress-and-producer-gina-torres-urges-hispanic-americans-to-prioritize-cholesterol-care 2024-10-29 daily 0.5 https://www.amgen.com/stories/2024/05/a-journey-to-inclusion-during-asian-american-pacific-islander-month 2024-05-15 daily 0.5 https://www.amgen.com/stories/2024/05/an-underrecognized-risk-factor-for-heart-disease 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/05/at-milken-global-conference-bradway-calls-for-protecting-u-s--policy-ecosystem-that-fosters-innovation 2024-05-20 daily 0.5 https://www.amgen.com/stories/2024/06/bradways-advice-to-amgens-summer-interns---dont-hold-back 2024-06-27 daily 0.5 https://www.amgen.com/stories/2024/06/amgen-leaders-hail-southern-californias-emergence-as-biotech-innovation-hub 2024-06-11 daily 0.5 https://www.amgen.com/stories/2024/06/celebrating-our-lgbtq-colleagues-this-pride-month-and-beyond 2024-06-03 daily 0.5 https://www.amgen.com/stories/2024/06/amgen-continues-to-propel-bite-technology-innovation 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/06/bringing-cardiovascular-care-to-the-heart-of-communities 2024-09-11 daily 0.5 https://www.amgen.com/stories/2024/06/empowering-women-insights-from-the-womens-health-health-lab-event 2025-01-29 daily 0.5 https://www.amgen.com/stories/2024/07/south-asian-heritage-month-empowering-and-enriching-diversity-and-community 2024-07-17 daily 0.5 https://www.amgen.com/stories/2024/08/working-at-amgen 2024-09-18 daily 0.5 https://www.amgen.com/stories/2024/08/amgen-expands-no-cost-cholesterol-testing-program-to-help-address-leading-public-health-crisis 2024-10-29 daily 0.5 https://www.amgen.com/stories/2024/08/amplifying-indigenous-voices-on-international-day-of-the-worlds-indigenous-peoples 2024-08-07 daily 0.5 https://www.amgen.com/stories/2024/08/customized-initiatives-tackling-cardiovascular-disease-across-four-continents 2024-10-29 daily 0.5 https://www.amgen.com/stories/2024/09/embracing-diversity-in-patient-care-during-hispanic-heritage-month-and-throughout-the-year 2024-09-18 daily 0.5 https://www.amgen.com/stories/2024/09/esmo-2024---targeting-the-root-cause-of-cancers 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/09/amgen-biotech-experience-celebrates-reaching-one-million-students-worldwide 2024-09-13 daily 0.5 https://www.amgen.com/stories/2024/09/amgen-on-the-green-at-the-kpmg-womens-irish-open 2024-09-03 daily 0.5 https://www.amgen.com/stories/2024/09/from-rural-france-to-cutting-edge-science---murielles-journey-to-obesity-research 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/09/rasmus-hoejgaard-wins-2024-amgen-irish-open-as-over-200000-pounds-is-raised-for-make-a-wish-ireland 2024-09-18 daily 0.5 https://www.amgen.com/stories/2024/10/actress-and-producer-la-la-anthony-gets-personal-about-her-plaque-psoriasis-journey 2024-10-24 daily 0.5 https://www.amgen.com/stories/2024/10/collaboration-and-community-engagement---two-powerful-ways-to-improve-health 2024-10-31 daily 0.5 https://www.amgen.com/stories/2024/10/championing-inclusivity-during-national-disability-employment-awareness-month 2024-10-02 daily 0.5 https://www.amgen.com/stories/2024/10/sandra-rodriguez-toledo-vice-president-site-operations-at-amgen-ohio-inducted-into-women-in-manufacturing-hall-of-fame 2024-10-15 daily 0.5 https://www.amgen.com/stories/2024/11/a-journey-of-courage---empowering-others-with-gastric-cancer 2024-11-14 daily 0.5 https://www.amgen.com/stories/2024/11/army-veteran-mike-berke-helping-lead-the-charge-in-research-automation 2024-12-04 daily 0.5 https://www.amgen.com/stories/2024/11/championing-quality-every-day 2024-11-01 daily 0.5 https://www.amgen.com/stories/2024/11/new-apprentice-program-draws-talent-from-unexpected-sources 2024-11-26 daily 0.5 https://www.amgen.com/stories/2024/11/reflecting-on-two-patients-perseverance-and-strength-during-lung-cancer-awareness-month 2024-11-22 daily 0.5 https://www.amgen.com/stories/2024/11/understanding-cardiovascular-risk---the-role-of-ldl-c-comorbidities-and-early-intervention 2024-11-13 daily 0.5 https://www.amgen.com/stories/2024/12/a-fight-for-hope-inspiring-others-through-childhood-b-all 2024-12-06 daily 0.5 https://www.amgen.com/stories/2024/12/amgens-nobel-laureate-network---a-catalyst-for-innovation 2025-01-17 daily 0.5 https://www.amgen.com/stories/2024/12/ten-years-of-blincyto---celebrating-the-history-impact-and-future 2025-03-11 daily 0.5 https://www.amgen.com/stories/2023/01/amgens-highest-honor-awarded-to-peter-kufer-for-bite-technology 2023-01-26 daily 0.5 https://www.amgen.com/stories/2023/01/collaborating-to-address-moderate-to-severe-atopic-dermatitis 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/01/healthier-habits-for-2023 2023-03-17 daily 0.5 https://www.amgen.com/stories/2023/01/innovate-or-die-says-bob-bradway-in-interview-with-morgan-stanley 2023-01-10 daily 0.5 https://www.amgen.com/stories/2023/01/leaders-in-patient-advocacy-share-accomplishments-and-aspirations 2023-01-24 daily 0.5 https://www.amgen.com/stories/2023/01/one-common-mission-to-serve-patients---amgen-operations-shine-with-us-biosimilar-launch 2023-01-31 daily 0.5 https://www.amgen.com/stories/2023/01/what-you-need-to-know-about-biosimilar-medicines 2023-01-11 daily 0.5 https://www.amgen.com/stories/2023/02/heart-studys-goal-better-understand-and-serve-the-underrepresented 2024-09-12 daily 0.5 https://www.amgen.com/stories/2023/02/3d-tissue-models-mimic-the-human-immune-system-to-inform-drug-development 2023-03-17 daily 0.5 https://www.amgen.com/stories/2023/02/5-things-you-need-to-know-about-heart-attacks 2023-02-24 daily 0.5 https://www.amgen.com/stories/2023/02/amgen-foundation-donates-to-relief-efforts-in-turkiye-and-syria-following-earthquake 2023-02-09 daily 0.5 https://www.amgen.com/stories/2023/02/amgen-invests-$150-million-in-new-fund-to-scale-minority-owned-businesses 2023-02-02 daily 0.5 https://www.amgen.com/stories/2023/02/amgen-origins---the-single-arm-that-relieved-many-backs 2023-03-17 daily 0.5 https://www.amgen.com/stories/2023/02/howard-university-students-finish-amgen-fellows-program-with-new-skills-and-new-outlook-on-career-paths 2023-02-17 daily 0.5 https://www.amgen.com/stories/2023/02/world-cancer-day-2023-amgen-stories-from-around-the-world 2023-03-02 daily 0.5 https://www.amgen.com/stories/2023/02/8-things-to-know-about-lipoproteina 2024-10-28 daily 0.5 https://www.amgen.com/stories/2023/03/2022-letter-to-shareholders 2023-04-14 daily 0.5 https://www.amgen.com/stories/2023/03/amgen-at-acc-a-bold-mission-to-cut-heart-attacks-and-strokes-in-half-by-2030 2024-10-28 daily 0.5 https://www.amgen.com/stories/2023/03/cardiovascular-disease---a-public-health-crisis-with-underutilized-solutions 2024-10-28 always https://www.amgen.com/stories/2023/03/how-genetic-validation-helped-innovate-medicine-for-patients-with-high-cholesterol 2023-03-02 daily 0.5 https://www.amgen.com/stories/2023/03/impact2---conversations-on-the-power-of-shared-purpose-in-public-health 2023-03-20 always https://www.amgen.com/stories/2023/03/the-air-between-us-all-sparks-transparent-conversations-about-asthma 2023-03-02 always https://www.amgen.com/stories/2023/03/three-amgen-leaders-honored-for-furthering-the-advancement-of-women 2023-04-14 always https://www.amgen.com/stories/2023/03/women-find-purpose-and-support-at-amgen 2023-04-14 daily 0.5 https://www.amgen.com/stories/2023/04/addressing-toughest-challenges-in-lung-cancer 2023-04-18 daily 0.5 https://www.amgen.com/stories/2023/04/he-used-to-work-crime-scenes--now-he-works-to-keep-amgen-products-safe 2023-05-11 daily 0.5 https://www.amgen.com/stories/2023/04/the-power-of-patient-stories-and-advocacy-in-addressing-health-equity-challenges 2024-09-11 daily 0.5 https://www.amgen.com/stories/2023/05/advancing-carbon-reduction-health-equity-and-workplace-diversity 2023-05-11 daily 0.5 https://www.amgen.com/stories/2023/05/amgen-in-boston-for-bio2023 2023-06-01 daily 0.5 https://www.amgen.com/stories/2023/05/a-mother-shares-her-severe-asthma-story 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/05/community-based-approach-reduces-barriers-to-asthma-care 2024-09-11 daily 0.5 https://www.amgen.com/stories/2023/05/defying-assumptions 2023-05-18 daily 0.5 https://www.amgen.com/stories/2023/05/donations-to-non-profit-following-murder-of-george-floyd-help-hundreds-of-black-students 2023-05-31 daily 0.5 https://www.amgen.com/stories/2023/05/mothers-day 2023-05-11 daily 0.5 https://www.amgen.com/stories/2023/05/taking-on-vasculitis-together 2023-05-15 daily 0.5 https://www.amgen.com/stories/2023/05/us-national-osteoporosis-awareness-month-and-esceo-2023-congress 2023-05-31 daily 0.5 https://www.amgen.com/stories/2023/06/2023-pride-month---amgen-supports-pride-month 2023-06-01 daily 0.5 https://www.amgen.com/stories/2023/06/a-fathers-journey-of-parenting-and-loss 2023-06-27 daily 0.5 https://www.amgen.com/stories/2023/06/amgen-announces-finalists-in-health-equity-challenge 2023-06-27 daily 0.5 https://www.amgen.com/stories/2023/06/amgen-welcomes-apprenticeship-participants 2023-06-13 daily 0.5 https://www.amgen.com/stories/2023/06/bob-bradway-talks-biotech-on-leading-financial-podcast-money-maze 2023-06-29 daily 0.5 https://www.amgen.com/stories/2023/06/bradway-at-financial-times-summit---investing-in-innovation-is-smart-choice-for-aging-societies 2023-06-05 daily 0.5 https://www.amgen.com/stories/2023/06/harnessing-real-world-evidence-to-drive-meaningful-change-in-patient-care 2023-06-07 daily 0.5 https://www.amgen.com/stories/2023/06/scientist-mural-unveiled-at-amgen-headquarters 2023-06-28 daily 0.5 https://www.amgen.com/stories/2023/06/see-what-amgen-is-sharing-at-asco-2023 2023-06-02 daily 0.5 https://www.amgen.com/stories/2023/06/tackling-health-equity-requires-sustained-comprehensive-and-collaborative-interventions 2024-09-11 daily 0.5 https://www.amgen.com/stories/2023/07/battling-vasculitis-with-strength-and-optimism 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/07/impact2---conversation-on-the-power-of-collaboration-to-help-improve-the-lives-of-people-living-with-psoriatic-disease 2024-09-11 daily 0.5 https://www.amgen.com/stories/2023/07/no-better-time-than-now-to-work-in-biotech-amgen-ceo-tells-summer-interns 2023-07-28 daily 0.5 https://www.amgen.com/stories/2023/07/ray-deshaies-and-yale-universitys-craig-crews-win-25th-gabbay-award-for-protac-work 2023-07-13 daily 0.5 https://www.amgen.com/stories/2023/08/4-ways-amgen-works-to-cut-heart-attacks-and-strokes-through-ldl-c-testing 2024-10-28 daily 0.5 https://www.amgen.com/stories/2023/08/amgen-joins-forces-with-american-heart-association-on-lower-your-ldl-cholesterol-now 2024-09-11 daily 0.5 https://www.amgen.com/stories/2023/08/a-passion-for-science---a-love-of-culture 2023-08-09 daily 0.5 https://www.amgen.com/stories/2023/08/a-womans-struggle-with-moderate-to-severe-genital-psoriasis 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/08/traveling-with-severe-asthma 2023-08-30 daily 0.5 https://www.amgen.com/stories/2023/09/bond-between-amgen-foundation-and-nurses-goes-back-decades 2023-09-29 daily 0.5 https://www.amgen.com/stories/2023/09/post-9-11-doras-legacy-endures-through-cancer-care 2023-09-11 daily 0.5 https://www.amgen.com/stories/2023/09/amgen-partners-of-choice-inaugural-summit-convenes-clinical-leaders-to-improve-patient-care 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/09/arleen-paulino-svp-of-manufacturing-inducted-into-women-in-manufacturing-hall-of-fame 2024-02-21 daily 0.5 https://www.amgen.com/stories/2023/09/big-data-and-ai-give-patients-with-genetic-cholesterol-disorder-a-head-start-on-better-health 2024-10-28 daily 0.5 https://www.amgen.com/stories/2023/09/one-simple-way-people-whove-had-a-heart-attack-or-stroke-can-reduce-cardiovascular-risk 2024-10-28 daily 0.5 https://www.amgen.com/stories/2023/09/paving-her-own-path 2023-09-29 daily 0.5 https://www.amgen.com/stories/2023/10/bringing-cutting-edge-science-to-classrooms-across-the-world 2023-11-08 daily 0.5 https://www.amgen.com/stories/2023/10/celebrating-national-disability-employment-awareness-month 2023-10-20 daily 0.5 https://www.amgen.com/stories/2023/10/how-ai-and-life-sciences-research-are-revolutionizing-protein-drug-development 2024-02-21 daily 0.5 https://www.amgen.com/stories/2023/10/know-your-lungs---two-people-share-their-treatment-journey-following-a-lung-cancer-diagnosis 2023-11-13 daily 0.5 https://www.amgen.com/stories/2023/10/navigating-middle-school-with-severe-eczema 2023-10-18 daily 0.5 https://www.amgen.com/stories/2023/10/recognizing-the-current-state-of-osteoporosis-globally 2024-09-05 daily 0.5 https://www.amgen.com/stories/2023/10/three-things-to-look-forward-to-at-esmo23 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/10/uplift-funds-creative-solutions-to-global-psoriasis-gaps 2023-10-26 daily 0.5 https://www.amgen.com/stories/2023/11/a-conversation-at-aha-2023---prioritizing-lipid-management-for-cardiovascular-disease-prevention 2024-10-28 daily 0.5 https://www.amgen.com/stories/2023/11/any-target-every-time 2023-11-27 daily 0.5 https://www.amgen.com/stories/2023/11/at-amgen-quality-is-everyones-responsibility 2023-11-04 daily 0.5 https://www.amgen.com/stories/2023/11/being-choctaw-proud 2023-11-27 daily 0.5 https://www.amgen.com/stories/2023/11/finding-strength-in-community---how-living-with-a-rare-disease-changes-your-outlook-on-life 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/11/he-died-of-cancer-but-fought-until-the-end 2023-11-08 daily 0.5 https://www.amgen.com/stories/2023/11/meet-nifemi-adeoye 2023-11-27 daily 0.5 https://www.amgen.com/stories/2023/11/serving-our-country-and-our-patients 2023-11-10 daily 0.5 https://www.amgen.com/stories/2023/11/she-had-not-flown-in-25-years---that-all-changed-in-october 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/12/ash23-advancements-for-tough-to-treat-blood-cancers 2024-08-29 daily 0.5 https://www.amgen.com/stories/2023/12/prioritizing-health-for-the-holidays---how-to-communicate-around-severe-asthma-with-loved-ones 2023-12-08 daily 0.5 https://www.amgen.com/stories/2023/12/reflection-progress-and-partnership-to-advance-health-equity 2023-12-05 daily 0.5 https://www.amgen.com/stories/2023/12/understanding-patient-communities-is-vital-for-clinical-trial-education 2023-12-11 daily 0.5 https://www.amgen.com/stories/2022/01/going-beyond-skin-deep-when-managing-plaque-psoriasis 2022-07-25 daily 0.5 https://www.amgen.com/stories/2022/01/teneobio-acquisition-adds-talent-and-new-types-of-antibodies-to-amgen 2022-09-16 daily 0.5 https://www.amgen.com/stories/2022/01/amgen-plugs-in---electric-vehicle-pilot-program-advances-carbon-neutrality-goal 2022-02-25 daily 0.5 https://www.amgen.com/stories/2022/02/american-heart-month-harnessing-the-power-of-collaborations-to-improve-cardiovascular-health 2022-03-16 daily 0.5 https://www.amgen.com/stories/2022/02/amgen-oncology-supports-closing-the-cancer-care-gap-this-world-cancer-day 2022-02-04 daily 0.5 https://www.amgen.com/stories/2022/02/recognizing-black-history-months-focus-on-health-and-wellness 2022-02-25 daily 0.5 https://www.amgen.com/stories/2022/02/the-journey-from-patient-to-scientist---q-and-a-with-dr-primal-kaur 2022-02-25 daily 0.5 https://www.amgen.com/stories/2022/02/how-the-different-seasons-can-affect-your-asthma 2022-02-25 monthly 1.0 https://www.amgen.com/stories/2022/03/amgen-ceo-bob-bradways-2021-letter-to-shareholders 2023-03-20 daily 0.5 https://www.amgen.com/stories/2022/03/message-from-amgen-ceo-bob-bradway-on-ukraine-and-amgen-foundation-grant 2022-03-21 daily 0.5 https://www.amgen.com/stories/2022/03/providing-healing-promoting-hope---womens-history-month-2022 2022-05-03 daily 0.5 https://www.amgen.com/stories/2022/03/three-amgen-leaders-recognized-for-advancing-gender-equity 2022-03-24 daily 0.5 https://www.amgen.com/stories/2022/03/amgen-breaks-ground-on-new-drug-substance-manufacturing-facility-in-north-carolina 2022-03-24 daily 0.5 https://www.amgen.com/stories/2022/03/increasing-communication-and-collaboration-among-cancer-care-teams-to-improve-biomarker-testing-in-nsclc 2022-03-16 daily 0.5 https://www.amgen.com/stories/2022/04/5-things-amgen-is-doing-to-help-bend-the-curve-in-cardiovascular-disease 2025-06-06 daily 0.5 https://www.amgen.com/stories/2022/04/amgens-manufacturing-site-in-puerto-rico-celebrates-30-years-of-producing-medicines-reaching-patients-around-the-world 2022-05-02 daily 0.5 https://www.amgen.com/stories/2022/04/every-patient-counts-every-story-matters---the-power-of-storytelling-to-chronicle-a-diverse-range-of-health-experiences 2022-11-10 daily 0.5 https://www.amgen.com/stories/2022/04/fighting-the-fight---breaking-down-barriers-to-equal-cancer-care 2022-04-11 daily 0.5 https://www.amgen.com/stories/2022/04/improving-diversity-in-our-clinical-trials-for-long-term-health-equity 2022-08-03 daily 0.5 https://www.amgen.com/stories/2022/04/one-womans-inspiring-journey-from-cleaning-labs-to-cleaning-the-planet 2022-04-25 daily 0.5 https://www.amgen.com/stories/2022/05/5-takeaways-from-amgens-annual-health-equity-summit 2022-05-05 daily 0.5 https://www.amgen.com/stories/2022/05/amgen-chronicles---supporting-working-moms 2022-05-17 daily 0.5 https://www.amgen.com/stories/2022/05/cross-sector-alliances-show-success-in-empowering-both-healthcare-professionals-and-patients-to-improve-bone-health 2022-08-09 daily 0.5 https://www.amgen.com/stories/2022/05/do-a-double-take-to-learn-the-signs-of-psoriatic-arthritis 2022-05-11 daily 0.5 https://www.amgen.com/stories/2022/05/helping-to-reduce-the-burden-of-asthma-in-communities-most-at-risk 2022-05-03 daily 0.5 https://www.amgen.com/stories/2022/05/japanese-american-staff-member-overcomes-racial-stereotyping 2022-05-25 daily 0.5 https://www.amgen.com/stories/2022/05/lets-talk-asthma---conversation-tips 2022-05-26 daily 0.5 https://www.amgen.com/stories/2022/05/osteoporosis-by-the-numbers 2024-09-05 daily 0.5 https://www.amgen.com/stories/2022/05/recognizing-asian-american-and-pacific-islander-heritage-month 2022-05-25 daily 0.5 https://www.amgen.com/stories/2022/05/reflecting-on-the-power-of-early-research-during-national-cancer-research-month 2024-08-29 daily 0.5 https://www.amgen.com/stories/2022/05/searching-for-solutions-for-cardiovascular-disease 2022-06-22 daily 0.5 https://www.amgen.com/stories/2022/06/8-ways-$30-million-from-amgen-foundation-commitment-will-improve-stem-education-globally 2023-03-17 daily 0.5 https://www.amgen.com/stories/2022/06/amgen-chronicles---why-fathers-day-has-new-meaning-for-one-dad-at-amgen 2022-07-13 daily 0.5 https://www.amgen.com/stories/2022/06/at-home-in-california-at-bio2022 2022-06-14 daily 0.5 https://www.amgen.com/stories/2022/06/at-medical-innovation-forum-bob-bradway-hails-progress-against-cancer-and-heart-disease 2022-06-14 daily 0.5 https://www.amgen.com/stories/2022/06/behind-one-biotechs-water-conservation-efforts-saving-every-drop 2022-06-09 daily 0.5 https://www.amgen.com/stories/2022/06/decoding-disease 2022-08-03 daily 0.5 https://www.amgen.com/stories/2022/06/generative-biology--designing-biologics-with-greater-speed-and-success 2023-01-23 daily 0.5 https://www.amgen.com/stories/2022/06/introducing-generative-biology-revolution---a-new-serial-podcast-from-amgen-research-and-development 2022-06-22 daily 0.5 https://www.amgen.com/stories/2022/06/our-differences-lead-to-better-science 2022-06-22 daily 0.5 https://www.amgen.com/stories/2022/06/smarter-stronger-healthier-together---empowerment-in-cancer-care 2022-06-22 daily 0.5 https://www.amgen.com/stories/2022/06/taking-pride---amgen-celebrates-the-contributions-of-our-lgbtqplus-colleagues 2022-07-18 daily 0.5 https://www.amgen.com/stories/2022/07/amgen-origins---how-a-concert-wristband-led-to-an-easy-to-open-drug-box-for-those-with-arthritis 2022-09-07 daily 0.5 https://www.amgen.com/stories/2022/07/amid-the-great-resignation-why-some-amgen-employees-stayed 2022-08-03 daily 0.5 https://www.amgen.com/stories/2022/07/ceos-advice-to-amgens-summer-interns---get-fired-up-about-biotech 2023-01-05 daily 0.5 https://www.amgen.com/stories/2022/07/patrick-dempsey-reflects-on-the-power-of-support-for-people-with-cancer 2022-07-18 daily 0.5 https://www.amgen.com/stories/2022/07/the-house-she-grew-up-in-became-a-home-for-ukrainian-refugees 2022-07-18 daily 0.5 https://www.amgen.com/stories/2022/07/three-things-to-know-about-the-u-s--marketplace-with-biosimilars 2022-07-19 daily 0.5 https://www.amgen.com/stories/2022/08/amgen-named-a-best-employer-for-women 2023-03-02 daily 0.5 https://www.amgen.com/stories/2022/08/biotech-takes-center-stage-at-deutsches-museum 2022-08-10 daily 0.5 https://www.amgen.com/stories/2022/08/fresh-water-and-fresher-ideas-about-sustainability-in-puerto-rico 2022-09-21 daily 0.5 https://www.amgen.com/stories/2022/08/how-amgen-is-propelling-precision-medicine-forward 2022-08-24 daily 0.5 https://www.amgen.com/stories/2022/08/wrapping-up-amgens-summer-of-science-instagram-series 2022-08-29 daily 0.5 https://www.amgen.com/stories/2022/09/asthma-peak-week---what-you-need-to-know-about-indoor-air-pollution 2022-09-13 daily 0.5 https://www.amgen.com/stories/2022/09/celebrating-hispanic-heritage-month 2022-10-07 daily 0.5 https://www.amgen.com/stories/2022/09/whats-next-at-esmo22 2022-09-09 daily 0.5 https://www.amgen.com/stories/2022/09/listen-in-to-innovating-clinical-trials-the-next-amgen-r-and-d-serial-podcast 2022-09-01 daily 0.5 https://www.amgen.com/stories/2022/09/amgen-is-ready-to-meet-growing-demand-for-innovative-medicines-says-bradway-in-bloomberg-tv-interview 2022-09-21 daily 0.5 https://www.amgen.com/stories/2022/09/09-20-amgen-china-marks-ten-years-of-serving-patients 2022-09-26 daily 0.5 https://www.amgen.com/stories/2022/10/amgen-officially-opens-new-state-of-the-art-research-and-development-site-in-san-francisco 2022-10-06 daily 0.5 https://www.amgen.com/stories/2022/10/amgen-staff-around-the-world-volunteer-for-international-coastal-cleanup 2022-10-26 daily 0.5 https://www.amgen.com/stories/2022/10/chores-are-a-pain---but-for-susan-fractures-due-to-osteoporosis-make-them-excruciating 2024-09-05 daily 0.5 https://www.amgen.com/stories/2022/10/climate-change-and-human-health 2022-10-26 daily 0.5 https://www.amgen.com/stories/2022/10/creating-impact-through-supplier-diversity 2022-10-25 daily 0.5 https://www.amgen.com/stories/2022/10/leslie-camacho-shares-her-successful-journey-in-a-male-dominated-industry 2022-10-14 daily 0.5 https://www.amgen.com/stories/2022/10/parkinsons-disease-changed-his-life-but-not-his-competitive-spirit 2022-10-24 daily 0.5 https://www.amgen.com/stories/2022/10/patient-stories-inspire-staff-around-the-world-at-amgens-mission-week 2022-10-17 daily 0.5 https://www.amgen.com/stories/2022/10/recognizing-global-diversity-awareness-month 2022-10-25 daily 0.5 https://www.amgen.com/stories/2022/10/recognizing-national-disability-employment-awareness-month 2022-10-25 daily 0.5 https://www.amgen.com/stories/2022/10/introducing-human-data-era-a-new-serial-podcast-from-amgen-r-and-d 2022-10-25 daily 0.5 https://www.amgen.com/stories/2022/10/amgen-honored-by-foundation-of-national-institutes-of-health 2022-10-28 daily 0.5 https://www.amgen.com/stories/2022/11/amgens-latest-acquisition-puts-a-spotlight-on-rare-autoimmune-disease 2022-11-30 daily 0.5 https://www.amgen.com/stories/2022/11/biomarker-testing-informs-lung-cancer-treatment---one-patient-tells-her-story 2023-06-08 daily 0.5 https://www.amgen.com/stories/2022/11/building-a-path-to-greater-health-equity-through-storytelling 2022-12-12 daily 0.5 https://www.amgen.com/stories/2022/11/janet-franklin-one-of-the-fiercest-women-in-life-sciences 2022-12-12 daily 0.5 https://www.amgen.com/stories/2022/11/recognizing-veterans-day 2022-11-11 daily 0.5 https://www.amgen.com/stories/2022/11/thanksgiving-in-kentucky-brings-gratitude-for-psoriasis-patient 2022-12-12 daily 0.5 https://www.amgen.com/stories/2022/12/10-ways-amgen-supported-patients-and-communities-in-2022 2023-01-05 daily 0.5 https://www.amgen.com/stories/2022/12/alliances-help-connect-patients-with-lung-cancer-to-precision-medicine-treatments 2023-03-20 daily 0.5 https://www.amgen.com/stories/2022/12/a-need-for-progress-for-adult-patients-with-all 2023-01-05 daily 0.5 https://www.amgen.com/stories/2022/12/pioneering-epidemiologist-to-retire-and-data-reveals-hers-was-a-great-career-at-amgen 2022-12-21 daily 0.5 https://www.amgen.com/stories/2022/12/targeting-obesity-using-biology-not-behavior 2025-09-02 daily 0.5 https://www.amgen.com/stories/2022/12/unwrap-the-gift-of-science-with-amgen-leaders 2023-01-05 daily 0.5 https://www.amgen.com/stories/2022/12/when-it-comes-to-biosimilar-manufacturing-heritage-and-expertise-matter 2022-12-12 daily 0.5 https://www.amgen.com/science/clinical-trials/clinical-data-transparency-practices/clinical-trial-data-sharing-request 2020-12-07 monthly 0.5 https://www.amgen.com/science/clinical-trials/clinical-trial-representation/clinical-trials-representation---phrma 2026-03-02 monthly 0.5 https://www.amgen.com/science/clinical-trials/information-for-healthcare-professionals/research-philosophy 2020-12-07 monthly 0.5 https://www.amgen.com/science/clinical-trials/information-for-healthcare-professionals/investigator-resources 2020-12-07 monthly 0.5 https://www.amgen.com/science/clinical-trials/information-for-healthcare-professionals/investigator-survey 2020-12-07 monthly 0.5 https://www.amgen.com/science/manufacturing/Stories/biotech-manufacturing-environment-facts 2021-05-03 daily 0.5 https://www.amgen.com/science/manufacturing/Stories/six-things-about-biotech-medicines 2021-05-03 daily 0.5 https://www.amgen.com/science/manufacturing/Stories/biotechnology-big-picture 2021-05-03 daily 0.5 https://www.amgen.com/science/manufacturing/Stories/biotechnology-manufacturing-excellence 2021-05-03 daily 0.5 https://www.amgen.com/science/manufacturing/Stories/biotech-manufacturing-advance 2021-05-03 daily 0.5 https://www.amgen.com/science/manufacturing/Stories/biologic-therapy-supply-elements 2021-05-03 daily 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses 2020-12-07 monthly 0.5 https://www.amgen.com/partners/academic-collaborations/new-requests/australia 2020-12-07 monthly 0.5 https://www.amgen.com/partners/academic-collaborations/requests-for-refill-or-amendment/australia 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/board-of-directors-guidelines-for-director-qualifications-and-evaluations 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/duties-and-responsibilities-of-the-lead-independent-director 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/board-of-directors-corporate-governance-principles 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/audit-committee 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/compensation-and-management-development-committee 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/corporate-responsibility-and-compliance-committee 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/equity-award-committee 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/executive-committee-charter 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/governance-and-nominating-committee 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/board-of-directors-code-of-conduct 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/staff-code-of-conduct 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/supplier-code-of-conduct 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/code-of-ethics-for-ceo-and-senior-financial-officers 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/amgen-policy-on-recovery-of-erroneously-awarded-compensation 2024-01-16 monthly 0.5 https://www.amgen.com/about/how-we-operate/corporate-governance/rights-plan-policy 2024-01-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/artificial-intelligence-vision 2024-04-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/biodiversity-position-statement 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/climate-change-position-statement 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/corporate-giving 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research 2024-12-06 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ftc-consent-order-in-horizon-therapeutics-acquisition 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/global-tax-strategy 2024-12-06 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/human-rights-commitment 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/human-rights-position-statement 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/international-trade 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/privacy-pledge-to-patients 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information 2023-07-28 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures 2024-10-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/work-environment 2020-12-07 monthly 0.5 https://www.amgen.com/about/leadership/senior-management/alper-ureten 2024-06-03 daily 0.5 https://www.amgen.com/about/leadership/senior-management/andrew-h-martin 2025-06-27 daily 0.5 https://www.amgen.com/about/leadership/senior-management/annalisa-pizzarello 2022-10-26 daily 0.5 https://www.amgen.com/about/leadership/senior-management/arleen-paulino 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/senior-management/brenda-torres 2024-03-01 daily 0.5 https://www.amgen.com/about/leadership/senior-management/david-m-reese 2024-01-02 daily 0.5 https://www.amgen.com/about/leadership/senior-management/derek-miller 2022-03-14 daily 0.5 https://www.amgen.com/about/leadership/senior-management/emily-razaqi 2024-08-19 daily 0.5 https://www.amgen.com/about/leadership/senior-management/esteban-santos 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/senior-management/gilles-marrache 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/senior-management/greg-portner 2022-11-03 daily 0.5 https://www.amgen.com/about/leadership/senior-management/howard-chang 2024-12-03 daily 0.5 https://www.amgen.com/about/leadership/senior-management/jackie-elbonne 2022-02-18 daily 0.5 https://www.amgen.com/about/leadership/senior-management/james-bradner 2024-12-03 daily 0.5 https://www.amgen.com/about/leadership/senior-management/jasper-van-grunsven 2026-01-14 daily 0.5 https://www.amgen.com/about/leadership/senior-management/jean-charles-soria 2021-07-30 daily 0.5 https://www.amgen.com/about/leadership/senior-management/jerry-murry 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/senior-management/jonathan-graham 2023-01-06 daily 0.5 https://www.amgen.com/about/leadership/senior-management/justin-claeys 2026-01-05 daily 0.5 https://www.amgen.com/about/leadership/senior-management/kave-niksefat 2024-08-19 daily 0.5 https://www.amgen.com/about/leadership/senior-management/marc-doble 2025-08-15 daily 0.5 https://www.amgen.com/about/leadership/senior-management/mark-j-taisey 2021-06-03 daily 0.5 https://www.amgen.com/about/leadership/senior-management/murdo-gordon 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/senior-management/my-linh-kha 2025-06-20 daily 0.5 https://www.amgen.com/about/leadership/senior-management/nancy-grygiel 2024-01-02 daily 0.5 https://www.amgen.com/about/leadership/senior-management/narimon-honarpour 2023-09-06 daily 0.5 https://www.amgen.com/about/leadership/senior-management/paul-burton 2023-06-23 daily 0.5 https://www.amgen.com/about/leadership/senior-management/peter-griffith 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/senior-management/rachna-khosla 2021-09-13 daily 0.5 https://www.amgen.com/about/leadership/senior-management/robert-a-bradway 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/senior-management/sam-guhan 2024-11-05 daily 0.5 https://www.amgen.com/about/leadership/senior-management/scott-skellenger 2024-11-05 daily 0.5 https://www.amgen.com/about/leadership/senior-management/sean-bruich 2024-08-23 daily 0.5 https://www.amgen.com/about/leadership/senior-management/som-chattopadhyay 2026-01-06 daily 0.5 https://www.amgen.com/about/leadership/senior-management/susan-logan 2026-02-04 daily 0.5 https://www.amgen.com/about/leadership/senior-management/susan-sweeney 2024-08-19 daily 0.5 https://www.amgen.com/about/leadership/senior-management/susie-tappouni 2024-04-24 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/amy-e-miles 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/brian-j-druker 2025-07-11 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/charles-m-holley 2025-07-11 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/ellen-j-kullman 2022-06-01 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/greg-c-garland 2025-07-11 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/mary-e--klotman 2024-05-30 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/michael-v-drake 2022-08-03 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/robert-a-bradway 2025-07-11 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/robert-a-eckert 2025-07-11 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/s--omar-ishrak 2021-07-30 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/tyler-jacks 2021-03-18 daily 0.5 https://www.amgen.com/about/leadership/board-of-directors/wanda-m-austin 2025-07-11 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/alan-r-tall 2023-04-14 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/alfred-l-george-jr 2022-03-22 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/daniel-drucker 2025-04-14 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/daniel-p-kelly 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/david-baltimore 2021-06-03 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/david-j-anderson 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/diane-mathis 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/e-dale-abel 2022-05-06 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/elliott-sigal 2021-09-17 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/fabrice-andre 2024-06-27 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/frank-mccormick 2024-06-27 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/george-georgiou 2023-04-14 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/gordon-tomaselli 2022-03-22 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/james-p-allison 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/john-kuriyan 2023-09-06 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/jonathan-s-weissman 2022-03-17 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/lillian-l-siu 2022-03-22 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/marlene-rabinovitch 2025-01-29 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/peter-libby 2022-05-06 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/richard-o-hynes 2022-03-17 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/robert-tjian 2022-03-17 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/ron-evans 2022-03-16 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/r-sanders-williams 2024-11-25 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/ruslan-medzhitov 2022-03-17 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/s-gail-eckhardt-md-fasco 2023-09-26 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/siwen-hu-lieskovan 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/thomas-quertermous 2020-12-07 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/maria-abreu 2025-05-12 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/emma-guttman 2022-11-28 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/meilan-han 2025-05-12 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/alexander-marson 2022-11-28 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/alexander-sasha-rudensky 2023-06-14 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/arlene-sharpe 2025-05-12 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/dean-sheppard 2025-02-17 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/randy-seeley 2025-02-17 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/viviana-gradinaru 2026-02-13 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/patrick-hsu 2026-01-28 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/david-mooney 2026-01-28 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/eran-segal 2026-01-28 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/james-zou 2026-01-28 daily 0.5 https://www.amgen.com/about/leadership/scientific-advisory-boards/phil-zamore 2026-01-28 daily 0.5 https://www.amgen.com/about/therapy-areas/oncology/monoclonal-antibodies 2025-05-07 monthly 0.5 https://www.amgen.com/about/therapy-areas/oncology/small-molecules 2025-05-07 monthly 0.5 https://www.amgen.com/about/therapy-areas/oncology/t-cell-engagers 2024-08-27 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/amgen-foundation 2023-02-27 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/staff-engagement-programs 2023-12-08 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/us-healthcare-donations 2022-04-26 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/equipment-donations 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/non-healthcare-donations-and-sponsorships 2023-08-21 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/independent-medical-education-funding 2023-08-04 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/amgen-patient-advocacy-and-strategic-alliances 2024-11-20 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines/reimbursement-and-financial-assistance-programs 2025-01-29 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines/access--to-healthcare-programs-and-partnerships-in-low--and-middle-income-countries 2024-08-30 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines/our-approach-to-pricing-access-and-affordability 2023-12-13 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines/access-to-investigational-medicines 2023-04-27 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/health-equity/health-equity-overview 2022-12-20 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/environmental-sustainability/approach 2024-05-14 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/environmental-sustainability/energy-and-carbon 2024-05-14 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/environmental-sustainability/water 2024-07-29 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/environmental-sustainability/waste 2024-05-14 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/environmental-sustainability/product-sustainability 2024-05-14 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/environmental-sustainability/amgen-ecovation 2025-01-13 monthly 0.5 https://www.amgen.com/responsibility/healthy-planet/responsible-sourcing/california-supply-chain-transparency-act 2022-04-15 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/our-workforce/diversity-and-inclusion 2025-12-15 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/our-workforce/human-capital-management 2025-12-15 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/business-ethics-and-compliance/annual-declaration-of-compliance 2022-06-03 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/business-ethics-and-compliance/elements-of-an-effective-compliance-program 2022-04-27 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/business-ethics-and-compliance/amgens-culture-of-compliance 2025-04-14 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/business-ethics-and-compliance/staff-code-of-conduct 2023-03-17 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/business-ethics-and-compliance/corporate-compliance-policies 2025-04-24 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/business-ethics-and-compliance/reporting-a-concern 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report 2022-04-27 monthly 0.5 https://www.amgen.com/newsroom/press-releases/2026/01/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline 2026-01-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/01/amgen-announces-webcast-of-2025-fourth-quarter-and-full-year-financial-results 2026-01-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/01/amgen-to-present-at-the-44th-annual-j-p--morgan-healthcare-conference 2026-02-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/02/amgen-reports-fourth-quarter-and-full-year-2025-financial-results 2026-02-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/02/amgen-to-present-at-citis-2026-virtual-oncology-leadership-summit 2026-02-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/02/amgen-to-present-at-the-46th-annual-td-cowen-health-care-conference 2026-02-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/02/european-commission-approves-amgens-uplizna-for-generalized-myasthenia-gravis 2026-02-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/03/amgen-announces-2026-second-quarter-dividend 2026-03-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/03/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference 2026-03-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2026/03/repatha-cuts-risk-of-first-major-cardiovascular-events-by-31-in-highrisk-patients-without-known-significant-atherosclerosis 2026-03-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/01/amgen-to-present-at-43rd-annual-j-p--morgan-healthcare-conference 2025-01-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/01/fda-approves-lumakras-sotorasib-in-combination-with-vectibix-panitumumab-for-chemorefractory-kras-g12cmutated-metastatic-colorectal-cancer 2025-01-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/02/amgen-reports-fourth-quarter-and-full-year-2024-financial-results 2025-03-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/02/amgen-to-present-at-citis-2025-virtual-oncology-leadership-summit 2025-02-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/02/amgen-to-present-at-the-35th-annual-oppenheimer-healthcare-life-sciences-conference 2025-02-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/02/amgen-to-present-at-the-45th-annual-td-cowen-health-care-conference 2025-02-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/03/amgen-and-kyowa-kirin-provide-top-line-results-from-rocatinlimab-phase-3-ignite-study-in-adults-with-moderate-to-severe-atopic-dermatitis 2025-03-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/03/amgen-announces-2025-second-quarter-dividend 2025-03-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/03/positive-results-from-tezspire-tezepelumabekko-phase-3-waypoint-trial-highlight-rapid-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps 2025-03-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/03/uplizna-inebilizumabcdon-significantly-improves-generalized-myasthenia-gravis-symptoms-in-acetylcholine-receptor-autoantibodypositive-patients-over-52-weeks 2025-03-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/04/amgen-announces-900-million-manufacturing-expansion-creation-of-350-new-jobs-in-ohio 2025-04-25 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/04/amgen-announces-webcast-of-2025-first-quarter-financial-results 2025-04-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/04/imdelltra-demonstrated-superior-overall-survival-in-small-cell-lung-cancer 2025-04-11 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/04/uplizna-inebilizumabcdon-is-now-the-first-and-only-fdaapproved-treatment-for-igg4related-disease 2025-04-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/05/amgen-reports-first-quarter-2025-financial-results 2025-05-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/05/amgen-to-present-at-jefferies-global-healthcare-conference 2025-05-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/05/amgen-to-present-at-the-2025-rbc-capital-markets-global-healthcare-conference 2025-05-18 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2025-05-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/06/amgen-and-football-legend-barry-sanders-highlight-dangers-of-bad-cholesterol-in-new-documentary 2025-06-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/06/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-firstline-gastric-cancer 2025-06-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/06/amgens-phase-2-maritide-data-to-be-presented-at-the-american-diabetes-association-85th-scientific-sessions 2025-06-18 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/06/amgen-to-present-at-goldman-sachs-46th-annual-global-healthcare-conference 2025-06-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/06/imdelltra-significantly-reduced-risk-of-death-by-40-in-small-cell-lung-cancer-patients 2025-06-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/06/results-from-amgens-phase-2-obesity-study-of-monthly-maritide-presented-at-the-american-diabetes-association-85th-scientific-sessions 2025-06-23 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/07/amgen-announces-webcast-of-2025-second-quarter-financial-results 2025-07-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/08/amgen-announces-2025-third-quarter-dividend 2025-08-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/08/amgen-reports-second-quarter-2025-financial-results 2025-08-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/08/amgen-to-present-at-the-2025-wells-fargo-healthcare-conference 2025-08-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/08/repatha-now-indicated-for-adults-at-increased-risk-for-major-adverse-cardiovascular-events-due-to-uncontrolled-ldl-c 2025-08-25 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/09/amgen-and-kyowa-kirin-announce-top-line-results-from-rocatinlimab-phase-3-ascend-long-term-extension-study-in-adults-with-moderate-to-severe-atopic-dermatitis 2025-09-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/09/amgen-announces-650m-expansion-of-us-manufacturing-creating-hundreds-of-new-jobs 2025-09-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/09/amgen-investing-more-than-half-a-billion-dollars-in-new-stateoftheart-center-for-science-and-innovation-at-us-global-headquarters 2025-09-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/09/amgen-to-present-at-the-morgan-stanley-23rd-annual-global-healthcare-conference 2025-09-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/10/amgen-announces-2025-fourth-quarter-dividend 2025-10-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/10/amgen-announces-webcast-of-2025-third-quarter-financial-results 2025-10-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/10/amgen-makes-repatha-available-through-amgennow-a-directtopatient-program-in-the-us 2025-10-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/10/amgens-landmark-phase-3-repatha-data-to-be-presented-as-late-breaker-at-the-american-heart-association-scientific-sessions-2025 2025-10-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/10/fda-approves-tezspire-for-chronic-rhinosinusitis-with-nasal-polyps 2025-10-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/10/landmark-phase-3-trial-vesaliuscv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients 2025-10-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/11/amgen-reports-third-quarter-2025-financial-results 2025-11-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/11/amgens-repatha-cuts-risk-of-first-major-adverse-cardiovascular-events-by-25-in-landmark-phase-3-vesaliuscv-trial 2025-11-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/11/amgen-to-present-at-citis-2025-global-healthcare-conference 2025-11-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/11/amgen-to-present-at-the-8th-annual-evercore-isi-healthconx-conference 2025-11-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/11/fda-grants-full-approval-to-amgens-imdelltra-in-extensive-stage-small-cell-lung-cancer 2025-11-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/12/amgen-announces-2026-first-quarter-dividend 2025-12-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/12/amgen-takes-action-with-the-u-s--government-to-lower-the-cost-of-medicines-for-american-patients 2025-12-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2025/12/fda-approves-uplizna-for-adults-with-generalized-myasthenia-gravis 2025-12-11 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/01/amgen-to-present-at-the-42nd-annual-j-p--morgan-healthcare-conference 2024-01-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/02/amgen-announces-webcast-of-2023-fourth-quarter-and-full-year-financial-results 2024-02-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/02/amgen-opens-state-of-the-art-biomanufacturing-site-in-central-ohio 2024-02-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/02/amgen-reports-fourth-quarter-and-full-year-2023-financial-results 2024-02-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/02/amgen-to-host-conference-call-on-rare-disease 2024-02-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/02/amgen-to-present-at-the-34th-annual-oppenheimer-healthcare-life-sciences-conference 2024-02-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/02/amgen-to-present-at-the-44th-annual-td-cowen-health-care-conference 2024-02-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/03/amgen-announces-2024-second-quarter-dividend 2024-03-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/03/amgen-presents-new-research-on-otezla-apremilast-at-aad-2024 2024-03-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/04/amgen-announces-webcast-of-2024-first-quarter-financial-results 2024-04-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/04/amgen-to-present-tezspire-phase-2a-copd-data-at-ats-2024 2024-05-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/04/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency 2024-04-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/05/amgen-highlights-new-copd-asthma-and-vasculitis-research-at-ats-2024 2024-05-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/05/amgen-reports-first-quarter-2024-financial-results 2024-05-25 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/05/amgen-to-host-conference-call-following-ats-2024 2024-05-15 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2024-05-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/05/amgen-to-present-innovative-research-from-its-robust-oncology-portfolio-at-asco-2024 2024-05-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/05/fda-approves-imdelltra-tarlatamabdlle-the-first-and-only-tcell-engager-therapy-for-the-treatment-of-extensivestage-small-cell-lung-cancer 2024-05-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/05/new-data-presented-at-ats-2024-show-the-potential-of-tezspire-to-help-patients-living-with-copd 2024-05-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/06/amgen-announces-positive-results-for-phase-3-registrational-trial-evaluating-uplizna-inebilizumabcdon-for-treatment-of-immunoglobulin-g4related-disease-igg4rd 2024-06-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/06/amgen-to-present-at-goldman-sachs-45th-annual-global-healthcare-conference 2024-06-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/06/amgen-to-present-at-jefferies-global-healthcare-conference 2024-06-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/06/amgen-to-present-innovative-rheumatology-research-at-eular-2024 2024-06-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/06/fda-approves-blincyto-blinatumomab-in-cd19positive-philadelphia-chromosomenegative-bcell-precursor-acute-lymphoblastic-leukemia-ball-in-the-consolidation-phase 2024-06-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/08/amgen-announces-2024-third-quarter-dividend 2024-08-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/08/amgen-announces-webcast-of-2024-second-quarter-financial-results 2024-08-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/08/amgen-reports-second-quarter-2024-financial-results 2024-08-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/08/amgen-to-present-at-the-2024-wells-fargo-healthcare-conference 2024-08-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/08/amgen-to-present-at-the-morgan-stanley-22nd-annual-global-healthcare-conference 2024-08-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/08/otezla-apremilast-now-available-in-the-us-for-moderate-to-severe-pediatric-plaque-psoriasis 2024-08-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/09/amgen-presents-new-data-for-firstinclass-imdelltra-tarlatamabdlle-in-small-cell-lung-cancer-at-wclc-2024 2024-09-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/09/amgen-to-host-conference-call-to-discuss-new-topline-data-in-inflammation-and-rare-disease 2024-09-23 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/09/amgen-to-present-data-from-multiple-early-stage-clinical-trials-at-esmo-2024 2024-09-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/09/tepezza-teprotumumab-receives-approval-in-japan-for-the-treatment-of-active-thyroid-eye-disease 2024-09-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/10/amgen-announces-2024-fourth-quarter-dividend 2024-10-25 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/10/amgen-announces-webcast-of-2024-third-quarter-financial-results 2024-10-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/10/amgen-presents-positive-phase-3-data-for-uplizna-inebilizumabcdon-in-generalized-myasthenia-gravis-gmg-at-aanem-2024 2024-10-15 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/10/amgen-reports-third-quarter-2024-financial-results 2024-10-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/10/la-la-anthony-partners-with-amgen-to-share-candid-behindthescenes-look-at-how-plaque-psoriasis-affects-her-life 2024-10-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52-weeks-in-a-phase-2-study 2025-05-27 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/amgen-announces-senior-executive-research-appointment 2024-11-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/amgen-presents-new-data-across-rare-inflammatory-diseases-at-acr-2024 2024-11-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/amgen-provides-statement-on-maritide-phase-1-data 2024-11-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/amgen-to-host-webcast-to-discuss-maritide-phase-2-results-and-progress-on-development-program 2024-11-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/amgen-to-present-at-the-2024-ubs-global-healthcare-conference 2024-11-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/amgen-to-present-at-the-7th-annual-evercore-healthconx-conference 2024-11-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/11/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic-rhinosinusitis-with-nasal-polyps 2024-11-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/12/amgen-announces-$1-billion-manufacturing-expansion-in-north-carolina 2024-12-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/12/amgen-announces-2025-first-quarter-dividend 2024-12-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/12/amgen-to-present-at-citis-2024-global-healthcare-conference 2024-12-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2024/12/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-bcell-precursor-acute-lymphoblastic-leukemia-ball 2024-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/01/amgen-and-biolabs-la-at-the-lundquist-institute-announce-nammi-therapeutics-to-receive-the-third-amgen-golden-ticket 2023-01-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/01/amgen-announces-webcast-of-2022-fourth-quarter-and-full-year-financial-results 2023-01-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/01/amgen-reports-fourth-quarter-and-full-year-2022-financial-results 2023-01-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/01/amgen-to-present-at-the-41st-annual-j-p--morgan-healthcare-conference 2023-01-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/01/amjevita-adalimumabatto-first-biosimilar-to-humira-now-available-in-the-united-states 2023-01-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/02/amgen-announces-cardiovascular-study-to-evaluate-association-between-lipoproteina-and-cardiovascular-risk-in-african-americans 2023-02-23 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/02/amgen-posts-full-transcript-and-audio-replay-of-fourth-quarter-and-full-year-2022-earnings-webcast 2023-02-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/02/amgen-to-present-at-the-2023-svb-securities-global-biopharma-conference 2023-02-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/02/tezspire-approved-for-self-administration-in-the-u-s--with-a-new-pre-filled-pen 2023-02-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/03/amgen-announces-2023-second-quarter-dividend 2023-03-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/03/amgen-to-present-at-the-33rd-annual-oppenheimer-healthcare-conference 2023-04-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/03/amgen-to-present-at-the-43rd-annual-td-cowen-healthcare-conference 2023-03-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/03/amgen-to-present-new-repatha-evolocumab-and-olpasiran-data-at-acc 2023-03-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/04/amgen-announces-webcast-of-2023-first-quarter-financial-results 2023-04-21 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/04/amgen-reports-first-quarter-financial-results 2023-04-27 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/04/amgen-wins-patent-appeal-on-otezla-apremilast 2023-04-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/05/amgen-and-tscan-therapeutics-announce-collaboration-to-identify-novel-targets-in-crohns-disease 2023-05-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/05/amgen-presents-new-research-on-otezla-apremilast-in-psoriatic-arthritis-at-eular-2023 2023-05-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/05/amgen-responds-to-ftc-action-re-proposed-acquisition-of-horizon-therapeutics 2023-05-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/05/amgen-to-present-at-the-2023-bank-of-america-merrill-lynch-global-healthcare-conference 2023-05-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/05/amgen-to-present-at-the-td-cowen-4th-annual-oncology-innovation-summit 2023-05-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/05/new-data-from-amgens-prolia-denosumab-demonstrates-significant-reduction-in-osteoporotic-fracture-risk-compared-to-alendronate 2023-05-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/06/amgen-presents-new-lumakras-sotorasib-codebreak-200-cns-data-at-asco-2023 2023-06-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/06/amgen-presents-new-scientific-and-clinical-research-across-its-diverse-oncology-portfolio-and-pipeline-at-asco-2023 2023-06-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/06/amgen-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference 2023-06-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/06/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-minimal-residual-diseasepositive-bcell-precursor-acute-lymphoblastic-leukemia 2023-06-21 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/07/amgen-announces-webcast-of-2023-second-quarter-financial-results 2023-07-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/08/amgen-announces-2023-third-quarter-dividend 2023-08-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/08/amgen-presents-late-breaking-phase-2-olpasiran-data-at-esc-2023 2023-08-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/08/amgen-reports-second-quarter-financial-results 2023-08-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/08/amgen-to-discuss-application-for-lumakras-sotorasib-for-the-treatment-of-kras-g12cpositive-nsclc-at-fda-advisory-committee-meeting 2023-08-21 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/08/amgen-to-present-at-the-2023-wells-fargo-healthcare-conference-and-the-citi-global-healthcare-conference 2023-08-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/09/amgen-and-horizon-therapeutics-plc-resolve-ftc-lawsuit-clearing-path-to-close-acquisition 2023-09-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/09/amgen-launches-partners-of-choice-network-of-eight-leading-oncology-academic-centers 2023-09-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/09/amgen-presents-new-lumakras-sotorasib-plus-chemotherapy-data-in-firstline-kras-g12c-nsclc-at-wclc 2023-09-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2023-09-11 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2023-09-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-announces-2023-fourth-quarter-dividend 2023-10-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-announces-webcast-of-2023-third-quarter-financial-results 2023-10-25 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-completes-acquisition-of-horizon-therapeutics-plc 2023-10-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-presents-new-lumakras-sotorasib-plus-vectibix-panitumumab-data-in-patients-with-kras-g12cmutated-metastatic-colorectal-cancer 2023-10-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-presents-new-tarlatamab-data-in-small-cell-lung-cancer 2023-10-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-reports-third-quarter-financial-results 2023-10-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-to-present-new-research-from-oncology-portfolio-and-pipeline-at-esmo-2023 2023-10-18 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/10/amgen-to-webcast-investor-call-at-esmo-2023 2023-10-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/11/amgen-presents-new-cardiovascular-research-at-aha-2023 2023-11-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/11/amgen-presents-new-data-from-phase-2-trial-of-dazodalibep-in-sjgrens-syndrome-at-acr-2023 2023-11-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/11/amgen-presents-new-data-that-show-blood-pressure-decreases-for-adults-treated-with-krystexxa-pegloticase 2023-11-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/11/amgen-presents-new-research-in-early-psoriatic-arthritis-at-acr-2023 2023-11-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/11/amgen-to-present-at-the-evercore-isi-healthconx-conference 2023-11-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/11/amgen-to-present-data-at-acr-2023-across-expanded-rheumatology-pipeline-and-portfolio 2023-11-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/12/amgen-announces-2024-first-quarter-dividend-increase-to-$2-25-per-share 2023-12-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/12/amgen-announces-executive-appointments-to-accelerate-innovation 2023-12-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/12/amgen-highlights-hematology-portfolio-at-ash-2023 2023-12-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/12/amgen-provides-regulatory-update-on-status-of-lumakras-sotorasib 2023-12-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/12/amgen-to-sponsor-the-irish-open 2023-12-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2023/12/fda-grants-priority-review-to-amgens-tarlatamab-application-for-advanced-small-cell-lung-cancer 2023-12-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/01/amgen-and-arrakis-therapeutics-announce-multi-target-collaboration-to-identify-novel-rna-degrader-small-molecule-therapeutics 2022-07-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/01/amgen-and-biolabs-la-at-the-lundquist-institute-announce-that-karma-biotechnologies-will-receive-the-second-amgen-golden-ticket 2022-01-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/01/amgen-and-generate-biomedicines-announce-multitarget-multimodality-research-collaboration-agreement 2022-01-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/01/amgen-to-present-at-the-40th-annual-j-p--morgan-healthcare-conference 2022-01-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/01/european-commission-approves-lumykras-sotorasib-for-patients-with-kras-g12cmutated-advanced-nonsmall-cell-lung-cancer 2022-01-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/01/lumakras-sotorasib-receives-approval-in-japan-for-patients-with-kras-g12cmutated-advanced-nonsmall-cell-lung-cancer 2022-01-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/01/tezspire-tezepelumabekko-now-available-in-the-united-states-for-the-treatment-of-severe-asthma 2022-01-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/amgen-and-plexium-announce-multiyear-drug-discovery-collaboration-to-identify-novel-targeted-protein-degradation-therapies 2022-02-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/amgen-issues-inaugural-green-bond-to-advance-esg-goals 2022-02-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/amgen-outlines-growth-strategy-through-2030-at-virtual-business-review 2022-02-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/amgen-provides-long-term-guidance-through-2030-during-business-review-meeting 2022-02-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/amgen-recognized-for-outstanding-esg-performance 2022-02-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/amgen-reports-fourth-quarter-and-full-year-2021-financial-results 2022-02-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/amgen-to-host-virtual-business-review-meeting 2022-02-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/lumakras-sotorasib-shows-encouraging-and-clinically-meaningful-anticancer-activity-in-patients-with-kras-g12cmutated-advanced-pancreatic-cancer-in-codebreak-100-trial 2022-02-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/02/new-data-further-reinforce-efficacy-of-tezspire-tezepelumabekko-in-a-broad-population-of-severe-asthma-patients 2022-02-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/03/amgen-announces-2022-second-quarter-dividend 2022-03-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/03/amgen-announces-new-otezla-apremilast-data-at-aad-congress-2022 2022-03-25 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/03/amgen-to-present-at-the-32nd-annual-oppenheimer-healthcare-conference 2022-03-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/03/amgen-to-present-at-the-42nd-annual-cowen-healthcare-conference 2022-03-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/03/amgen-to-present-longterm-outcomes-for-lumakras-sotorasib-in-kras-g12cmutated-nsclc-at-aacr-2022 2022-03-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/03/global-biotechnology-leader-amgen-breaks-ground-on-new-manufacturing-facility-in-north-carolina 2022-03-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/04/amgen-announces-positive-topline-results-from-phase-3-study-of-abp-654-biosimilar-candidate-to-stelara-ustekinumab 2022-04-18 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/04/amgen-announces-results-from-two-open-label-extension-studies-of-repatha-evolocumab 2022-04-27 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/04/amgen-announces-webcast-of-2022-first-quarter-financial-results 2022-04-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/04/amgen-reports-first-quarter-2022-financial-results 2022-04-27 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/04/lumakras-sotorasib-codebreak-100-study-shows-twoyear-overall-survival-of-325-in-patients-with-kras-g12cmutated-advanced-nonsmall-cell-lung-cancer 2022-06-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/05/amgen-and-lance-bass-partner-to-encourage-people-to-do-a-double-take-to-recognize-the-early-signs-of-psoriatic-arthritis 2022-05-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/05/amgen-announces-positive-topline-phase-2-data-for-investigational-olpasiran-in-adults-with-elevated-lipoproteina 2022-05-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/05/amgen-announces-webcast-of-2022-bank-of-america-healthcare-conference 2022-05-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/05/amgen-releases-annual-environmental-social--governance-report 2022-05-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/05/new-data-showcases-how-amgen-is-advancing-all-angles-of-cancer-care-through-innovative-oncology-portfolio-and-pipeline-at-asco-2022 2022-05-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/06/amgen-announces-webcast-of-2022-jefferies-healthcare-conference 2022-06-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/06/amgen-announces-webcast-of-goldman-sachs-43rd-annual-healthcare-conference 2022-06-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/06/amgen-foundation-more-than-doubles-commitment-to-labxchange-free-virtual-science-education-platform 2022-06-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/06/fda-approves-riabni-rituximabarrx-a-biosimilar-to-rituxan-rituximab-for-adults-with-moderate-to-severe-rheumatoid-arthritis 2022-06-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/06/new-headtohead-data-show-vectibix-panitumumab-demonstrated-superior-overall-survival-compared-to-bevacizumab-in-combination-with-chemotherapy-in-japanese-patients-with-wildtype-ras-colorectal-cancer 2022-06-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-announces-2022-third-quarter-dividend 2022-08-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-announces-positive-topline-results-from-phase-3-study-of-abp-959-biosimilar-candidate-to-soliris-eculizumab 2022-08-23 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-announces-topline-data-from-lumakras-sotorasib-phase-3-trial-in-nonsmall-cell-lung-cancer 2022-08-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-announces-webcast-of-2022-second-quarter-financial-results 2022-08-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-appoints-michael-v--drake-to-board-of-directors 2022-08-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-data-at-wclc-2022-highlights-potential-to-deliver-transformative-medicines-for-historically-difficult-to-treat-lung-cancers 2022-08-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-presents-new-tarlatamab-clinical-data-at-wclc-2022 2022-08-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-reports-second-quarter-2022-financial-results 2022-08-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-acquire-chemocentryx-for-$4-billion-in-cash 2022-08-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-present-new-data-at-esc-congress-2022-highlighting-up-to-85-years-of-repatha-evolocumab-safety-and-tolerability-data-in-highrisk-ascvd-patient-populations 2022-08-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-present-new-positive-clinical-and-realworld-data-across-inflammation-portfolio-at-eadv-2022 2022-08-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/amgen-to-webcast-investor-meeting-at-wclc-2022 2022-08-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/08/new-amgen-data-at-esc-2022-show-longterm-ldlc-lowering-with-repatha-evolocumab-was-welltolerated-for-more-than-8-years 2022-08-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/amgen-announces-positive-new-data-at-eadv-2022-for-otezla-apremilast 2022-09-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/amgen-announces-webcast-of-2022-bank-of-america-merrill-lynch-global-healthcare-conference 2022-09-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/amgen-announces-webcast-of-2022-citi-global-healthcare-conference 2022-09-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/amgen-announces-webcast-of-2022-morgan-stanley-global-healthcare-conference 2022-09-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/amgen-announces-webcast-of-2022-wells-fargo-healthcare-conference 2022-09-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/amgen-to-webcast-investor-call-at-esmo-2022 2022-09-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/lumakraslumykras-sotorasib-demonstrates-superior-progressionfree-survival-over-docetaxel-in-first-positive-phase-3-trial-of-a-kras-g12c-inhibitor-in-nonsmall-cell-lung-cancer 2022-09-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/09/lumakras-sotorasib-combined-with-vectibix-panitumumab-shows-confirmed-30-objective-response-rate-in-patients-with-kras-g12cmutated-metastatic-colorectal-cancer 2022-09-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/10/amgen-announces-2022-fourth-quarter-dividend 2022-10-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/10/amgen-announces-webcast-of-2022-third-quarter-financial-results 2022-10-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/10/amgen-opens-new-state-of-the-art-research-and-development-laboratory-site-in-san-francisco-bay-area 2022-10-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/10/amgens-annual-trends-report-finds-competition-created-by-biosimilars-contributed-21-billion-in-us-healthcare-system-savings 2022-10-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/10/amgen-successfully-completes-acquisition-of-chemocentryx 2022-10-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-announces-webcast-of-2022-credit-suisse-global-healthcare-conference 2022-11-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-announces-webcast-of-2022-evercore-isi-healthcare-conference 2022-11-23 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-presents-new-phase-2-data-that-show-olpasiran-delivers-significant-reduction-in-lipoproteina-levels 2022-11-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-presents-new-repatha-evolocumab-data-at-aha-2022 2022-11-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-reports-third-quarter-2022-financial-results 2022-11-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-to-present-new-research-across-serious-inflammatory-and-bone-diseases-at-acr-2022 2022-11-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-to-webcast-investor-call-at-aha-2022 2022-11-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/11/amgen-to-webcast-investor-call-at-wcirdc-2022 2022-11-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/12/amgen-announces-10-increase-in-2023-first-quarter-dividend 2022-12-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/12/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022 2022-12-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/12/amgen-to-host-webcast-investor-call-following-announced-acquisition-of-horizon-therapeutics 2022-12-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/12/announcement-for-the-purposes-of-rule-2-12-of-the-irish-takeover-panel-act 2022-12-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/12/blincyto-blinatumomab-added-to-consolidation-chemotherapy-significantly-improves-survival-in-adult-patients-with-measurable-residual-diseasenegative-blineage-acute-lymphoblastic-leukemia-ball 2022-12-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2022/12/rule-2-7-announcement-amgen-inc-to-acquire-horizon-therapeutics-plc 2022-12-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/01/amgen-announces-breakthrough-therapy-designation-granted-for-sotorasib-in-china 2021-02-18 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/01/amgen-announces-webcast-of-2020-fourth-quarter-and-full-year-financial-results 2021-01-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/01/amgens-investigational-kras-g12c-inhibitor-sotorasib-demonstrated-rapid-deep-and-durable-responses-in-previously-treated-patients-with-advanced-nonsmall-cell-lung-cancer 2021-01-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/01/amgen-to-achieve-carbon-neutrality-by-2027 2021-03-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/01/amgen-to-present-at-the-39th-annual-j-p--morgan-healthcare-conference 2021-01-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/01/amgen-to-showcase-next-frontier-of-innovation-in-lung-cancer-therapies-at-wclc-2020 2021-01-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/01/amgen-to-webcast-investor-meeting-at-2020-world-conference-on-lung-cancer 2021-01-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/amgen-reports-fourth-quarter-and-full-year-2020-financial-results 2021-03-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/amgen-sponsors-golden-ticket-at-biolabs-la-at-the-lundquist-institute-to-help-accelerate-life-science-startups 2021-03-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/amgen-submits-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mildtomoderate-plaque-psoriasis 2021-02-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/amgen-to-present-at-guggenheim-healthcare-talks-oncology-day 2021-02-18 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/amgen-to-present-at-the-cowen-41st-annual-healthcare-conference 2021-02-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/amgen-to-webcast-investor-meeting-at-aaaai-virtual-annual-meeting 2021-02-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer 2021-02-18 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/02/tezepelumab-is-the-first-biologic-to-significantly-reduce-exacerbations-in-broad-population-of-patients-with-severe-uncontrolled-asthma 2021-03-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/03/amgen-announces-2021-second-quarter-dividend 2021-03-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/03/amgen-to-acquire-five-prime-therapeutics-for-$1-9-billion-in-cash 2021-03-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/03/amgen-to-acquire-rodeo-therapeutics-corporation 2021-03-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/03/amgen-to-present-at-the-oppenheimer-31st-annual-healthcare-conference 2021-03-11 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/03/blincyto-blinatumomab-demonstrated-significantly-prolonged-eventfree-survival-compared-with-consolidation-chemotherapy-in-pediatric-patients-with-relapsed-acute-lymphoblastic-leukemia 2021-03-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/04/amgen-announces-webcast-of-2021-first-quarter-financial-results 2021-04-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/04/amgen-launches-biomarker-assist-a-program-to-help-more-patients-with-nonsmall-cell-lung-cancer-gain-access-to-biomarker-testing 2021-04-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/04/amgen-provides-updated-information-on-lumakras-sotorasib-dose-comparison-study 2025-12-15 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/04/amgen-reports-first-quarter-2021-financial-results 2021-07-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/04/amgens-investigational-targeted-treatment-bemarituzumab-granted-breakthrough-therapy-designation 2021-04-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/04/amgen-successfully-completes-acquisition-of-five-prime-therapeutics 2021-04-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/04/otezla-apremilast-significantly-improved-measures-of-disease-severity-in-adults-with-mildtomoderate-plaque-psoriasis 2021-04-23 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/amgen-announces-tezepelumab-biologics-license-application-submitted-to-u-s--fda 2021-05-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/amgen-to-present-at-the-2021-bank-of-america-merrill-lynch-healthcare-conference 2021-05-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/amgen-to-present-at-the-2021-jefferies-healthcare-conference 2021-05-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/amgen-to-present-at-the-cowen-2nd-annual-virtual-oncology-innovation-summit 2021-05-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/amgen-to-showcase-new-data-from-oncology-portfolio-at-asco-2021 2021-05-19 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/efficacy-of-repatha-evolocumab-across-highrisk-patient-populations-reinforced-at-acc21 2021-05-11 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/fda-accepts-amgens-supplemental-new-drug-application-for-otezla-apremilast-for-adults-with-mildtomoderate-plaque-psoriasis 2021-05-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12cmutated-locally-advanced-or-metastatic-nonsmall-cell-lung-cancer 2021-05-28 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/05/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-severe-asthma-patients 2021-05-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/06/acclaimed-makeup-artist-allan-avendao-opens-up-about-personal-skin-condition-provides-inside-look-at-life-with-plaque-psoriasis 2021-06-15 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/06/amgen-and-kyowa-kirin-to-jointly-develop-and-commercialize-khk4083-a-phase-3ready-potential-firstinclass-treatment-for-atopic-dermatitis 2021-06-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/06/amgen-announces-approval-of-aimovig-erenumab-in-japan-for-the-suppression-of-onset-of-migraine-attacks-in-adults 2021-06-23 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/06/amgen-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference 2021-06-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/06/amgen-to-webcast-investor-meeting-at-asco-2021 2021-06-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/06/phase-2-fight-trial-continues-to-show-improved-overall-survival-with-bemarituzumab-plus-chemotherapy-in-patients-with-fgfr2b-gastric-and-gastroesophageal-cancers 2021-06-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/06/results-from-phase-2-codebreak-100-show-lumakras-sotorasib-is-the-first-and-only-kras-g12c-inhibitor-with-overall-survival-data 2021-06-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/07/amgen-and-the-international-federation-of-psoriasis-associations-launch-uplift-innovation-challenge 2021-07-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/07/amgen-announces-2021-third-quarter-dividend 2021-07-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/07/amgen-announces-webcast-of-2021-second-quarter-financial-results 2021-07-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/07/amgen-appoints-s--omar-ishrak-to-board-of-directors 2021-07-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/07/amgen-to-acquire-privately-held-teneobio-for-$900-million-in-cash-with-future-contingent-milestone-payments 2021-07-27 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/07/tezepelumab-granted-priority-review-by-u-s--fda 2021-07-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/08/amgen-reports-second-quarter-2021-financial-results 2021-08-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/08/new-data-at-esc-congress-2021-shows-repatha-evolocumab-improves-features-of-plaque-stability-in-patients-with-acute-coronary-syndrome-acs 2021-08-27 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-and-the-lundquist-institute-announce-that-diadem-therapeuctics-will-receive-the-first-amgen-golden-ticket-to-biolabs-la 2021-09-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-presents-new-data-from-thoracic-oncology-portfolio-at-wclc21 2021-09-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-releases-8th-edition-of-biosimilar-trends-report 2021-09-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-to-present-at-the-16th-annual-citi-biopharma-conference 2021-09-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-to-present-at-the-19th-annual-morgan-stanley-global-healthcare-conference 2021-09-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-to-present-at-the-2021-bank-of-america-merrill-lynch-global-healthcare-conference 2021-09-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-to-present-at-the-2021-cantor-global-healthcare-conference 2021-09-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-to-showcase-new-data-from-inflammation-portfolio-at-eadv-virtual-congress-2021 2021-09-13 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-to-webcast-investor-call-at-eadv-2021 2021-09-29 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-to-webcast-investor-call-at-esmo-2021 2021-11-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/amgen-wins-patent-case-on-otezla-apremilast 2021-09-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/fda-approves-repatha-evolocumab-in-pediatric-patients-age-10-and-older-with-heterozygous-familial-hypercholesterolemia 2021-09-25 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/lumakras-sotorasib-combined-with-vectibix-panitumumab-showed-encouraging-efficacy-and-safety-in-patients-with-kras-g12cmutated-colorectal-cancer 2021-09-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/09/new-tezepelumab-data-show-86-reduction-in-exacerbations-in-patients-with-severe-asthma-and-comorbid-nasal-polyps 2021-09-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/amgen-and-kyowa-kirin-present-positive-late-breaking-data-from-phase-2-study-of-amg-451khk4083-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-at-eadv-congress 2026-02-09 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/amgen-and-neumora-therapeutics-announce-strategic-rd-collaboration-to-accelerate-novel-precision-therapies-for-brain-diseases 2021-10-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/amgen-announces-2021-fourth-quarter-dividend 2021-10-21 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/amgen-announces-new-data-highlighting-global-trends-in-hip-fracture-incidence-and-treatment 2021-10-04 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/amgen-announces-new-lumakras-sotorasib-combination-data-from-phase-1b-codebreak-101-study-in-patients-with-kras-g12cmutated-cancers-at-aacrncieortc-2021 2021-11-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/amgen-announces-webcast-of-2021-third-quarter-financial-results 2021-11-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/amgen-successfully-completes-acquisition-of-teneobio-inc 2021-10-21 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/10/fortune-and-great-place-to-work-name-amgen-one-of-the-worlds-best-workplaces-in-2021 2021-10-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/amgen-awards-the-bath-institute-of-rheumatic-diseases-25000-through-uplift-innovation-challenge 2021-11-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/amgen-begins-construction-on-new-biomanufacturing-plant-in-central-ohio 2021-11-05 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/amgen-named-to-dow-jones-sustainability-world-index-for-eighth-consecutive-year 2021-11-30 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/amgen-reports-third-quarter-2021-financial-results 2021-11-02 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/amgen-to-present-at-the-2021-annual-cowen-io-summit 2021-11-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/amgen-to-present-at-the-2021-evercore-isi-healthcare-conference 2021-11-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/amgen-to-present-at-the-2021-piper-sandler-healthcare-conference 2021-11-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/first-and-only-randomized-doubleblind-headtohead-study-comparing-aimovig-erenumabaooe-an-anticgrp-pathway-therapy-to-topiramate-published-in-cephalalgia 2021-11-08 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/11/lumykras-sotorasib-receives-positive-opinion-from-ema-chmp-for-patients-with-kras-g12cmutated-advanced-nonsmall-cell-lung-cancer 2021-11-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/12/amgen-announces-10-increase-in-2022-first-quarter-dividend 2021-12-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/12/amgen-announces-new-data-being-presented-at-ash-2021 2021-12-06 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/12/amgen-announces-positive-topline-results-from-otezla-apremilast-phase-3-discreet-study-in-moderate-to-severe-genital-psoriasis 2021-12-01 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/12/amgen-to-present-at-the-goldman-sachs-14th-annual-healthcare-ceos-unscripted-conference 2021-12-24 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/12/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-faspro-daratumumab-and-hyaluronidasefihj-and-dexamethasone-for-patients-with-multiple-myeloma-at-first-or-subsequent-relapse 2022-01-12 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/12/fda-approves-otezla-apremilast-for-the-treatment-of-adult-patients-with-plaque-psoriasis-regardless-of-severity-level 2021-12-20 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2021/12/fda-approves-tezspire-tezepelumabekko-in-the-us-for-severe-asthma 2021-12-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-and-mckesson-launch-strategic-agreement-to-advance-cancer-innovation-in-communities 2020-12-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-and-novartis-partner-with-karamo-brown-to-support-and-empower-people-living-with-migraine 2020-12-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-announces-10-increase-in-2021-first-quarter-dividend 2020-12-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-awards-two-local-biotech-start-ups-with-golden-ticket-to-labcentral 2020-12-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-licenses-amg-634-an-investigational-treatment-for-tuberculosis-and-leprosy-to-medicines-development-for-global-health 2020-12-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-nonsmall-cell-lung-cancer-patients-with-kras-g12c-mutation 2020-12-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-submits-sotorasib-marketing-authorization-application-to-the-european-medicines-agency 2020-12-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-submits-sotorasib-new-drug-application-to-u-s--fda-for-advanced-or-metastatic-non-small-cell-lung-cancer-with-kras-g12c-mutation 2020-12-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-to-present-first-clinical-data-for-bcma-targeted-half-life-extended-bite-therapy-amg-701-at-ash-2020 2020-12-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-to-transfer-listing-of-debt-securities-to-nasdaq 2020-12-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/amgen-to-webcast-investor-call-at-ash-2020 2020-12-10 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/fda-approves-amgens-riabni-rituximabarrx-a-biosimilar-to-rituxan-rituximab 2020-12-17 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/12/update-on-source-phase-3-trial-for-tezepelumab-in-patients-with-severe-oral-corticosteroiddependent-asthma 2020-12-22 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-announces-new-data-being-presented-at-ash-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-presents-first-clinical-data-for-amg-757-at-sitc-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-showcases-new-data-across-cardiovascular-portfolio-at-aha-scientific-sessions-2020-a-virtual-experience 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-to-present-at-the-29th-annual-credit-suisse-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-to-present-at-the-cowen-4th-annual-io-summit 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-to-present-at-the-evercore-isi-virtual-healthconx-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-to-present-at-the-jefferies-virtual-london-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/amgen-to-transition-development-and-commercial-rights-for-omecamtiv-mecarbil-and-amg-594-to-cytokinetics 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/tezepelumab-navigator-phase-3-trial-met-primary-endpoint-of-a-statistically-significant-and-clinically-meaningful-reduction-in-exacerbations-in-a-broad-population-of-patients-with-severe-asthma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/11/worlds-leading-life-science-companies-now-enrolling-community-a-global-platform-trial-for-hospitalized-patients-with-covid19 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/amgen-announces-2020-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/amgen-announces-fiveyear-data-that-reinforce-the-safety-and-efficacy-profile-of-aimovig-erenumabaooe-in-adult-patients-with-episodic-migraine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/amgen-announces-participation-of-systemic-lupus-erythematosus-sle-adaptive-clinical-trial-in-the-fda-complex-innovative-trial-designs-cid-pilot-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/amgen-announces-positive-topline-phase-2-results-for-investigational-kras-g12c-inhibitor-sotorasib-in-advanced-non-small-cell-lung-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/amgen-announces-webcast-of-2020-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/amgen-cytokinetics-and-servier-announce-topline-results-from-galactichf-a-phase-3-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/amgen-reports-third-quarter-2020-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/10/global-coalition-for-adaptive-research-amgen-and-eisai-announce-first-patient-enrolled-in-international-covid19-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/amgen-to-present-at-the-15th-annual-citi-biopharma-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/amgen-to-present-at-the-18th-annual-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/amgen-to-present-at-the-2020-bank-of-america-virtual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/amgen-to-showcase-data-from-oncology-pipeline-during-esmo-virtual-congress-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/amgen-to-webcast-investor-calls-at-esmo-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/clinical-data-from-full-phase-1-cohort-of-investigational-sotorasib-published-in-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/09/lilly-and-amgen-announce-manufacturing-collaboration-for-covid-19-antibody-therapies 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/08/amgen-announces-early-tender-results-of-senior-notes-exchange-offers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/08/amgen-announces-positive-data-from-phase-3b-study-of-repatha-evolocumab-in-pediatric-patients-with-heterozygous-familial-hypercholesterolemia-at-esc-congress-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/08/amgen-announces-pricing-terms-for-senior-notes-exchange-offers-increases-the-maximum-notes-exchange-cap-and-accepts-tendered-notes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/08/amgen-foundation-commits-100000-to-beirut-relief-efforts-following-explosions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/08/fda-approves-new-kyprolis-carfilzomib-combination-regimen-with-darzalex-daratumumab-and-dexamethasone-in-both-once-and-twiceweekly-dosing-regimens 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/08/members-of-the-covid-rd-alliance-and-quantum-leap-healthcare-collaborative-enroll-first-patients-in-ispy-covid-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/08/new-amgen-data-to-be-presented-at-esc-congress-2020-highlighting-repatha-evolocumab-efficacy-in-highrisk-patient-populations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/amgen-announces-2020-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/amgen-announces-additional-investment-in-beigene 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/amgen-announces-webcast-of-2020-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/amgen-appoints-amy-e--miles-to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/amgen-commences-exchange-offers-for-certain-series-of-outstanding-senior-notes-from-exchange-eligible-holders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/amgen-foundation-awards-khan-academy-an-additional-$3-million-to-support-science-learning-and-educational-equity-amid-covid-19 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/amgen-reports-second-quarter-2020-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/07/appeals-court-affirms-validity-of-enbrel-etanercept-patents-injunction-against-sandozs-infringement-stands 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/06/amgen-is-supporting-advancement-of-amg-634-for-global-health-diseases-in-developing-countries 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/06/amgen-to-present-at-the-bmo-capital-markets-2020-prescriptions-for-success-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/06/amgen-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/06/new-capture-the-fracture-partnership-aims-for-25-reduction-in-the-incidence-of-hip-and-vertebral-fractures-due-to-osteoporosis-by-2025 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-announces-positive-topline-results-from-otezla-apremilast-phase-3-advance-study-in-mildtomoderate-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-presents-new-amg-510-clinical-data-across-multiple-solid-tumors-during-asco20-virtual-scientific-program 2021-02-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-showcases-oncology-pipeline-at-asco-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-virtual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-to-present-at-the-jefferies-2020-virtual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-to-present-at-the-suntrust-robinson-humphrey-life-sciences-summit-virtual-meeting-series 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/amgen-to-webcast-investor-meeting-at-56th-annual-meeting-of-the-american-society-of-clinical-oncology-asco 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/fda-grants-fast-track-designation-for-omecamtiv-mecarbil-in-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/05/kyprolis-carfilzomib-patents-upheld-against-generic-manufacturer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/04/amgen-and-adaptive-biotechnologies-announce-strategic-partnership-to-develop-a-therapeutic-to-prevent-or-treat-covid-19 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/04/amgen-and-adaptive-biotechnologies-to-participate-in-webinar-on-covid-19-strategic-collaboration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/04/amgen-announces-webcast-of-2020-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/04/amgen-establishes-wholly-owned-affiliate-in-japan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/04/amgen-reports-first-quarter-2020-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/04/iceland-provides-a-picture-of-the-early-spread-of-covid-19-in-a-population-with-a-cohesive-public-health-response 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/03/amgen-and-the-amgen-foundation-commit-up-to-$12-5-million-to-support-covid-19-relief-efforts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/03/amgen-announces-2020-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/03/amgen-announces-positive-results-at-acc20wcc-from-phase-3b-study-of-repatha-evolocumab-in-people-living-with-hiv-who-have-high-ldlcholesterol 2020-12-07 daily 0.5 https://www.amgen.com/newsroom/press-releases/2020/02/amgen-cytokinetics-and-servier-announce-continuation-of-galactichf-following-planned-interim-analysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/02/amgen-to-present-at-the-cowen-40th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/01/amgen-announces-global-diagnostic-collaborations-to-expand-molecular-testing-for-patients-with-non-small-cell-lung-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/01/amgen-announces-webcast-of-2019-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/01/amgen-commences-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/01/amgen-reports-fourth-quarter-and-full-year-2019-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/01/amgen-to-present-at-the-38th-annual-j-p--morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/01/amgen-to-present-at-the-goldman-sachs-12th-annual-healthcare-ceos-unscripted-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2020/01/free-labxchange-science-education-accelerator-launched-by-amgen-foundation-and-harvards-faculty-of-arts-and-sciences 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/12/amgen-and-allergan-submit-biologics-license-application-for-abp-798-biosimilar-candidate-to-rituxan-rituximab-to-us-food-and-drug-administration 2021-02-26 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/12/amgen-announces-10-increase-in-2020-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/12/amgen-announces-data-being-presented-at-ash-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/12/amgen-data-from-phase-3-candor-study-combining-kyprolis-carfilzomib-and-darzalex-daratumumab-to-be-presented-during-latebreaking-session-at-american-society-of-hematology-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/12/amgen-selects-location-for-rd-facility-in-the-south-san-francisco-biotechnology-hub 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/12/european-commission-approves-evenity-romosozumab-for-the-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/12/fda-approves-amgens-avsola-infliximabaxxq-for-the-same-indications-as-remicade-infliximab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/11/amgen-and-the-duke-clinical-research-institute-announce-initiation-of-first-large-scale-registry-to-evaluate-real-world-lipid-management-and-the-effectiveness-of-pcsk9-inhibitors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/11/amgen-announces-new-fourier-analysis-showing-benefit-of-repatha-evolocumab-in-highrisk-patients-who-have-experienced-a-recent-heart-attack 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/11/amgen-completes-acquisition-of-otezla-apremilast 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/11/amgen-highlights-data-to-be-presented-at-aha-2019-across-cardiovascular-portfolio 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/11/amgen-to-present-at-the-28th-annual-credit-suisse-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/11/new-results-from-cosmic-hf-presented-at-aha-2019-show-treatment-of-heart-failure-patients-with-omecamtiv-mecarbil-was-associated-with-neutral-or-improved-measures-of-diastolic-function 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/amgen-announces-2019-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/amgen-announces-webcast-of-2019-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/amgen-enters-into-strategic-collaboration-with-beigene-to-expand-oncology-presence-in-china 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/amgen-foundation-launches-amgen-biotech-experience-in-pittsburgh 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/amgen-recommends-rejection-of-minitender-offer-from-trc-capital-corporation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/amgen-reports-third-quarter-2019-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/amgen-to-make-repatha-evolocumab-available-exclusively-at-its-lower-list-price-option-in-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/david-meline-amgens-chief-financial-officer-to-retire 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/evenity-romosozumab-receives-positive-chmp-opinion-for-the-treatment-of-severe-osteoporosis-in-postmenopausal-women-at-high-risk-of-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/nplate-romiplostim-now-approved-for-earlier-use-in-adults-with-immune-thrombocytopenia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/sports-anchor-and-multiple-myeloma-patient-rod-gilmore-joins-amgens-myeloma-mvp-team 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/10/the-discovery-of-amgens-novel-investigational-krasg12c-inhibitor-amg-510-published-in-nature 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-announces-new-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-in-larger-patient-group-at-wclc-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-announces-new-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-in-patients-with-solid-tumors-at-esmo-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-announces-phase-3-candor-study-combining-kyprolis-carfilzomib-and-darzalex-daratumumab-meets-primary-endpoint-of-progressionfree-survival 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-announces-positive-results-from-two-phase-3-blincyto-blinatumomab-studies-in-pediatric-patients-with-relapsed-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-highlights-new-data-from-kyprolis-carfilzomib-and-oncology-pipeline-at-imw-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-showcases-new-data-from-oncology-pipeline-and-portfolio-at-esmo-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-to-webcast-investor-call-at-esmo-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/amgen-to-webcast-investor-call-at-iaslc-2019-world-conference-on-lung-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/09/heart-attack-survivors-are-taking-steps-to-reduce-their-cardiovascular-risk--but-are-they-the-right-ones 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/08/amgen-and-allergan-announce-positive-topline-results-from-comparative-clinical-study-of-abp-798-biosimilar-candidate-to-rituxan-rituximab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/08/amgen-announces-2019-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/08/amgen-to-acquire-otezla-for-134-billion-in-cash-or-approximately-112-billion-net-of-anticipated-future-cash-tax-benefits 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/08/amgen-wins-patent-case-on-enbrel-etanercept 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/08/new-amgen-data-to-be-presented-at-esc-congress-2019-highlight-additional-evidence-for-repatha-evolocumab-effectiveness-in-cardiovascular-disease-across-multiple-patient-groups 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/07/amgen-and-allergans-mvasi-bevacizumabawwb-and-kanjinti-trastuzumabanns-now-available-in-the-united-states 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/07/amgen-announces-the-outcome-of-the-recommended-public-cash-offer-to-the-shareholders-of-nuevolution-declares-the-offer-unconditional-and-completes-the-offer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/07/amgen-announces-webcast-of-2019-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/07/amgen-controls-98-of-the-shares-in-nuevolution-after-the-end-of-the-extended-acceptance-period 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/07/amgen-novartis-and-banner-alzheimers-institute-discontinue-clinical-research-program-with-bace-inhibitor-cnp520-for-alzheimers-prevention 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/07/amgen-reports-second-quarter-2019-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce-unique-strategic-research-partnership 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-and-ucb-provide-regulatory-update-on-status-of-evenity-romosozumab-in-the-eu 2025-12-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-blincyto-blinatumomab-fiveyear-overall-survival-data-at-eha-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-highlights-the-versatility-of-the-bite-immuno-oncology-platform-in-multiple-tumor-types-at-asco-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-publishes-offer-document-with-respect-to-the-recommended-public-cash-offer-to-the-shareholders-of-nuevolution 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/amgen-to-present-at-the-goldman-sachs-40th-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/fda-approves-amgen-and-allergans-kanjinti-trastuzumabanns-a-biosimilar-to-herceptin-trastuzumab 2022-10-31 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/06/intermountain-healthcare-and-decode-genetics-launch-groundbreaking-dna-study-of-500000-people-to-find-new-links-between-genetics-and-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/additional-irrevocable-undertakings-to-accept-amgens-recommended-public-cash-offer-to-the-shareholders-of-nuevolution 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-and-syapse-enter-precision-medicine-collaboration-in-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-announces-a-recommended-public-cash-offer-to-the-shareholders-of-nuevolution 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-ignites-a-social-fitness-movement-to-support-the-fight-against-heart-disease-and-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-joins-with-community-oncology-networks-for-new-research-collaboration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-sets-official-guinness-world-record-for-most-osteoporosis-screenings-for-an-osteoporosis-campaign-in-24-hours 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-showcases-oncology-pipeline-at-asco-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-to-highlight-extensive-longterm-safety-and-efficacy-data-of-aimovig-erenumabaooe-across-the-spectrum-of-migraine-at-aan-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-to-present-at-the-rbc-healthcare-conference-and-the-ubs-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/05/amgen-to-webcast-investor-meeting-at-55th-annual-meeting-of-the-american-society-of-clinical-oncology-asco 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/04/amgen-announces-webcast-of-2019-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/04/amgen-foundation-launches-amgen-biotech-experience-in-tampa-florida 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/04/amgen-presents-new-data-at-wco-iof-esceo-2019-revealing-osteoporosis-treatment-gap-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/04/amgen-reports-first-quarter-2019-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/04/evenity-romosozumabaqqg-now-available-in-the-united-states-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/04/fda-approves-evenity-romosozumabaqqg-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/03/amgen-and-jay-leno-partner-to-sound-the-alarm-on-high-cholesterol-and-its-link-to-heart-attack-and-stroke-in-patients-most-at-risk 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/03/amgen-announces-2019-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/03/amgen-announces-new-fouryear-outcomes-study-to-examine-longterm-effects-of-repatha-evolocumab-in-highrisk-cardiovascular-disease-cvd-patients-without-prior-heart-attack-or-stroke 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/03/amgen-cytokinetics-and-servier-announce-continuation-of-galactichf-following-planned-interim-analysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/03/amgen-to-present-at-the-cowen-and-company-39th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/03/new-data-from-amgen-to-be-presented-at-acc19-continues-to-build-evidence-for-repatha-evolocumab-across-multiple-patient-populations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/02/amgen-cytokinetics-and-servier-announce-start-of-meteorichf-the-second-phase-3-clinical-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/02/amgen-highlights-progress-of-innovative-early-oncology-pipeline-with-new-data-at-aacr-2019 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/02/jury-upholds-amgens-patents-on-repatha-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/amgen-and-allergan-announce-positive-topline-results-from-phase-1-phase-3-study-of-abp-798-biosimilar-candidate-to-rituximab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/amgen-and-ucb-receive-positive-vote-from-fda-advisory-committee-in-favor-of-approval-for-evenity-romosozumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/amgen-announces-webcast-of-2018-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/amgen-makes-all-repatha-evolocumab-device-options-available-in-the-us-at-a-60-percent-reduced-list-price 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/amgen-receives-nmpa-approval-for-repatha-evolocumab-in-china-to-reduce-the-risk-of-cardiovascular-events 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/amgen-reports-fourth-quarter-and-full-year-2018-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/amgen-to-present-at-the-37th-annual-j-p--morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/european-commission-approves-blincyto-blinatumomab-in-patients-with-philadelphia-chromosome-negative-minimal-residual-diseasepositive-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2019/01/evenity-romosozumab-receives-approval-in-japan-for-the-treatment-of-osteoporosis-in-patients-at-high-risk-of-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-and-direct-relief-partner-to-aid-cancer-patients-in-18-developing-countries 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-and-lazarex-cancer-foundation-team-up-to-allow-more-diversity-in-clinical-trials 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-and-magellan-rx-management-collaborate-to-improve-patient-care-for-chronic-difficulttotreat-conditions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-and-molecular-partners-announce-strategic-collaboration-in-immuno-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-announces-10-percent-increase-in-2019-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-announces-first-in-human-data-evaluating-investigational-novel-bite-immunotherapies-amg-420-and-amg-330-at-ash-2018 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-engages-cambridge-biotech-community-to-select-2018-labcentral-golden-ticket-winners 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-submits-biologics-license-application-for-abp-710-biosimilar-infliximab-to-us-food-and-drug-administration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-submits-supplemental-biologics-license-application-for-nplate-romiplostim 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/amgen-to-present-at-the-citi-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/decode-genetics-an-amgen-subsidiary-and-somalogic-announce-collaboration-to-perform-largescale-protein-analysis-of-up-to-40000-human-samples 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/12/fda-approves-nplate-romiplostim-for-use-in-pediatric-patients-with-immune-thrombocytopenia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-and-provention-bio-announce-co-development-collaboration-in-celiac-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-and-ucb-announce-fda-advisory-committee-meeting-to-review-evenity-romosozumab-for-the-treatment-of-osteoporosis-in-postmenopausal-women-at-high-risk-for-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-announces-presentation-of-research-reinforcing-the-longterm-safety-and-efficacy-of-repatha-evolocumab-in-highrisk-patients-at-aha-scientific-sessions-2018 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-foundation-deepens-commitment-to-aspiring-scientists-worldwide-by-expanding-amgen-scholars-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-foundation-pledges-500000-in-relief-to-victims-of-ventura-and-los-angeles-county-wildfires 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-presents-results-highlighting-the-longterm-safety-and-efficacy-of-repatha-evolocumab-in-the-longest-duration-study-of-a-pcsk9-inhibitor-to-date-at-aha-scientific-sessions-2018 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-receives-chmp-positive-opinion-to-expand-use-of-blincyto-blinatumomab-in-patients-with-minimal-residual-diseasepositive-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-to-present-at-the-piper-jaffray-and-evercore-isi-healthcare-conferences 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-to-present-new-data-showcasing-extensive-portfolio-and-exciting-early-oncology-pipeline-at-ash-2018 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/11/amgen-to-webcast-investor-call-at-ash-2018 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/amgen-announces-2018-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/amgen-announces-new-fourier-analysis-showing-benefit-with-repatha-evolocumab-in-highrisk-patients-with-established-cardiovascular-disease-and-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/amgen-announces-webcast-of-2018-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/amgen-invests-50-million-66-million-in-oxford-nanopore-technologies 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/amgen-launches-amgevita-biosimilar-adalimumab-in-markets-across-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/amgen-makes-repatha-evolocumab-available-in-the-us-at-a-60-percent-reduced-list-price 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/amgen-reports-third-quarter-2018-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/fda-approves-kyprolis-carfilzomib-onceweekly-70-mgm2-in-combination-with-dexamethasone-kd70-for-patients-with-relapsed-or-refractory-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/10/first-headtohead-trial-of-a-tnf-inhibitor-versus-methotrexate-monotherapy-in-psoriatic-arthritis-shows-enbrel-etanercept-monotherapy-and-combination-therapy-both-superior-to-methotrexate 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/09/amgen-and-labcentral-open-nomination-process-for-lab-residency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/09/amgen-and-los-angeles-county-announce-collaboration-to-support-life-science-innovation-hub---biola 2021-02-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/09/blincyto-blinatumomab-approved-in-japan-for-the-treatment-of-relapsed-or-refractory-bcell-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/09/tezepelumab-granted-breakthrough-therapy-designation-by-us-fda-for-the-treatment-of-patients-with-severe-asthma-without-an-eosinophilic-phenotype 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/09/worlds-largest-alzheimers-survey-reveals-most-adults-believe-a-cure-will-be-developed-in-their-lifetime 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/08/amgen-submits-supplemental-new-drug-application-for-kyprolis-carfilzomib-onceweekly-70-mgm2-in-combination-with-dexamethasone 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/08/amgen-to-present-robust-data-exploring-the-impact-of-treatment-with-repatha-evolocumab-across-patient-subgroups-and-highrisk-populations-at-esc-congress-2018 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/08/european-commission-approves-blincyto-blinatumomab-for-use-in-pediatric-patients-with-philadelphia-chromosomenegative-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/amgen-and-cedars-sinai-partner-for-improved-healthcare-quality 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/amgen-and-ucb-resubmit-biologics-license-application-bla-for-evenity-romosozumab-to-the-us-fda 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/amgen-announces-2018-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/amgen-announces-succession-plans-for-two-executive-officers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/amgen-announces-webcast-of-2018-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/amgen-breaks-ground-on-next-generation-biomanufacturing-plant-in-rhode-island 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/amgen-reports-second-quarter-2018-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/07/former-major-league-baseball-mlb-allstars-dave-winfield-and-steve-garvey-team-up-with-amgen-to-launch-myeloma-mvp-and-encourage-patients-to-create-their-most-valuable-plan-for-managing-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-and-health-and-benefits-consultant-piper-jordan-partner-on-first-migraine-project-with-employers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-and-mbc-biolabs-announce-winners-of-the-amgen-golden-ticket 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-and-novartis-highlight-findings-from-a-large-global-patient-survey-revealing-that-worldwide-approximately-60-percent-of-employed-people-with-migraine-missed-on-average-a-week-of-work-in-a-month 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-and-novartis-present-new-data-demonstrating-longterm-efficacy-safety-and-tolerability-of-aimovig-erenumabaooe-in-patients-with-chronic-and-episodic-migraine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-announces-topline-results-from-phase-3-study-of-abp-710-biosimilar-candidate-to-infliximab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-oklahoma-health-care-authority-and-university-of-oklahomas-pharmacy-management-consultants-partner-to-improve-medicaid-outcomes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-receives-european-commission-approval-to-add-overall-survival-data-to-blincyto-blinatumomab-label 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/amgen-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/european-commission-approves-prolia-denosumab-for-patients-with-glucocorticoidinduced-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/fda-approves-addition-of-positive-overall-survival-data-from-phase-3-aspire-trial-to-kyprolis-carfilzomib-label 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/new-data-show-amgens-repatha-evolocumab-significantly-reduced-ldlc-and-nonhdlc-in-highrisk-patients-with-type-2-diabetes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/phase-3-arrow-interim-analysis-shows-onceweekly-70-mgm2-kyprolis-carfilzomib-regimen-significantly-extended-progressionfree-survival-versus-a-twiceweekly-27-mgm2-regimen-in-patients-with-relapsed-and-refractory-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/06/preventing-infections-in-cancer-patients-program-to-launch-innovative-tools-to-improve-patient-provider-conversations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/amgen-and-md-anderson-announce-collaboration-to-accelerate-early-stage-treatments-for-leukemia-myelodysplastic-syndromes-multiple-myeloma-smallcell-lung-and-other-smallcell-cancers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/amgen-enters-groundbreaking-collaboration-to-improve-symptom-management-during-cancer-treatment 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/amgen-foundation-and-harvard-team-up-to-offer-free-online-science-education-platform 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/amgen-receives-european-commission-approval-for-repatha-evolocumab-to-prevent-heart-attack-and-stroke-in-adults-with-established-cardiovascular-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-2018-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/fda-approves-aimovig-erenumabaooe-a-novel-treatment-developed-specifically-for-migraine-prevention 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/05/fda-approves-prolia-denosumab-for-glucocorticoidinduced-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/amgen-announces-rhode-island-will-be-location-of-first-us-next-generation-biomanufacturing-plant 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/amgen-announces-webcast-of-2018-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/amgen-presents-firstofitskind-data-at-aan-annual-meeting-reinforcing-robust-and-consistent-efficacy-of-aimovig-erenumab-for-migraine-patients-with-multiple-treatment-failures 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/amgen-receives-positive-chmp-opinion-to-add-overall-survival-results-from-the-phase-3-aspire-study-to-kyprolis-carfilzomib-label 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/amgen-receives-positive-chmp-opinion-to-expand-use-of-prolia-denosumab-to-patients-with-glucocorticoidinduced-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/amgen-reports-first-quarter-2018-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/amgen-to-present-new-pre-clinical-data-showcasing-robust-approach-to-evaluating-potential-anti-cancer-therapies-at-aacr-2018 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/04/european-commission-approves-expanded-indication-for-amgens-xgeva-denosumab-for-the-prevention-of-skeletalrelated-events-in-patients-with-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-980-biosimilar-herceptin-for-the-treatment-of-three-types-of-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/amgen-announces-2018-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/amgen-announces-final-results-of-tender-offer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/amgen-announces-preliminary-results-of-tender-offer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/amgen-receives-positive-chmp-opinion-recognizing-that-repatha-evolocumab-prevents-heart-attacks-and-strokes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/amgen-to-present-at-the-cowen-and-company-38th-annual-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/fda-approves-blincyto-blinatumomab-to-treat-minimal-residual-diseasepositive-bcell-precursor-acute-lymphoblastic-leukemia-in-adults-and-children 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/03/new-analyses-show-payer-utilization-management-criteria-deny-access-to-pcsk9-inhibitors-for-patients-at-the-highest-risk-for-subsequent-cardiovascular-events 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/amgen-announces-fda-advisory-committee-meeting-to-review-potential-new-use-of-blincyto-blinatumomab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/amgen-ceo-robert-a--bradway-becomes-phrma-board-chairman 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/amgen-receives-positive-chmp-opinion-for-delivery-system-of-neulasta-pegfilgrastim 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/amgen-receives-positive-opinion-expanding-use-of-xgeva-denosumab-to-cover-prevention-of-skeletalrelated-events-in-patients-with-multiple-myeloma-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/amgen-reports-fourth-quarter-and-full-year-2017-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/amgen-to-present-at-the-7th-annual-leerink-partners-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/amgen-to-present-new-data-from-repatha-evolocumab-clinical-trials-at-acc18 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/02/results-from-phase-3-xgeva-denosumab-study-in-patients-with-multiple-myeloma-published-in-the-lancet-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/amgen-announces-webcast-of-2017-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/amgen-receives-chmp-positive-opinion-to-add-updated-overall-survival-data-to-kyprolis-carfilzomib-label 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/amgen-reports-aimovig-erenumab-met-all-primary-and-secondary-endpoints-in-unique-phase-3b-study-in-episodic-migraine-patients-who-have-failed-multiple-prior-preventive-treatments 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/amgen-to-present-at-the-36th-annual-j-p--morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/european-commission-approves-amgen-and-allergans-mvasi-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/european-medicines-agency-accepts-filing-for-evenity-romosozumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/fda-approves-addition-of-overall-survival-data-to-kyprolis-carfilzomib-label 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/fda-approves-xgeva-denosumab-for-the-prevention-of-skeletalrelated-events-in-patients-with-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2018/01/overall-survival-analysis-from-kyprolis-carfilzomib-phase-3-aspire-trial-published-in-the-journal-of-clinical-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/12/amgen-announces-15-percent-increase-in-2018-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/12/amgen-foundation-pledges-up-to-500000-in-relief-to-victims-of-the-southern-california-wildfires 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/12/amgen-teams-up-with-cambridge-biotech-community-to-select-two-startups-to-receive-golden-tickets-at-labcentral 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/12/amgen-to-webcast-investor-call-at-ash-2017 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/12/fda-approves-amgens-repatha-evolocumab-to-prevent-heart-attack-and-stroke 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/12/kyprolis-carfilzomib-extended-overall-survival-in-patients-with-relapsed-or-refractory-multiple-myeloma-in-phase-3-aspire-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/12/new-data-to-be-presented-at-ash-2017-underscore-amgens-commitment-to-improving-lives-and-changing-outcomes-for-patients-with-difficulttotreat-blood-cancers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/aimovig-erenumab-phase-3-strive-data-published-in-the-new-england-journal-of-medicine-demonstrate-significant-sustained-efficacy-in-migraine-prevention 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-215-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/amgen-and-novartis-announce-expanded-collaboration-with-banner-alzheimers-institute-in-pioneering-prevention-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/amgen-announces-new-analyses-of-highrisk-patient-subgroups-from-repatha-evolocumab-cardiovascular-outcomes-study-at-aha-scientific-sessions-2017 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector-that-is-ergonomically-designed-for-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/amgen-receives-positive-chmp-opinion-to-expand-use-of-nplate-romiplostim-in-pediatric-patients-with-chronic-immune-thrombocytopenic-purpura 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/amgen-to-present-at-the-evercore-isi-2017-biopharma-catalystdeep-dive-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/11/new-analyses-presented-at-aha-2017-show-repatha-evolocumab-significantly-reduced-cardiovascular-events-in-patients-with-peripheral-artery-disease-and-in-patients-with-a-history-of-heart-attacks 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-and-boston-childrens-hospital-enter-a-collaboration-to-find-new-genes-and-drug-targets-for-severe-pain-syndromes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-and-cytomx-therapeutics-announce-strategic-collaboration-in-immuno-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-and-labcentral-open-nomination-process-for-lab-residency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-announces-2017-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-announces-appointment-of-wanda-m--austin-to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-announces-webcast-of-2017-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-foundation-awards-khan-academy-$3-million-to-support-development-of-free-comprehensive-biology-lessons 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/amgen-reports-third-quarter-2017-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/awardwinning-journalist-and-cancer-survivor-joan-lunden-partners-with-amgen-to-launch-at-home-with-joan-to-empower-patients-battling-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/fda-accepts-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocorticoidinduced-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/first-randomized-study-to-evaluate-imlygic-talimogene-laherparepvec-an-oncolytic-viral-therapy-in-combination-with-a-checkpoint-inhibitor-published-in-the-journal-of-clinical-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/kirin-amgen-joint-venture-to-become-wholly-owned-subsidiary-of-amgen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/10/phase-3-arrow-study-of-onceweekly-kyprolis-carfilzomib-regimen-meets-primary-endpoint-of-progressionfree-survival-in-relapsed-and-refractory-multiple-myeloma-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-and-abbvie-agree-to-settlement-allowing-commercialization-of-amgevita 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-and-allergan-present-phase-3-data-on-biosimilar-trastuzumab-candidate-abp-980-at-the-european-society-for-medical-oncology-2017-congress 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-and-simcere-announce-strategic-collaboration-to-co-develop-and-commercialize-biosimilars-in-china 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-foundation-pledges-up-to-$5-million-to-hurricane-maria-relief-efforts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-highlights-the-latest-evenity-romosozumab-and-prolia-denosumab-research-at-the-american-society-for-bone-and-mineral-research-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-provides-update-on-hurricane-maria 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/evenity-romosozumab-arch-study-results-published-in-the-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/fda-approves-amgen-and-allergans-mvasi-bevacizumabawwb-for-the-treatment-of-five-types-of-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/new-data-demonstrate-aimovig-erenumab-reduced-monthly-migraine-days-in-patients-who-failed-previous-preventive-therapies 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/new-fourier-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-with-diabetes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/09/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/amgen-and-humana-partner-for-improved-health-outcomes-and-efficiency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/amgen-foundation-expands-the-amgen-biotech-experience-bringing-total-program-reach-to-900000-high-school-students-by-2020 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/amgen-to-present-new-data-from-the-repatha-evolocumab-cardiovascular-outcomes-study-at-esc-congress-2017 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/european-commission-approves-expanded-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-children-with-endstage-renal-disease-on-dialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/fda-accepts-amgens-filing-of-a-supplemental-new-drug-application-to-add-overall-survival-results-to-kyprolis-carfilzomib-label 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/longterm-analysis-of-phase-3-headtohead-study-confirms-kyprolis-carfilzomib-regimen-extends-overall-survival-in-patients-with-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/new-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-with-history-of-stroke 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/new-economic-analysis-based-on-repatha-evolocumab-outcomes-data-published-in-jama-cardiology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/new-repatha-evolocumab-analysis-demonstrates-cardiovascular-outcomes-efficacy-and-safety-of-achieving-very-low-ldlc-levels 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/new-virtual-histology-substudy-evaluates-impact-of-repatha-evolocumab-on-coronary-artery-plaque-composition 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/overall-survival-analysis-from-kyprolis-carfilzomib-phase-3-endeavor-trial-published-in-the-lancet-oncology 2021-02-03 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/08/repatha-evolocumab-phase-3-cognitive-function-study-results-published-in-the-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-980-to-us-food-and-drug-administration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-and-allergan-to-discuss-data-supporting-biologics-license-application-for-abp-215-a-biosimilar-candidate-to-avastin-bevacizumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-and-array-biopharma-announce-preclinical-license-and-collaboration-agreement-in-inflammation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-and-qb3953-announce-winners-of-the-amgen-golden-ticket 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-and-ucb-provide-update-on-regulatory-status-of-evenity-romosozumab-in-the-us 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-announces-2017-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-announces-webcast-of-2017-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-reports-second-quarter-2017-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-submits-regulatory-applications-in-us-and-europe-to-include-overall-survival-data-in-kyprolis-carfilzomib-label 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/amgen-submits-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocorticoidinduced-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/fda-accepts-biologics-license-application-for-aimovig-erenumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/fda-grants-full-approval-for-blincyto-blinatumomab-to-treat-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia-in-adults-and-children 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/fda-grants-priority-review-for-amgens-supplemental-biologics-license-application-for-repatha-evolocumab-to-include-data-on-reducing-risk-of-cardiovascular-events 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/07/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-and-allergan-announce-fda-advisory-committee-meeting-to-review-abp-215-a-biosimilar-candidate-to-bevacizumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-presents-erenumab-data-at-the-59th-annual-scientific-meeting-of-the-american-headache-society 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-patients-with-multiple-myeloma-at-asco-2017 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-presents-new-phase-2-data-on-imlygic-talimogene-laherparepvec-investigational-combination-at-asco-2017 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-receives-positive-chmp-opinion-to-expand-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-certain-children-with-endstage-renal-disease-on-dialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-showcases-a-legacy-of-science-innovation-and-collaboration-in-cambridge 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-submits-regulatory-applications-for-repatha-evolocumab-cardiovascular-outcomes-data-in-us-and-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/amgen-to-present-new-data-at-22nd-congress-of-the-european-hematology-association 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/fda-accepts-amgens-supplemental-biologics-license-application-to-expand-indication-for-xgeva-denosumab-to-include-multiple-myeloma-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/06/fda-approves-vectibix-panitumumab-for-use-in-wildtype-ras-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/05/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomesbased-refund-contract-for-repatha-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/05/amgen-and-ucb-announce-topline-phase-3-data-from-activecomparator-study-of-evenity-romosozumab-in-postmenopausal-women-with-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/05/amgen-highlights-data-to-be-presented-at-asco-2017-across-oncology-portfolio 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/05/amgen-submits-biologics-license-application-to-the-fda-for-erenumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-2017-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/05/repatha-evolocumab-reduced-cardiovascular-events-in-patients-with-baseline-ldlc-levels-below-current-targets 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/04/amgen-and-ucb-report-new-data-at-endo-2017-examining-the-option-of-a-second-course-of-treatment-with-evenity-romosozumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/04/amgen-announces-expanded-commercial-collaboration-with-novartis-for-erenumab-in-migraine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/04/amgen-announces-webcast-of-2017-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/04/amgen-launches-neulasta-pegfilgrastim-onpro-narratives 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/04/amgen-reports-first-quarter-2017-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/04/amgen-submits-applications-in-the-us-and-europe-to-expand-current-indication-for-xgeva-denosumab-to-include-patients-with-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/04/amgen-to-participate-in-the-2017-world-medical-innovation-forum-focused-on-cardiovascular-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-announces-2017-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-awards-three-golden-tickets-for-labcentral-residency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-highlights-landmark-repatha-evolocumab-cardiovascular-outcomes-study-amongst-data-to-be-presented-at-acc17 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-multiple-myeloma-patients-at-the-16th-international-myeloma-workshop 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-presents-overall-survival-data-from-kyprolis-carfilzomib-phase-3-endeavor-trial-at-16th-international-myeloma-workshop 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-to-highlight-new-preclinical-data-at-the-american-association-for-cancer-research-aacr-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-to-present-at-the-cowen-and-company-37th-annual-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-to-present-at-the-oppenheimer-global-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-to-present-new-kyprolis-carfilzomib-and-xgeva-denosumab-data-at-the-16th-international-myeloma-workshop 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiology-scientific-sessions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/analyses-of-pcsk9-inhibitor-prescription-rejection-rates-demonstrate-significant-access-barriers-for-appropriate-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/blincyto-blinatumomab-significantly-improved-overall-survival-in-patients-with-bcell-precursor-acute-lymphoblastic-leukemia-compared-to-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/fda-grants-priority-review-for-amgens-blincyto-blinatumomab-supplemental-biologics-license-application 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/journal-of-clinical-oncology-publishes-data-on-blincyto-blinatumomab-in-highrisk-patients-with-philadelphia-chromosomepositive-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/landmark-outcomes-study-shows-that-repatha-evolocumab-decreases-ldlc-to-unprecedented-low-levels-and-reduces-risk-of-cardiovascular-events-with-no-new-safety-issues 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/lowering-ldl-levels-with-repatha-evolocumab-did-not-adversely-affect-cognitive-function-in-landmark-phase-3-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/repatha-evolocumab-demonstrates-reduced-need-for-apheresis-in-patients-with-high-ldl-cholesterol-in-phase-3-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/03/repatha-evolocumab-fouryear-openlabel-followup-study-published-in-jama-cardiology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/02/amgen-announces-appointment-of-charles-m--holley-jr--to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/02/amgen-announces-repatha-evolocumab-significantly-reduced-the-risk-of-cardiovascular-events-in-fourier-outcomes-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/02/amgen-reports-fourth-quarter-and-full-year-2016-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/02/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab-in-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/02/fda-approves-amgens-parsabiv-etelcalcetide-first-new-treatment-in-more-than-a-decade-for-secondary-hyperparathyroidism-in-adult-patients-on-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/02/phase-3-headtohead-trial-showed-kyprolis-carfilzomib-significantly-improved-overall-survival-compared-to-velcade-bortezomib-in-relapsed-or-refractory-multiple-myeloma-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/02/repatha-evolocumab-receives-european-commission-approval-for-new-420-mg-singledose-delivery-option 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/amgen-and-davita-enter-into-new-sourcing-and-supply-agreement 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/amgen-and-immatics-enter-strategic-collaboration-to-develop-novel-bispecific-cancer-immunotherapies 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/amgen-announces-webcast-of-2016-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/amgen-receives-positive-chmp-opinion-for-abp-501-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/amgen-statement-on-january-9-2017-us-district-court-decision 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/amgen-to-present-at-the-35th-annual-j-p--morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/court-grants-permanent-injunction-for-infringement-of-amgens-repatha-patents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2017/01/study-results-published-in-the-journal-of-the-american-medical-association-show-amgens-parsabiv-etelcalcetide-significantly-reduced-serum-parathyroid-hormone-in-adults-with-secondary-hyperparathyroidism-on-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/12/amgen-and-allergan-submit-biosimilar-marketing-authorization-application-to-european-medicines-agency-for-abp-215-a-biosimilar-candidate-to-bevacizumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/12/amgen-and-ucb-announce-submission-of-application-for-investigational-osteoporosis-medication-romosozumab-in-japan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/12/amgen-announces-15-percent-increase-in-2017-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/12/amgen-announces-launch-of-blood-counts-and-collaboration-with-storycorps-to-record-and-share-stories-of-those-impacted-by-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/12/amgen-to-present-at-the-citi-2016-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/12/new-repatha-evolocumab-dose-delivery-option-receives-positive-chmp-opinion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-215-to-u-s--food-and-drug-administration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/amgen-announces-collaboration-with-janssen-to-cofund-studies-with-kyprolis-carfilzomib-and-darzalex-daratumumab-in-patients-with-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-episodic-migraine-in-second-phase-3-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/amgen-announces-presentation-of-new-data-in-acute-lymphoblastic-leukemia-multiple-myeloma-and-immune-thrombocytopenia-at-ash-2016 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/amgen-appoints-lori-johnston-as-senior-vice-president-human-resources 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/amgen-to-present-at-the-credit-suisse-25th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessions-2016 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/data-to-be-presented-at-acrarhp-2016-annual-meeting-show-amgens-ongoing-commitment-to-therapies-for-patients-with-serious-inflammatory-and-bone-diseases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adults-on-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/fda-approves-expanded-use-of-enbrel-etanercept-to-treat-children-with-chronic-moderatetosevere-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/new-ten-to-watch-list-highlights-top-amgen-scholars-poised-to-impact-the-future-of-science-and-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/repatha-evolocumab-regresses-atherosclerosis-in-patients-with-coronary-artery-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/results-from-phase-3-bridge-study-show-romosozumab-significantly-increases-bone-mineral-density-in-men-with-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/11/the-lancet-publishes-results-from-cosmic-hf-trial-showing-omecamtiv-mecarbil-significantly-improved-cardiac-function-in-patients-with-chronic-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-announces-2016-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-announces-appointment-of-ellen-j--kullman-to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-announces-positive-topline-results-from-xgeva-denosumab-phase-3-trial-for-delay-of-bone-complications-in-multiple-myeloma-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-announces-webcast-of-2016-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-highlights-repatha-evolocumab-glagov-imaging-study-amongst-data-to-be-presented-at-aha-scientific-sessions-2016 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-reports-third-quarter-2016-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-to-invest-in-israel-based-ehealth-ventures 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/amgen-to-participate-in-citi-biotech-rd-conference-call 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/new-amgen-data-in-melanoma-and-metastatic-colorectal-cancer-to-be-presented-at-the-european-society-for-medical-oncology-2016-congress 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/10/new-retrospective-analyses-confirm-vectibix-panitumumab-treatment-provided-survival-benefit-over-chemotherapy-with-or-without-bevacizumab-in-metastatic-colorectal-cancer-patients-with-tumors-of-leftsided-origin 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-and-arrowhead-pharmaceuticals-announce-two-cardiovascular-collaborations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-and-servier-extend-omecamtiv-mecarbil-collaboration-in-chronic-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-and-ucb-announce-u-s--fda-acceptance-of-biologics-license-application-for-romosozumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-episodic-migraine-in-first-phase-3-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-announces-positive-topline-results-from-phase-3-glagov-imaging-study-of-repatha-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-announces-topline-results-from-phase-3-kyprolis-carfilzomib-clarion-study-in-newly-diagnosed-multiple-myeloma-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-obtains-global-development-and-commercial-rights-from-boehringer-ingelheim-for-investigational-bite-immuno-oncology-drug-for-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-opens-nomination-process-for-labcentral-residency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-presents-positive-data-at-ehmtic-2016-demonstrating-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-chronic-migraine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-receives-positive-chmp-opinion-for-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adult-patients-with-chronic-kidney-disease-on-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-to-highlight-19-abstracts-on-osteoporosis-disease-state-and-treatment-at-american-society-for-bone-and-mineral-research-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/amgen-to-webcast-investor-call 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/fda-approves-amgens-amjevita-adalimumabatto-for-treatment-of-seven-inflammatory-diseases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/fda-approves-blincyto-blinatumomab-for-use-in-pediatric-patients-with-philadelphia-chromosomenegative-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/09/results-from-phase-3-frame-study-of-romosozumab-showed-significant-reductions-in-both-new-vertebral-and-clinical-fractures-in-postmenopausal-women-with-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/08/amgen-and-advaxis-enter-global-cancer-immunotherapies-collaboration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/08/amgen-announces-positive-topline-results-from-phase-3-study-of-prolia-denosumab-in-patients-receiving-glucocorticoid-therapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/08/amgen-provides-update-on-status-of-parsabiv-etelcalcetide-new-drug-application-nda-submitted-to-the-us-food-and-drug-administration-fda 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/08/new-data-add-to-understanding-of-repatha-evolocumab-in-multiple-patient-populations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/08/new-repatha-evolocumab-analyses-show-efficacy-and-safety-across-risk-groups-in-results-presented-at-esc-congress-2016 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-and-allergan-announce-top-line-results-from-phase-3-study-evaluating-abp-980-compared-with-trastuzumab-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-early-breast-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-and-daiichi-sankyo-announce-agreement-to-commercialize-biosimilars-in-japan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-and-ucb-submit-biologics-license-application-for-romosozumab-to-the-fda 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-announces-2016-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-announces-settlement-of-securities-litigation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-announces-webcast-of-2016-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-reports-second-quarter-2016-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/amgen-to-discuss-data-supporting-biologics-license-application-for-abp-501-a-biosimilar-candidate-to-adalimumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/european-commission-approves-extended-indication-for-amgens-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/07/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/amgen-announces-erenumab-amg-334-significantly-reduces-patients-monthly-migraine-days-in-phase-2-study-for-the-prevention-of-chronic-migraine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/amgen-announces-expiration-and-final-results-of-senior-notes-exchange-offers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/amgen-announces-fda-advisory-committee-meeting-to-review-abp-501-a-biosimilar-candidate-to-adalimumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/amgen-announces-launch-of-kyprolis-carfilzomib-central-an-online-news-resource-demonstrating-the-impact-of-relapsed-multiple-myeloma-on-the-lives-of-patients-and-caregivers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/amgen-appoints-esteban-santos-executive-vice-president-operations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/amgen-sponsors-qb3953-incubator-for-life-science-startups 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/amgen-to-present-at-the-goldman-sachs-37th-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/blincyto-blinatumomab-improved-overall-survival-in-patients-with-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/new-analyses-from-pivotal-phase-3-studies-show-kyprolis-carfilzomib-allows-patients-with-relapsed-multiple-myeloma-to-live-longer-without-disease-progression 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/new-national-survey-sheds-light-on-how-to-better-engage-students-in-science-education 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/06/new-phase-3-secondary-analysis-shows-progressionfree-survival-benefit-in-early-relapsing-multiple-myeloma-patients-treated-with-kyprolis-carfilzomibbased-regimen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-announces-early-tender-results-of-senior-notes-exchange-offers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-announces-pricing-terms-of-senior-notes-exchange-offers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-commences-exchange-offers-for-certain-series-of-outstanding-senior-notes-from-exchange-eligible-holders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-data-to-be-presented-at-asco-2016-demonstrates-more-insights-into-treatment-options-for-patients 2022-09-16 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-highlights-data-to-be-presented-at-21st-congress-of-the-european-hematology-association 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-receives-positive-chmp-opinion-to-extend-indication-of-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgens-breakaway-from-cancer-public-service-announcement-delivers-message-that-education-resources-and-hope-are-essential-in-the-fight-against-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/fda-grants-priority-review-for-amgens-supplemental-biologics-license-application-for-blincyto-blinatumomab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/hall-of-fame-quarterback-joe-montana-and-amgen-team-up-to-launch-breakaway-from-heart-disease-to-make-heart-health-a-priority 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/kyprolis-carfilzomib-demonstrates-economic-value-in-relapsed-or-refractory-multiple-myeloma-manuscript-published-in-journal-of-medical-economics 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/landmark-decode-genetics-study-points-to-a-new-mechanism-that-affects-cholesterol-levels-and-the-risk-of-heart-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/05/platelet-biogenesis-wins-amgen-golden-ticket-for-labcentral 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/04/amgen-and-ucb-present-positive-data-at-endo-2016-comparing-romosozumab-with-teriparatide 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/04/amgen-announces-webcast-of-2016-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/04/amgens-first-quarter-2016-revenues-increased-10-percent-to-55-billion-and-adjusted-earnings-per-share-eps-increased-17-percent-to-290 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/04/amgen-to-participate-in-the-2016-world-medical-innovation-forum-on-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/04/nplate-romiplostim-study-in-the-lancet-shows-significant-increase-in-durable-platelet-response-among-children-with-immune-thrombocytopenia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/04/positive-efficacy-and-tolerability-study-of-repatha-evolocumab-in-statinintolerant-patients-published-in-journal-of-the-american-medical-association 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/03/amgen-and-ucb-announce-positive-top-line-results-from-phase-3-study-evaluating-romosozumab-in-men-with-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/03/amgen-announces-2016-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/03/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/03/amgen-to-present-at-the-cowen-and-company-36th-annual-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/03/amgen-to-present-repatha-evolocumab-data-at-acc16 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/03/amgen-wins-patent-case-on-repatha-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/03/fda-accepts-amgens-supplemental-biologics-license-application-for-the-expanded-use-of-enbrel-etanercept-to-treat-pediatric-patients-with-chronic-severe-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/02/amgen-and-ucb-announce-positive-top-line-results-from-the-phase-3-study-of-romosozumab-in-postmenopausal-women-with-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/02/amgen-announces-positive-topline-results-from-phase-3-gauss3-trial-of-repatha-evolocumab-in-statinintolerant-patients-with-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/02/amgen-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/02/phase-3-study-demonstrates-aranesp-darbepoetin-alfa-reduces-red-blood-cell-transfusions-in-patients-with-myelodysplastic-syndrome-mds 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/02/phase-3-study-of-blincyto-blinatumomab-met-primary-endpoint-of-overall-survival-in-patients-with-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/01/amgen-announces-webcast-of-2015-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/01/amgens-2015-revenues-increased-8-percent-to-217-billion-and-adjusted-earnings-per-share-eps-increased-19-percent-to-1038 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/01/amgens-repatha-evolocumab-approved-as-first-pcsk9-inhibitor-in-japan-for-the-treatment-of-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/01/amgen-to-present-at-the-34th-annual-j-p--morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/01/fda-accepts-amgens-biosimilar-biologics-license-application-for-abp-501 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/01/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2016/01/vectibix-panitumumab-and-best-supportive-care-improves-overall-survival-compared-to-best-supportive-care-in-chemorefractory-kras-and-ras-wildtype-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/amgen-and-merck-announce-cancer-immunotherapy-collaboration-for-patients-with-non-hodgkin-lymphoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/amgen-announces-27-percent-increase-in-2016-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/amgen-presents-data-from-three-trials-evaluating-blincyto-blinatumomab-in-acute-lymphoblastic-leukemia-at-ash-2015 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/amgen-reacquires-all-product-rights-to-prolia-denosumab-xgeva-denosumab-and-vectibix-panitumumab-from-gsk-in-48-countries 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/amgens-first-biosimilar-marketing-authorization-application-submitted-to-european-medicines-agency-for-abp-501 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/amgen-submits-application-in-europe-to-expand-indication-of-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/european-commission-approves-amgens-imlygic-talimogene-laherparepvec-as-first-oncolytic-immunotherapy-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/new-analyses-presented-at-ash-2015-demonstrate-the-potential-of-kyprolis-carfilzomib-as-backbone-therapy-in-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/12/pivotal-headtohead-endeavor-study-results-published-in-the-lancet-oncology-demonstrate-superiority-of-kyprolis-carfilzomib-combination-over-velcade-bortezomib-combination 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-and-cytokinetics-announce-late-breaking-presentation-of-cosmic-hf-trial-at-aha-scientific-sessions-2015 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-announces-repatha-preferred-position-on-cvs-health-commercial-formularies 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-highlights-data-to-be-presented-at-2015-american-college-of-rheumatology-and-association-for-rheumatology-health-professionals-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-presents-detailed-data-comparing-etelcalcetide-with-cinacalcet-in-patients-with-secondary-hyperparathyroidism-receiving-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-presents-detailed-results-from-phase-3-study-demonstrating-clinical-equivalence-of-biosimilar-candidate-abp-501-with-adalimumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgens-first-biosimilar-biologics-license-application-for-abp-501-submitted-to-us-food-and-drug-administration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-to-highlight-cardiovascular-portfolio-at-american-heart-association-scientific-sessions-2015 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-to-present-at-the-credit-suisse-24th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/amgen-to-present-imlygic-talimogene-laherparepvec-data-at-the-2015-international-congress-of-the-society-for-melanoma-research 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/european-commission-approves-amgens-blincyto-blinatumomab-for-the-treatment-of-adults-with-philadelphia-chromosomenegative-relapsed-or-refractory-bprecursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/european-commission-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/fda-accepts-amgens-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/11/key-data-for-amgen-medicines-in-relapsed-multiple-myeloma-and-acute-lymphoblastic-leukemia-to-be-presented-at-ash-2015 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-and-cytokinetics-announce-positive-topline-results-from-cosmichf-a--phase-2-trial-of-omecamtiv-mecarbil-in-patients-with-chronic-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-and-labcentral-announce-2015-golden-ticket-winners 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-announces-2015-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-announces-repatha-co-preferred-position-on-express-scripts-national-formulary 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-announces-webcast-of-2015-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-foundation-announces-new-$4-million-commitment-to-bring-hands-on-biotechnology-labs-to-secondary-school-students 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-receives-chmp-positive-opinion-for-imlygic-talimogene-laherparepvec 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgens-third-quarter-2015-revenues-increased-14-percent-to-57-billion-and-adjusted-earnings-per-share-eps-increased-18-percent-to-272 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-to-give-23-presentations-on-osteoporosis-disease-and-treatment-at-american-society-for-bone-and-mineral-research-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/amgen-to-present-at-the-barclays-biosimilars-symposium 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/new-data-show-consistent-safety-profile-for-up-to-10-years-with-prolia-denosumab-in-postmenopausal-women-with-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/new-data-show-greater-bone-mineral-density-gains-with-prolia-denosumab-compared-with-zoledronic-acid 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/10/new-exploratory-analysis-showed-romosozumab-increased-estimated-bone-strength-more-than-teriparatide 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-and-allergan-announce-positive-top-line-results-from-phase-3-study-of-biosimilar-candidate-abp-215 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-and-ucb-announce-positive-top-line-results-from-open-label-phase-3-study-of-romosozumab-compared-with-teriparatide 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-and-xencor-announce-strategic-collaboration-in-cancer-immunotherapy-and-inflammation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-enters-into-neuroscience-collaboration-with-novartis-for-alzheimers-disease-and-migraine-programs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-highlights-key-clinical-data-to-be-presented-at-european-cancer-congress-2015 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-receives-chmp-positive-opinions-for-two-new-treatment-options-for-patients-with-blood-cancer-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-submits-application-to-fda-for-new-delivery-option-for-monthly-administration-of-repatha-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-submits-marketing-authorization-application-for-novel-intravenous-calcimimetic-etelcalcetide-amg-416-to-the-european-medicines-agency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-to-acquire-privately-held-dezima-pharma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/amgen-to-present-new-kyprolis-carfilzomib-data-at-15th-international-myeloma-workshop 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/09/fda-grants-priority-review-for-amgens-supplemental-new-drug-application-for-expanded-labeling-of-kyprolis-carfilzomib-in-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/08/amgen-and-university-of-california-berkeley-announce-multiyear-partnership-to-assist-cancer-patient-advocacy-organizations-in-measuring-effectiveness-of-programs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/08/amgen-submits-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide-amg-416 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/08/amgen-to-present-new-longterm-repatha-evolocumab-data-analysis-at-esc-congress-2015 2022-04-14 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/08/fda-approves-amgens-new-cholesterollowering-medication-repatha-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/amgen-announces-2015-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/amgen-announces-appointment-of-fred-hassan-to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/amgen-announces-positive-blincyto-blinatumomab-phase-2-study-results-in-patients-with-relapsedrefractory-philadelphia-chromosomepositive-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/amgen-announces-webcast-of-2015-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/amgens-second-quarter-2015-revenues-increased-4-percent-to-54-billion-and-adjusted-earnings-per-share-eps-increased-8-percent-to-257 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/amgen-submits-supplemental-new-drug-application-for-kyprolis-carfilzomib-in-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/european-commission-approves-amgens-new-cholesterollowering-medication-repatha-evolocumab-the-first-pcsk9-inhibitor-to-be-approved-in-the-world-for-treatment-of-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/07/fda-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/06/amgen-announces-collaboration-with-roche-on-cancer-immunotherapy-study-with-investigational-medicines-talimogene-laherparepvec-and-atezolizumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/06/amgen-completes-enrollment-in-large-cardiovascular-outcomes-trial-of-repatha-evolocumab-in-patients-with-high-cholesterol-and-clinically-evident-cardiovascular-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/06/amgen-presents-open-label-extension-data-from-ongoing-phase-2-study-of-amg-334-in-the-prevention-of-episodic-migraine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/06/amgen-presents-phase-3-data-at-asco-showing-prolia-denosumab-significantly-reduced-bone-fractures-in-breast-cancer-patients-receiving-aromatase-inhibitors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/06/amgen-to-discuss-details-of-repatha-evolocumab-biologics-license-application-for-the-treatment-of-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/06/results-from-phase-3-trial-show-vectibix-panitumumab-improves-overall-survival-in-chemorefractory-wildtype-kras-metastatic-colorectal-cancer-versus-best-supportive-care 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-and-merck-announce-expansion-of-collaboration-to-support-studies-of-talimogene-laherparepvec-in-combination-with-keytruda-pembrolizumab-in-patients-with-head-and-neck-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-appoints-jonathan-p-graham-senior-vice-president-general-counsel-and-secretary 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-data-at-asco-2015-highlight-oncology-pipeline-and-portfolio 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-initiates-phase-3-study-evaluating-onceweekly-kyprolis-carfilzomib-in-patients-with-relapsed-and-refractory-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-launches-program-to-further-advance-basic-biology-research 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-presents-first-phase-2-data-for-amg-334-in-the-prevention-of-episodic-migraine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-presents-pooled-phase-3-amg-416-data-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-receives-positive-chmp-opinion-for-use-of-repatha-evolocumab-for-the-treatment-of-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgens-breakaway-from-cancer-announces-winners-of-its-nationwide-search-for-champions-in-the-fight-against-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-to-advance-understanding-of-the-treatment-of-blood-cancers-at-20th-congress-of-european-hematology-association-eha 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-to-present-amg-334-data-at-17th-congress-of-the-international-headache-society 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-to-present-at-the-deutsche-bank-40th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-to-present-at-the-jefferies-2015-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/amgen-to-terminate-participation-in-co-development-and-commercialization-of-brodalumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/05/pivotal-study-results-published-in-journal-of-clinical-oncology-showed-talimogene-laherparepvec-improved-durable-response-rates-in-patients-with-metastatic-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/04/amgen-announces-fda-advisory-committee-meeting-to-review--repatha-evolocumab-as-a-treatment-for-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/04/amgen-announces-webcast-of-2015-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/04/amgens-first-quarter-2015-revenues-increased-11-percent-to-50-billion-and-adjusted-earnings-per-share-eps-increased-33-percent-to-248 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/04/amgen-to-discuss-details-of-the-biologics-license-application-for-talimogene-laherparepvec-for-patients-with-metastatic-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/04/european-commission-approves-amgens-vectibix-panitumumab-as-firstline-treatment-in-combination-with-folfiri-chemotherapy-for-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/04/fda-approves-corlanor-ivabradine-to-reduce-the-risk-of-hospitalization-for-worsening-heart-failure-in-patients-with-chronic-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-announces-2015-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-announces-launch-of-new-neulasta-pegfilgrastim-delivery-kit 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-publishes-safety-analysis-of-investigational-cholesterollowering-medication-repatha-evolocumab-in-the-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-showcases-cardiovascular-pipeline-at-acc-15-with-new-cholesterol-lowering-and-chronic-heart-failure-data 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-submits-application-for-investigational-ldl-cholesterollowering-medication-repatha-evolocumab-in-japan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-to-present-10-abstracts-from-its-dermatology-portfolio-at-the-73rd-annual-meeting-of-the-american-academy-of-dermatology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-to-present-at-the-goldman-sachs-key-debates-in-biosimilars-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/amgen-to-webcast-investor-call-at-the-73rd-annual-meeting-of-the-american-academy-of-dermatology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/cancer-survivor-joan-lunden-named-2015-honorary-breakaway-from-cancer-champion-and-joins-nationwide-search-for-ten-champions-in-the-fight-against-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/fda-grants-amgen-priority-review-for-kyprolis-carfilzomib-supplemental-new-drug-application-for-the-treatment-of-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/new-detailed-data-from-phase-3-study-show-amgens-repatha-evolocumab-in-combination-with-statins-reduced-ldlc-by-6776-percent-compared-to-placebo-in-japanese-patients-with-high-cardiovascular-risk-and-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/phase-3-headtohead-endeavor-study-demonstrates-superiority-of-kyprolis-carfilzomib-over-velcade-bortezomib-in-patients-with-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/03/the-genomic-portrait-of-a-nation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/02/amgen-announces-fda-advisory-committees-to-review-talimogene-laherparepvec-for-the-treatment-of-patients-with-metastatic-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/02/amgen-announces-positive-results-from-head-to-head-study-comparing-the-efficacy-and-safety-of-amg-416-with-cinacalcet-in-patients-with-secondary-hyperparathyroidism-receiving-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/02/amgen-announces-positive-top-line-results-from-phase-3-study-evaluating-the-efficacy-and-safety-of-biosimilar-candidate-abp-501-compared-with-adalimumab-in-patients-with-moderate-to-severe-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/02/amgen-announces-the-european-medicines-agency-acceptance-of-kyprolis-carfilzomib-marketing-authorization-application-for-the-treatment-of-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/02/amgen-receives-positive-chmp-opinion-for-use-of-vectibix-panitumumab-as-firstline-treatment-in-combination-with-folfiri-chemotherapy-for-advanced-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/02/amgen-to-present-at-the-cowen-and-company-35th-annual-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgen-and-kite-pharma-announce-strategic-cancer-immunotherapy-collaboration-to-advance-the-application-of-novel-chimeric-antigen-receptor-car-t-cell-therapies 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgen-and-md-anderson-announce-agreement-to-develop-bite-therapies-for-myelodysplastic-syndrome 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgen-announces-webcast-of-2014-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgen-presents-new-data-supporting-firstline-use-of-vectibix-panitumumab-in-combination-with-folfox-in-patients-with-wildtype-ras-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgens-2014-revenues-increased-7-percent-to-201-billion-and-adjusted-earnings-per-share-eps-increased-14-percent-to-870 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgen-submits-applications-in-the-us-and-europe-for-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgen-the-familial-hypercholesterolemia-foundation-and-stanford-medicine-launch-find-fh-initiative-to-improve-diagnosis-and-care-for-people-with-familial-hypercholesterolemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2015/01/amgen-to-present-at-the-33rd-annual-j-p--morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/actress-adamari-lpez-and-amgen-launch-spanish-language-chemotherapy-myths-or-facts-website-and-resources 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/amgen-and-astrazeneca-to-present-results-from-phase-3-amagine-1-study-evaluating-brodalumab-in-patients-with-moderate-to-severe-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/amgen-and-onyx-announce-detailed-results-from-phase-3-aspire-study-of-kyprolis-carfilzomib-in-patients-with-relapsed-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/amgen-announces-30-percent-increase-in-2015-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/amgen-announces-new-data-from-phase-2-blincyto-blinatumomab-immunotherapy-study-in-patients-with-acute-lymphoblastic-leukemia-and-minimal-residual-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/amgen-joins-with-labcentral-to-support-lifesciences-and-biotech-startups-in-cambridge-massachusetts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/amgen-presents-data-from-pivotal-phase-2-study-of-blincyto-blinatumomab-immunotherapy-in-patients-with-relapsedrefractory-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-hematology-ash-56th-annual-meeting-and-exposition 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/fda-approves-amgens-xgeva-denosumab-for-the-treatment-of-hypercalcemia-of-malignancy-refractory-to-bisphosphonate-therapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/fda-approves-blincyto-blinatumomab-immunotherapy-for-the-treatment-of-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/12/new-trial-initiated-evaluating-amgens-talimogene-laherparepvec-in-combination-with-mercks-antipd1-therapy-keytruda-pembrolizumab-for-advanced-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-and-astrazeneca-announce-positive-results-from-second-pivotal-phase-3-study-of-brodalumab-in-patients-with-moderate-to-severe-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-and-astrazeneca-announce-positive-results-from-third-and-final-pivotal-phase-3-study-of-brodalumab-in-patients-with-moderate-to-severe-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-announces-termination-of-all-amgen-sponsored-clinical-studies-of-rilotumumab-in-advanced-gastric-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-announces-top-line-secondary-endpoint-results-of-phase-3-trebananib-trinova-1-trial-in-patients-with-recurrent-ovarian-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-highlights-new-data-in-the-treatment-of-blood-cancers-at-ash-2014 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-presents-long-term-data-showing-efficacy-and-safety-of-investigational-cholesterol-lowering-medication-evolocumab-across-lipid-and-ldl-c-levels 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-to-highlight-new-data-for-investigational-cholesterol-lowering-medication-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-to-present-at-the-credit-suisse-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-to-present-at-the-jefferies-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/amgen-to-webcast-investor-call-at-upcoming-american-heart-association-scientific-sessions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/fda-accepts-amgens-biologics-license-application-for-ldl-cholesterollowering-medication-evolocumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/11/the-amgen-foundation-expands-amgen-scholars-program-to-17-top-educational-institutions-worldwide 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-announces-2014-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-announces-appointment-of-r--sanders-williams-to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-announces-moderate-to-severe-plaque-psoriasis-data-to-be-presented-at-the-23rd-congress-of-the-european-academy-of-dermatology-and-venereology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-announces-positive-top-line-results-from-phase-3-study-evaluating-the-efficacy-and-safety-of-biosimilar-candidate-abp-501-compared-with-adalimumab-in-patients-with-moderate-to-severe-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-announces-webcast-of-2014-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-files-lawsuit-against-sanofi-and-regeneron-for-patent-infringement 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-outlines-strategy-growth-objectives-and-capital-allocation-plans 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgens-bite-immunotherapy-blinatumomab-receives-fda-priority-review-designation-in-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-statement-regarding-third-point-investment 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgens-third-quarter-2014-revenues-increased-6-percent-to-50-billion-and-adjusted-earnings-per-share-eps-increased-19-percent-to-230 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/amgen-to-webcast-2014-business-review-meeting-on-october-28 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/10/the-lancet-publishes-two-phase-3-studies-showing-cholesterol-lowering-medication-evolocumab-significantly-reduced-ldl-cholesterol-in-patients-with-serious-genetic-disorders-that-cause-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-announces-23-abstracts-to-be-presented-at-the-american-society-for-bone-and-mineral-research-2014-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-announces-results-from-several-new-exploratory-analyses-evaluating-longterm-impact-of-treatment-with-prolia-denosumab-in-postmenopausal-women-with-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-foundation-commits-2-million-to-support-science-teachers-across-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-presents-analyses-of-phase-3-ivabradine-data-for-the-treatment-of-chronic-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-submits-biologics-license-application-for-investigational-bite-immunotherapy-blinatumomab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-submits-marketing-authorization-application-for-novel-investigational-ldl-cholesterol-lowering-medication-evolocumab-to-the-european-medicines-agency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-submits-marketing-authorization-application-for-talimogene-laherparepvec-to-the-european-medicines-agency 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-to-host-summary-webcast-of-kyprolis-carfilzomib-for-injection-data-presented-at-the-european-society-for-medical-oncology-esmo-2014-congress 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/09/new-analyses-of-phase-2-study-presented-at-asbmr-show-romosozumab-treatment-resulted-in-continued-increases-in-bone-mineral-density 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/amgen-announces-phase-3-aspire-trial-of-kyprolis-in-patients-with-relapsed-multiple-myeloma-met-primary-endpoint 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/amgen-announces-positive-top-line-results-from-phase-3-yukawa-2-trial-of-evolocumab-in-combination-with-statins-in-japanese-patients-with-high-cardiovascular-risk-and-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/amgen-announces-positive-top-line-results-from-second-phase-3-study-of-amg-416-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease-receiving-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/amgen-announces-top-line-results-from-phase-3-focus-trial-of-kyprolis-in-patients-with-relapsed-and-advanced-refractory-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/amgen-issues-voluntary-recall-of-aranesp-darbepoetin-alfa-500-mcg-prefilled-syringes-in-several-countries-outside-of-the-united-states-due-to-the-presence-of-visible-particulates 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/amgen-names-elliott-m-levy-md-senior-vice-president-global-development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/amgen-submits-biologics-license-application-for-novel-investigational-ldl-cholesterol-lowering-medication-evolocumab-to-the-fda 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/08/fda-grants-amgen-priority-review-designation-for-ivabradine-for-the-treatment-of-chronic-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/07/amgen-announces-2014-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/07/amgen-announces-positive-phase-3-results-for-amg-416-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease-receiving-hemodialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/07/amgen-announces-webcast-of-2014-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/07/amgen-receives-fda-breakthrough-therapy-designation-for-investigational-bite-antibody-blinatumomab-in-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/07/amgens-second-quarter-2014-revenues-increased-11-percent-to-52-billion-and-adjusted-earnings-per-share-eps-increased-25-percent-to-237 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/06/amgen-appoints-david-w--meline-executive-vice-president-and-chief-financial-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/06/amgen-joins-the-national-cancer-institute-and-research-partners-to-help-accelerate-development-of-personalized-treatment-approaches-for-squamous-cell-lung-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/06/amgen-presents-new-data-on-talimogene-laherparepvec-as-single-agent-and-combination-therapy-in-metastatic-melanoma-at-asco 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/06/brodalumab-treatment-improved-clinical-signs-and-symptoms-in-phase-2-psoriatic-arthritis-study-published-in-the-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/06/new-detailed-phase-3-data-show-amgens-novel-investigational-cholesterollowering-medication-evolocumab-significantly-reduced-ldl-cholesterol-in-patients-with-a-rare-and-serious-genetic-disorder-that-causes-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-and-astrazeneca-announce-positive-results-from-phase-3-study-of-brodalumab-amg-827-in-patients-with-moderatetosevere-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-and-onyx-data-at-asco-2014-highlight-oncology-pipeline-and-portfolio 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-highlights-phase-2-results-of-vectibix-panitumumab-versus-bevacizumab-in-combination-with-folfox-in-patients-with-wildtype-ras-kras-and-nras-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-names-steven-k-galson-senior-vice-president-global-regulatory-affairs-and-safety 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgens-breakaway-from-cancer-honors-four-california-cancer-survivors-during-the-ninth-annual-amgen-tour-of-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-to-host-postamerican-society-of-clinical-oncology-asco-summary-webcast 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-to-present-at-the-deutsche-bank-39th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/amgen-to-present-at-the-jefferies-2014-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/fda-approves-firstline-use-of-vectibix-panitumumab-plus-folfox-for-patients-with-wildtype-kras-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/journal-of-the-american-medical-association-publishes-phase-3-laplace-2-study-showing-evolocumab-significantly-reduced-ldl-cholesterol-in-patients-on-statins-regardless-of-statin-dose 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/05/the-new-england-journal-of-medicine-publishes-positive-proof-of-concept-data-for-new-asthma-treatment 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/04/amgen-announces-webcast-of-2014-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/04/amgen-provides-update-on-phase-3-study-of-talimogene-laherparepvec-in-patients-with-metastatic-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/04/amgens-first-quarter-2014-revenues-increased-7-percent-to-45-billion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/amgen-announces-2014-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/amgen-announces-positive-topline-results-from-phase-3-tesla-trial-of-evolocumab-amg-145-in-patients-with-homozygous-familial-hypercholesterolemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/amgen-names-david-piacquad-senior-vice-president-business-development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/amgens-talimogene-laherparepvec-reduced-size-of-melanoma-tumors-in-new-phase-3-retrospective-analysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/amgen-to-present-at-the-cowen-and-company-34th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiologys-63rd-annual-scientific-session 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/bayer-and-onyx-report-phase-3-study-results-of-nexavar-sorafenib-as-adjuvant-treatment-for-patients-with-liver-cancer-who-have-undergone-surgery-or-local-ablation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/data-from-phase-3-pivotal-studies-show-amgens-novel-investigational-cholesterollowering-medication-evolocumab-significantly-reduced-ldl-cholesterol-in-statin-intolerant-patients-and-in-patients-on-statins 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/new-detailed-data-from-three-phase-3-pivotal-studies-show-amgens-novel-investigational-cholesterollowering-medicine-evolocumab-significantly-reduced-ldl-cholesterol-by-5566-percent-compared-to-placebo-in-patients-with-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/03/phase-3-pivotal-data-on-amgens-novel-investigational-cholesterollowering-medicine-to-be-featured-at-the-american-college-of-cardiologys-63rd--annual-scientific-session 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/02/amgen-and-merck-announce-collaboration-to-evaluate-investigational-combination-treatment-for-advanced-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/02/amgen-to-present-at-the-rbc-capital-markets-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/amgen-announces-positive-topline-results-from-phase-3-gauss2-trial-of-evolocumab-amg-145-in-statin-intolerant-patients-with-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/amgen-announces-positive-topline-results-from-phase-3-laplace2-trial-of-evolocumab-amg-145-in-combination-with-statins-in-patients-with-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/amgen-announces-positive-topline-results-from-phase-3-rutherford2-trial-of-evolocumab-amg-145-in-patients-with-heterozygous-familial-hypercholesterolemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/amgen-announces-webcast-of-2013-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/amgens-2013-revenues-increased-8-percent-to-187-billion-and-adjusted-earnings-per-share-eps-increased-17-percent-to-760 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/amgen-to-present-at-the-32nd-annual-j-p--morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/chief-financial-officer-jonathan-m-peacock-to-leave-amgen-company-appoints-michael-a-kelly-acting-chief-financial-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/mass-general-broad-institute-and-amgen-will-work-to-discover-new-drugs-for-inflammatory-bowel-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2014/01/romosozumab-phase-2-data-published-in-new-england-journal-of-medicine-show-significant-increases-in-bone-mineral-density-at-both-spine-and-hip 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/12/amgen-announces-2014-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/12/amgen-announces-positive-topline-results-from-52week-phase-3-descartes-study-of-evolocumab-amg-145-in-patients-with-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/12/amgen-announces-positive-topline-results-from-phase-3-mendel2-trial-of-evolocumab-amg-145-in-patients-with-high-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/12/amgen-to-host-post-american-society-of-hematology-ash-summary-webcast 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-and-onyx-pharmaceuticals-announce-upcoming-data-presentations-at-55th-american-society-of-hematology-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-announces-evolocumab-amg-145-results-from-first-52week-study-of-a-pcsk9-inhibitor-to-reduce-ldl-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-foundation-commits-25-million-in-new-grants-to-engage-50000-students-each-year-in-the-thrill-of-scientific-inquiry 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-presents-interim-overall-survival-data-from-phase-3-study-of-talimogene-laherparepvec-in-patients-with-metastatic-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-statement-on-analyst-comments-concerning-kyprolis-trial-data 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-to-highlight-new-evolocumab-amg-145-data-at-upcoming-american-heart-association-scientific-sessions-2013 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-to-present-at-the-credit-suisse-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessions-2013 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/11/us-fda-approves-nexavar-sorafenib-for-the-treatment-of-patients-with-locally-recurrent-or-metastatic-progressive-differentiated-thyroid-carcinoma-refractory-to-radioactive-iodine-treatment 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-acquires-filgrastim-franchise-rights-from-roche-in-100-markets 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-and-astrazeneca-highlight-data-to-be-presented-at-22nd-congress-of-the-european-academy-of-dermatology-and-venereology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-announces-2013-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-announces-appointment-of-greg-c--garland-to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-announces-webcast-of-2013-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-presents-nearly-two-dozen-abstracts-from-romosozumab-and-prolia-denosumab-at-asbmr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-promotes-two-senior-executives-names-brian-mcnamee-executive-vice-president-and-stuart-tross-senior-vice-president 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgens-third-quarter-2013-revenues-increased-10-percent-to-47-billion-and-adjusted-earnings-per-share-eps-increased-16-percent-to-194 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/10/amgen-successfully-completes-onyx-pharmaceuticals-tender-offer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/amgen-and-cytokinetics-announce-the-first-presentation-of-data-from-phase-2-atomic-ahf-study-of-omecamtiv-mecarbil 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/amgen-and-onyx-pharmaceuticals-announce-early-termination-of-hsr-waiting-period-for-amgens-acquisition-of-onyx 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/amgen-highlights-data-to-be-presented-at-2013-european-cancer-congress 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/amgen-presents-new-data-from-phase-3-study-of-talimogene-laherparepvec-in-patients-with-metastatic-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/amgen-presents-pooled-analysis-showing-amg-145-significantly-reduced-ldl-cholesterol-in-over-1200-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/analysis-published-in-new-england-journal-of-medicine-highlights-discovery-of-new-predictive-biomarkers-for-vectibix-panitumumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/09/phase-3-trial-comparing-vectibix-panitumumab-to-erbitux-cetuximab-meets-primary-endpoint-of-noninferiority-of-overall-survival 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/08/amgen-and-servier-complete-product-collaboration-transaction 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/08/amgen-to-acquire-onyx-pharmaceuticals-for-$125-per-share-in-cash 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/08/amgen-to-highlight-new-data-at-upcoming-esc-congress-2013 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/08/amgen-to-participate-at-citis-8th-annual-biotech-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/07/amgen-and-servier-announce-product-collaboration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/07/amgen-announces-2013-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/07/amgen-announces-webcast-of-2013-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/07/amgens-second-quarter-2013-revenues-increased-5-percent-to-47-billion-and-adjusted-earnings-per-share-eps-increased-3-percent-to-189 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/07/the-lancet-oncology-publishes-results-of-xgeva-denosumab-in-patients-with-giant-cell-tumor-of-bone 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/06/amgen-and-astrazeneca-highlight-data-to-be-presented-at-european-league-against-rheumatism-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/06/amgen-and-cytokinetics-announce-expansion-of-license-for-omecamtiv-mecarbil 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/06/amgen-announces-topline-results-of-phase-3-trebananib-amg-386-trinova1-trial-in-recurrent-ovarian-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/06/amgen-award-for-science-teaching-excellence-honors-outstanding-teachers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/06/amgen-presents-positive-results-from-talimogene-laherparepvec-phase-3-study-in-patients-with-metastatic-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/06/amgen-to-present-at-the-goldman-sachs-34th-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/06/fda-approves-amgens-xgeva-denosumab-for-the-treatment-of-giant-cell-tumor-of-bone 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-and-astellas-announce-japan-alliance 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-and-zhejiang-beta-pharma-announce-planned-joint-venture-in-china 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-announces-topline-results-of-vectibix-panitumumab-phase-3-headtohead-study-against-erbitux-cetuximab-in-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-highlights-data-to-be-presented-at-american-society-of-clinical-oncology-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-to-present-at-the-deutsche-bank-38th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-to-present-at-the-ubs-global-life-sciences-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-clinical-oncology-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/four-californians-selected-as-breakaway-from-cancer-champions-to-be-honored-during-amgen-tour-of-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/05/new-analyses-identify-predictive-biomarkers-for-vectibix-panitumumab-in-patients-with-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/04/amgen-announces-webcast-of-2013-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/04/amgens-first-quarter-2013-revenues-increased-5-percent-to-42-billion-and-adjusted-earnings-per-share-eps-increased-22-percent-to-196 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/03/amgen-announces-2013-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/03/amgen-announces-top-line-results-of-phase-3-talimogene-laherparepvec-trial-in-melanoma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/03/amgen-to-present-at-the-cowen-and-company-33rd-annual-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/02/amgen-announces-call-for-nominations-for-2013-breakaway-from-cancer-champions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/02/amgen-outlines-long-term-strategy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/02/amgen-statement-on-government-budget-analysis-for-oral-only-treatments-for-dialysis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgen-announces-results-from-phase-3-paves-study-evaluating-neulasta-pegfilgrastim-in-patients-with-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgen-announces-topline-results-of-phase-3-aranesp-darbepoetin-alfa-redhf-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgen-announces-webcast-of-2012-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgen-backs-states-efforts-to-enact-biosimilar-legislation-that-allows-for-substitution-and-supports-patient-safety 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgens-full-year-2012-revenues-increased-11-percent-to-173-billion-and-adjusted-earnings-per-share-eps-increased-22-percent-to-651 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgen-to-build-state-of-the-art-manufacturing-facility-in-singapore 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgen-to-present-at-the-31st-annual-j-p--morgan-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2013/01/amgen-to-webcast-2013-business-review-meeting-on-february-7 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/12/amgen-announces-31-percent-increase-in-2013-first-quarter-dividend-and-increase-in-its-share-repurchase-authorization 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/12/amgen-announces-appointment-of-robert-a--eckert-to-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/12/amgen-finalizes-agreement-resolving-previously-announced-federal-investigations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/12/amgen-highlights-data-to-be-presented-at-american-society-of-hematology-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/12/amgen-names-robert-a--bradway-chairman-of-the-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/12/amgen-to-acquire-decode-genetics-a-global-leader-in-human-genetics 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/amgen-and-pfizer-highlight-data-to-be-presented-at-american-college-of-rheumatology-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/amgen-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/amgen-to-present-data-from-four-phase-2-studies-at-upcoming-american-heart-association-scientific-sessions-2012 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessions-2012 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/circulation-publishes-results-from-rutherford-study-which-showed-amg-145-significantly-reduced-ldl-cholesterol-in-patients-with-heterozygous-familial-hypercholesterolemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/journal-of-the-american-medical-association-publishes-amg-145-phase-2-gauss-study-showing-significant-reductions-in-ldl-cholesterol-in-statin-intolerant-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/phase-3-sensiparmimpara-evolvetm-trial-published-in-the-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/11/the-lancet-publication-of-laplace-timi-57-and-mendel-studies-showed-amg-145-significantly-reduced-ldl-cholesterol 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/10/amgen-announces-2012-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/10/amgen-announces-webcast-of-2012-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/10/amgen-appoints-cynthia-patton-senior-vice-president-and-chief-compliance-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/10/amgen-presents-several-sub-analyses-at-asbmr-from-the-ongoing-open-label-extension-study-of-the-pivotal-phase-3-prolia-fracture-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/10/amgens-third-quarter-2012-revenues-increased-10-percent-to-43-billion-and-adjusted-earnings-per-share-eps-increased-19-percent-to-167 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/09/amgen-names-ray-jordan-senior-vice-president-corporate-affairs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/09/fda-approves-new-indication-for-prolia-denosumab-for-the-treatment-of-bone-loss-in-men-with-osteoporosis-at-high-risk-for-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/08/amgen-announces-termination-of-ganitumab-phase-3-study-for-futility-in-metastatic-pancreatic-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/08/amgen-to-present-at-the-baird-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/07/amgen-announces-2012-third-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/07/amgen-announces-webcast-of-2012-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/07/amgen-completes-acquisition-of-kai-pharmaceuticals 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/07/amgens-second-quarter-2012-revenues-increased-13-percent-to-45-billion-and-adjusted-earnings-per-share-eps-increased-34-percent-to-183 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/06/20th-annual-amgen-award-for-science-teaching-excellence-honors-nine-outstanding-teachers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/06/actress-maura-tierney-and-amgen-launch-the-chemotherapy-myths-or-facts-tm-campaign 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/06/amgen-announces-topline-results-of-phase-3-sensiparmimpara-evolvetm-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/06/amgen-completes-acquisition-of-mustafa-nevzat-pharmaceuticals 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/amgens-bite-antibody-blinatumomab-amg-103-achieved-high-rate-of-complete-response-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/amgen-to-present-at-the-baird-growth-stock-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/amgen-to-present-at-the-deutsche-bank-37th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/amgen-to-provide-testimony-at-fda-stakeholder-hearing-on-biosimilars 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/analysis-of-rilotumumab-amg-102-data-identifies-a-potential-predictive-biomarker-for-patients-with-gastric-or-gastroesophageal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/cancer-support-community-launches-national-program-to-assist-patients-with-cancer-make-informed-decisions-about-care 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/cure-magazine-announces-winner-of-the-2012-extraordinary-healer-award-for-oncology-nursing 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/05/four-californians-selected-as-breakaway-from-cancer-champions-to-be-honored-during-amgen-tour-of-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/amgen-and-astrazeneca-announce-collaboration-to-jointly-develop-and-commercialize-clinical-stage-inflammation-portfolio 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/amgen-announces-webcast-of-2012-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/amgen-receives-complete-response-letter-from-fda-for-xgeva-sbla-for-prevention-of-bone-metastases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/amgens-first-quarter-2012-revenue-increased-9-percent-to-40-billion-and-adjusted-earnings-per-share-eps-increased-20-percent-to-161 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/amgen-to-acquire-mustafa-nevzat-a-leading-privately-held-turkish-pharmaceutical-company 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/amgen-to-acquire-privately-held-kai-pharmaceuticals 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/a-tribute-to-george-rathmann-amgens-founding-ceo-19272012 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/04/ucb-and-amgen-initiate-sclerostin-antibody-phase-3-program-in-patients-with-postmenopausal-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/03/amgen-announces-2012-second-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/03/amgen-announces-initial-results-of-tender-offer-for-outstanding-shares-of-micromet-inc-and-commencement-of-subsequent-offering-period 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/03/amgen-announces-phase-2-study-results-for-brodalumab-in-moderate-to-severe-plaque-psoriasis-published-in-the-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/03/amgen-completes-tender-offer-for-outstanding-shares-of-micromet-inc 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/03/amgens-pcsk9-inhibitor-reduced-ldl-cholesterol-up-to-81-percent-in-phase-1b-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/03/schwartz-center-receives-500000-grant-from-the-amgen-foundation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/amgen-and-european-schoolnet-launch-new-professional-development-initiative-for-life-science-teachers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/amgen-and-micromet-announce-early-termination-of-hsr-waiting-period-for-amgens-acquisition-of-micromet 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/amgen-names-michael-severino-md-senior-vice-president-global-development-and-corporate-chief-medical-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/amgen-to-discuss-application-for-new-use-of-xgeva-denosumab-at-fda-oncologic-drugs-advisory-committee-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/amgen-to-present-at-the-citi-2012-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/amgen-to-present-at-the-cowen-and-company-32nd-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/amgen-to-present-at-the-leerink-swann-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/02/cure-magazine-teams-up-with-amgen-oncology-and-breakaway-from-cancer-to-launch-2012-extraordinary-healer-award-for-oncology-nursing 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/01/amgen-announces-webcast-of-2011-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/01/amgens-full-year-2011-revenue-increased-4-percent-to-156-billion-and-adjusted-earnings-per-share-eps-increased-2-percent-to-533 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/01/amgen-to-acquire-micromet 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2012/01/amgen-to-present-at-the-30th-annual-j-p--morgan-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/amgen-and-fda-agree-to-modify-nplate-romiplostim-risk-evaluation-and-mitigation-strategy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/amgen-and-watson-announce-collaboration-to-develop-and-commercialize-oncology-biosimilars 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/amgen-announces-2012-first-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/amgen-announces-final-results-of-its-tender-offer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/amgen-announces-preliminary-results-of-its-tender-offer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/amgen-presents-final-results-from-the-largest-phase-3-openlabel-study-assessing-the-safety-and-efficacy-of-nplate-romiplostim 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/amgen-to-present-at-the-22nd-annual-oppenheimer-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/fda-to-review-potential-new-use-of-xgeva-denosumab-at-oncologic-drugs-advisory-committee-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/12/kevin-sharer-amgen-chairman-and-ceo-announces-plan-to-retire-with-robert-bradway-to-become-ceo-on-may-23-2012-sharer-will-continue-as-chairman-of-the-board-until-end-of-2012 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/11/amgen-announces-plan-to-launch-tender-offer-and-launch-of-senior-notes-offering 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/11/amgen-statement-on-european-investor-visit 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/11/enbrel-etanercept-patent-issued 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/11/prolia-denosumab-openlabel-extension-trial-showed-continued-increase-in-bone-mineral-density-over-six-years-with-similar-safety-profile-observed-in-original-fracture-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/11/the-lancet-publishes-results-demonstrating-xgeva-significantly-prolonged-bone-metastasis-free-survival-in-men-with-prostate-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/11/treatment-with-enbrel-etanercept-shows-significant-and-sustained-clinical-benefits-in-rheumatoid-arthritis-ra-patients-with-moderately-active-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/11/vectibix-panitumumab-granted-approval-for-expanded-indications-in-the-european-union 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/10/amgen-announces-2011-fourth-quarter-dividend 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/10/amgen-announces-webcast-of-2011-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/10/amgen-appoints-anthony-tony-hooper-executive-vice-president-global-commercial-operations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/10/amgen-appoints-robert-a-bradway-to-the-companys-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/10/amgens-third-quarter-2011-revenue-and-adjusted-earnings-per-share-eps-each-increased-3-percent-to-39-billion-and-140 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/amgen-highlights-data-to-be-presented-at-2011-european-multidisciplinary-cancer-congress 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/amgen-staff-volunteer-efforts-result-in-5000-for-each-of-their-favorite-nonprofits 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/amgen-to-present-at-the-baird-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/amgen-to-present-at-the-stifel-nicolaus-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/amgen-to-present-at-the-ubs-global-life-sciences-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/fda-approves-new-indications-for-prolia-denosumab-for-the-treatment-of-bone-loss-in-patients-with-prostate-or-breast-cancer-undergoing-hormone-ablation-therapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/09/prolia-denosumab-phase-2-extension-study-showed-continued-increase-in-bone-mineral-density-over-eight-years-of-treatment 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/08/amgen-announces-pdufa-date-for-xgeva-supplemental-biologics-license-application 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/08/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/08/awardwinning-actress-blythe-danner-and-amgen-launch-act-2-reduce-fracturestm-educational-campaign 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/07/amgen-and-ucb-team-up-with-nasa-on-final-space-shuttle-mission-to-conduct-preclinical-test-of-sclerostin-antibody-on-bone-loss 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/07/amgen-announces-webcast-of-2011-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/07/amgen-resolves-g-csf-patent-litigation-with-teva 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/07/amgens-second-quarter-2011-revenue-increased-4-percent-to-40-billion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/07/xgeva-denosumab-granted-marketing-authorization-in-the-european-union 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/06/amgen-announces-modifications-to-u-s--prescribing-information-for-use-of-erythropoiesis-stimulating-agents-in-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/06/amgen-receives-positive-chmp-opinion-for-vectibix-panitumumab-in-combination-with-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/06/amgen-submits-application-to-expand-indication-for-xgeva-denosumab-to-prevent-or-delay-spread-of-prostate-cancer-to-the-bone 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/06/notice-to-investors-regarding-2011-and-2015-guidance 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/06/teachers-and-schools-across-north-america-receive-10000-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/amgen-oncology-data-to-be-presented-at-asco-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/amgen-receives-chmp-positive-opinion-for-xgevatm-denosumab-in-the-european-union 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/amgen-to-webcast-investor-meeting-at-upcoming-american-urological-association-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/data-presented-at-two-global-medical-congresses-reinforce-benefit-of-enbrelr-etanercept-for-patients-with-chronic-inflammatory-conditions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/five-californians-selected-as-breakaway-from-cancerr-champions-to-be-honored-during-amgen-tour-of-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/patrick-dempsey-teams-up-with-breakaway-from-cancerr-to-help-connect-cancer-patients-to-free-resources 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/05/phase-3-data-demonstrate-xgevatm-denosumab-is-first-bone-targeted-therapy-to-prevent-spread-of-cancer-to-the-bone-in-men-with-advanced-prostate-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/04/amgen-and-ucb-announce-positive-phase-2-results-of-amg-785cdp7851-in-patients-with-postmenopausal-osteoporosis-pmo 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/04/amgen-announces-webcast-of-2011-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/04/amgen-establishes-commercial-operations-in-brazil 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/04/amgen-outlines-strategy-growth-objectives-and-capital-allocation-plans 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/04/amgens-first-quarter-2011-revenue-increased-3-percent-to-37-billion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/04/amgen-to-present-at-the-deutsche-bank-36th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/04/amgen-to-webcast-2011-business-review-meeting-on-april-21 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/amgen-completes-acquisition-of-biovex 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/amgen-donates-$1-million-to-help-japanese-disaster-victims 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/amgen-statement-on-chmp-opinion-on-vectibixr-panitumumab-use-with-chemotherapy-in-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/amgen-to-appeal-chmp-opinion-on-vectibixr-panitumumab-use-with-chemotherapy-in-metastatic-colorectal-cancer-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/amgen-to-present-at-the-cowen-and-company-31st-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/breakaway-from-cancerr-launches-newlyenhanced-website-offering-comprehensive-tailored-support-for-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/nbpts-and-amgen-foundation-join-to-bolster-science-education 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/proliar-denosumab-openlabel-extension-trial-showed-continued-increase-in-bone-mineral-density-over-five-years-of-treatment-with-similar-safety-profile-observed-in-pivotal-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/top-line-results-announced-of-pivotal-phase-3-motesanib-trial-in-advanced-non-squamous-non-small-cell-lung-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/treatment-with-proliar-denosumab-associated-with-significantly-greater-adherence-compliance-and-persistence-compared-to-alendronate 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/03/worldclass-professional-golfer-phil-mickelson-launches-on-course-with-phil-for-people-with-certain-inflammatory-joint-and-skin-conditions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/02/amgen-to-present-at-the-citi-2011-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/02/enbrelr-etanercept-significantly-improved-scalp-involvement-in-patients-with-moderate-to-severe-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/02/results-published-in-the-lancet-demonstrate-superiority-of-xgevatm-denosumab-in-the-prevention-of-bone-complications-for-men-with-bone-metastases-from-advanced-prostate-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/02/the-journal-of-clinical-oncology-publishes-phase-3-xgevatm-denosumab-results-in-advanced-cancer-patients-with-solid-tumors-or-multiple-myeloma 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/01/amgen-and-xencor-enter-option-deal-to-codevelop-xencors-novel-antibody-for-autoimmune-diseases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/01/amgen-announces-webcast-of-2010-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/01/amgens-fourth-quarter-2010-adjusted-earnings-per-share-increased-11-percent-to-117-full-year-2010-adjusted-earnings-per-share-increased-6-percent-to-521 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/01/amgen-to-acquire-biovex-a-privately-held-biotechnology-company-headquartered-in-woburn-mass 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/01/amgen-to-present-at-the-29th-annual-jp-morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/01/boehringer-ingelheim-to-purchase-amgens-fremont-california-facility 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2011/01/sensiparr-patents-upheld-by-district-court 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/12/amgen-highlights-data-to-be-presented-at-american-society-of-hematology-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/12/amgen-presents-new-xgevatm-denosumab-breast-cancer-skeletalrelated-event-prevention-data-at-sabcs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/12/amgens-nplater-maintains-platelet-counts-for-more-than-five-years-in-adults-with-chronic-itp 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/12/amgen-to-present-at-deutsche-banks-2010-biofest 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/12/teach-for-america-and-the-amgen-foundation-renew-partnership-to-improve-math-and-science-education-in-urban-and-rural-schools 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/12/three-innovative-ideas-receive-10000-prizes-in-patients--choices--empowerment-competition 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/12/xgevatm-denosumab-significantly-improved-bone-metastasisfree-survival-in-men-with-prostate-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/amgen-foundation-and-ashokas-changemakers-announce-finalists-in-patients--choices--empowerment-competition 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/amgen-foundation-awards-45-million-grant-to-mla-partner-schools-to-invest-in-las-promise 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/amgen-foundation-recognizes-outstanding-staff-volunteers-and-contributes-55000-to-their-favorite-local-nonprofits 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/amgen-pfizer-and-worldclass-professional-golfer-phil-mickelson-announce-partnership 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/amgen-scholars-undergraduate-summer-research-program-begins-phase-2 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/amgen-to-present-at-19th-annual-credit-suisse-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/amgen-to-provide-testimony-at-fda-hearing-on-biosimilars 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/call-for-applications-the-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/fda-approves-amgens-xgevatm-denosumab-for-the-prevention-of-skeletalrelated-events-in-patients-with-bone-metastases-from-solid-tumors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/proliatm-denosumab-receives-best-new-drug-honor-at-scrip-awards 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/published-results-show-denosumab-superior-to-zometar-in-delaying-or-preventing-bone-complications-in-patients-with-bone-metastases-from-advanced-breast-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/11/study-published-in-new-england-journal-of-medicine-shows-nplater-significantly-reduces-treatment-failure-and-splenectomy-rate-in-patients-with-chronic-itp 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/amgen-announces-webcast-of-2010-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-asbmr-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/amgen-highlights-key-clinical-data-to-be-presented-at-european-society-for-medical-oncology-congress 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/amgens-third-quarter-2010-revenue-unchanged-at-38-billion-versus-prior-year 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/amgen-to-review-results-from-treat-and-propose-updates-to-esa-labeling-for-chronic-renal-failure-patients-at-an-fda-advisory-committee-meeting-today 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/breakaway-from-cancerr-launches-striking-the-balance-podcast-series-to-inspire-action-and-change-across-the-cancer-continuum 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/integrated-analysis-demonstrates-that-denosumab-delays-the-onset-of-bone-complications-compared-to-zometar 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/two-pivotal-vectibixr-phase-3-studies-in-first-and-secondline-treatment-of-metastatic-colorectal-cancer-published-in-the-journal-of-clinical-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/10/updated-amg-386-data-demonstrate-promising-antitumor-activity-in-patients-with-recurrent-ovarian-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/09/amgen-and-pfizer-introduce-psophisticated-style-a-guide-to-everyday-style-and-psoriasistm-hosted-by-tim-gunn 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/09/amgen-initiates-voluntary-nationwide-recall-of-certain-lots-of-epogenr-and-procritr-epoetin-alfa 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/09/amgen-to-present-at-the-baird-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/09/amgen-to-present-at-the-ubs-global-life-sciences-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/08/amgen-announces-top-line-results-of-phase-3-head-and-neck-cancer-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/2010-addressing-psoriasistm-contest-winners-attend-a-style-consultation-with-tim-gunn-in-new-york-city 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/amgen-announces-webcast-of-2010-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/amgen-appoints-jonathan-m--peacock-executive-vice-president-and-chief-financial-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/amgen-appoints-ronald-d-sugar-to-the-companys-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/amgen-foundation-and-changemakers-launch-global-online-competition-to-empower-patients-for-better-outcomes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/amgen-scholars-summer-research-helps-lead-to-science-careers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/amgens-second-quarter-2010-adjusted-earnings-per-share-increased-7-percent-to-138 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/07/fda-grants-priority-review-designation-to-denosumab-biologics-license-application-for-the-reduction-of-skeletal-related-events-in-advanced-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/34-teachers-and-schools-across-north-america-receive-10000-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/amgen-to-present-at-the-jeffries-global-life-sciences-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/denosumab-demonstrated-superiority-over-zometar-in-delay-of-complications-due-to-bone-metastases-in-advanced-prostate-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/fda-approves-amgens-proliatm-denosumab-for-treatment-of-postmenopausal-women-with-osteoporosis-at-high-risk-for-fracture 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/new-amg-386-data-demonstrate-promising-antitumor-activity-in-patients-with-recurrent-ovarian-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/new-amg-479-phase-2-data-show-antitumor-activity-in-patients-with-metastatic-pancreatic-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/new-analyses-of-denosumab-pivotal-phase-3-trials-reinforce-potential-advantages-over-standard-of-care 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/06/striking-the-balance-community-experts-come-together-for-high-level-dialogue-on-cancer-care 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/05/amgen-highlights-key-clinical-data-to-be-presented-at-american-society-of-clinical-oncology-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/05/amgens-breakaway-from-cancerr-to-honor-cancer-survivors-at-amgen-tour-of-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/05/amgen-scientists-visit-biotechnology-classrooms-across-the-country-in-support-of-national-lab-day 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/05/amgen-submits-denosumab-biologics-license-application-to-fda-for-the-reduction-of-skeletal-related-events-in-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/05/proliar-denosumab-granted-marketing-authorization-in-the-european-union 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/04/amgen-announces-webcast-of-2010-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/04/amgen-appoints-robert-a--bradway-president-and-chief-operating-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/04/amgen-highlights-biomarker-and-preclinical-data-to-be-presented-at-american-association-for-cancer-research-aacr-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/04/amgen-preclinical-study-demonstrated-anti-tumor-activity-in-mammary-tumor-model 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/04/amgens-first-quarter-2010-adjusted-earnings-per-share-increased-20-percent-to-130 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/04/amgen-to-present-at-the-deutsche-bank-35th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/04/analysis-of-vectibixr-study-using-new-gene-technology-helps-to-advance-prospects-for-personalized-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/03/amgen-to-present-at-the-cowen-and-company-30th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/03/project-runways-tim-gunn-returns-to-address-psoriasistm-and-empower-patients-to-be-confident-in-their-personal-style 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/02/amgen-and-centocor-ortho-biotech-products-finalize-esa-risk-evaluation-and-mitigation-strategy-rems-with-fda 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/02/denosumab-demonstrated-superiority-over-zometar-in-pivotal-phase-3-headtohead-trial-in-prostate-cancer-patients-with-bone-metastases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/02/fda-classifies-proliatm-denosumab-complete-response-submission-and-targets-action-date 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/01/amgen-announces-webcast-of-2009-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/01/amgen-donates-2-million-establishes-earthquake-relief-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/01/amgen-presents-complete-results-from-two-pivotal-phase-3-studies-of-vectibixr-at-gastrointestinal-cancers-symposium 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/01/amgens-fourth-quarter-2009-adjusted-earnings-per-share-decreased-1-percent-to-105-full-year-2009-adjusted-earnings-per-share-increased-8-percent-to-491 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2010/01/amgen-to-present-at-the-28th-annual-jp-morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/amgen-board-authorizes-$5-billion-increase-in-stock-repurchase-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/amgen-presents-data-from-first-nplater-study-in-children-with-chronic-itp 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/amgen-receives-chmp-positive-opinion-for-proliatm-denosumab-in-the-european-union 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/amgen-resolves-epo-patent-dispute-with-roche 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/amgens-roger-m-perlmutter-md-phd-named-2009-aaas-fellow-recognized-for-discovery-development-of-novel-medicines 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/array-biopharma-and-amgen-partner-in-type-2-diabetes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/data-presented-at-san-antonio-breast-cancer-symposium-demonstrate-treatment-with-denosumab-is-superior-to-the-standard-of-care 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/new-amgen-scholars-web-site-launches-to-build-a-global-network-for-future-scientists 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/new-study-results-presented-at-2009-san-antonio-breast-cancer-symposium-show-importance-of-protecting-your-bones 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/12/nplater-data-from-mds-studies-presented-at-ash 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/11/amgen-announces-overall-survival-results-for-vectibixr-in-firstline-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/11/amgen-highlights-data-to-be-presented-at-ash 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/11/amgen-recognized-for-best-pipeline-and-best-new-drug-at-scrip-awards 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/11/amgen-to-present-at-18th-annual-credit-suisse-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/11/amgen-to-present-at-lazard-capital-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/11/call-for-applications-the-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/10/amgen-announces-webcast-of-2009-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/10/amgen-provides-update-on-status-of-proliatm-denosumab-biologics-license-application-bla-submitted-to-the-us-food-and-drug-administration-fda 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/10/amgens-third-quarter-2009-adjusted-earnings-per-share-increased-21-percent-to-149 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/10/enbrelr-etanercept-data-to-be-presented-at-the-2009-american-college-of-rheumatology-scientific-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/10/large-study-of-anemia-treatment-in-chronic-kidney-disease-patients-not-on-dialysis-published-in-the-new-england-journal-of-medicine-failed-to-meet-primary-efficacy-endpoints 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-asbmr-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-named-presenting-sponsor-of-the-dempsey-challenge-a-journey-for-hope 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-scholars-europe-programme-convenes-undergraduates-from-15-countries-for-innovative-science-research 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-to-present-at-the-baird-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-to-present-at-the-thomas-weisel-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-to-present-at-the-ubs-global-life-sciences-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/amgen-to-present-pivotal-data-from-four-phase-3-studies-at-the-ecco-15---esmo-34-congress 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/appeals-court-affirms-patent-infringement-rulings-against-roches-pegepo-product 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/data-show-medication-adherence-is-an-important-factor-in-the-treatment-of-postmenopausal-osteoporosis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/denosumab-demonstrates-superiority-over-zometar-in-delay-of-complications-due-to-bone-metastases-in-advanced-breast-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/edie-falco-and-cynthia-nixon-appear-in-new-stand-up-to-cancertm-psas-designed-to-educate-cancer-patients-about-the-importance-of-lowering-ones-risk-of-infection-during-treatment 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/phase-3-trial-shows-denosumab-delayed-skeletal-related-events-in-advanced-cancer-patients-with-bone-metastases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/tim-gunn-hosts-addressing-psoriasistm-fashion-show-to-raise-awareness-of-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/vectibixr-in-combination-with-chemotherapy-significantly-improves-progressionfree-survival-in-firstline-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/09/vectibixr-in-combination-with-chemotherapy-significantly-improves-progressionfree-survival-in-secondline-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/amgen-and-wyeth-statement-on-fda-announcement-about-tumor-necrosis-factor-tnf-blockers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/amgen-announces-positive-topline-results-for-denosumab-in-trial-for-delay-of-skeletal-related-events-in-bone-metastases-patients-compared-to-zometar 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/amgen-announces-topline-results-of-trial-to-reduce-cardiovascular-events-with-aranespr-therapy-treat-in-ckd-patients-with-type2-diabetes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/amgen-issues-statement-on-outcomes-of-advisory-committee-for-reproductive-health-drugs-acrhd-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/amgen-to-discuss-denosumab-data-at-todays-advisory-committee-for-reproductive-health-drugs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/studies-published-in-the-new-england-journal-of-medicine-highlight-potential-new-option-in-the-treatment-of-bone-loss 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/vectibixr-in-combination-with-chemotherapy-significantly-improved-progressionfree-survival-in-firstline-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/08/vectibixr-significantly-improved-progressionfree-survival-in-secondline-treatment-of-kras-wildtype-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/amgen-announces-kras-safety-update-to-us-prescribing-information-for-vectibixr-panitumumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/amgen-announces-webcast-of-2009-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/amgen-appoints-rebecca-m-henderson-to-the-companys-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/amgen-scholars-discover-their-potential-during-summer-science-research-program-and-national-symposium 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/amgens-second-quarter-2009-adjusted-earnings-per-share-increased-13-percent-to-129 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/amgen-to-collaborate-with-glaxosmithkline-to-commercialize-denosumab-in-europe-for-postmenopausal-osteoporosis-pmo 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/denosumab-demonstrates-superiority-over-zometar-in-pivotal-phase-3-headtohead-trial-in-breast-cancer-patients-with-bone-metastases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/07/winners-of-the-addressing-psoriasistm-contest-selected-to-walk-the-runway-in-new-york-city-fashion-show-hosted-by-tim-gunn 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/06/34-outstanding-teachers-and-schools-receive-10000-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/06/amgen-to-participate-in-reproductive-health-drugs-advisory-committee-meeting-in-august 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/06/new-study-shows-nplater-significantly-reduces-splenectomy-rate-and-treatment-failure-in-patients-with-chronic-itp 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/05/amgen-exercises-option-for-exclusive-license-to-cytokinetics-cardiac-contractility-program-that-includes-ck1827452 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/05/amgen-highlights-data-to-be-presented-at-asco 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/05/amgen-to-present-at-the-deutsche-bank-34th-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/05/new-survey-highlights-growing-concern-about-risk-of-infection-in-cancer-patients-and-emerging-antibiotic-resistance 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/05/video-from-medialink-and-amgen-new-survey-highlights-growing-concern-about-risk-of-infection-and-emerging-antibiotic-resistance-in-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/04/amgen-and-onsedge-partner-with-cancer-survivor-jan-ping-for-new-campaign 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/04/amgen-announces-webcast-of-2009-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/04/amgens-first-quarter-2009-adjusted-earnings-per-share-decreased-4-percent-to-108 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/04/photos-amgen-and-onsedge-partner-with-cancer-survivor-jan-ping-for-new-campaign 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/04/preclinical-data-from-amgens-oncology-pipeline-to-be-presented-at-aacr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/03/amgen-to-present-at-the-barclays-capital-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/03/amgen-to-present-at-the-citigroup-biotech-day 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/03/amgen-to-present-at-the-cowen-and-company-annual-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/03/project-runways-tim-gunn-launches-addressing-psoriasistm-campaign-to-advocate-that-patients-shouldnt-let-psoriasis-impact-personal-style 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/02/fda-accepts-amgens-submission-and-files-biologics-license-application-for-denosumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/02/independent-data-monitoring-committee-recommends-resuming-enrollment-of-non-squamous-nsclc-patients-in-the-motesanib-monet1-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/02/nplater-approved-in-the-european-union-for-the-treatment-of-chronic-immune-idiopathic-thrombocytopenic-purpura-itp 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/01/amgen-announces-webcast-of-2008-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/01/amgens-breakaway-from-cancer-initiative-expands-to-help-cancer-patients-access-broad-spectrum-of-cancer-resources-and-services 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/01/amgens-fourth-quarter-2008-adjusted-earnings-per-share-increased-6-percent-to-106-full-year-2008-adjusted-earnings-per-share-increased-6-percent-to-455 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2009/01/amgen-to-present-at-the-27th-annual-jp-morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/12/amgen-submits-biologics-license-application-for-fda-approval-of-denosumab-in-women-with-postmenopausal-osteoporosis-and-in-patients-undergoing-hormone-ablation-for-either-prostate-or-breast-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/12/longterm-follow-up-interim-data-show-nplatetm-increased-and-sustained-platelet-counts-in-adult-chronic-itp-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/12/oncology-biomarker-kras-to-be-discussed-at-fda-panel-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/11/amgen-foundation-announces-$2-5-million-expansion-of-amgen--scholars-program-to-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/11/amgen-positioned-to-deliver-attractive-growth-over-next-five-years 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/11/amgen-takeda-and-millennium-provide-update-on-phase-3-trial-of-motesanib-in-patients-with-nonsmall-cell-lung-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/11/amgen-to-webcast-2008-business-review-meeting-on-november-7-from-millennium-hotel-in-new-york 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/11/call-for-applications-the-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/11/nplatetm-romiplostim-receives-positive-opinion-for-marketing-authorisation-in-the-european-union 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/10/amgen-announces-webcast-of-2008-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/10/amgen-appoints-francois-de-carbonnel-to-the-companys-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/10/amgen-issues-statement-on-court-of-appeals-ruling-that-affirms-preliminary-injunction-against-roche 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/10/amgens-third-quarter-2008-adjusted-earnings-per-share-increased-14-percent-to-123 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/10/district-court-affirms-patent-infringement-rulings-and-finds-that-amgen-is-entitled-to-a-permanent-injunction-against-roche 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/10/enbrelr-etanercept-is-the-first-biologic-with-published-efficacy-and-safety-data-for-up-to-a-decade-of-continuous-use-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/amgen-and-wyeth-statement-on-the-fda-safety-announcement-regarding-tumor-necrosis-factor-tnf-blockers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/amgen-receives-executive-summary-from-independent-cochrane-collaboration-review-of-esas-in-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/amgen-to-present-at-the-merrill-lynch-global-pharmaceutical-biotech--medical-devices-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/amgen-to-present-at-ubs-global-life-sciences-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/amgen-to-present-important-clinical-trial-data-at-two-key-congresses 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/biovitrum-to-acquire-kepivancer-and-stemgenr-and-exclusively-license-kineretr-from-amgen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/09/denosumab-osteoporosis-trial-finds-patients-transitioned-from-alendronate-fosamaxr-to-denosumab-achieved-significantly-greater-gains-in-bone-mineral-density-versus-those-continuing-on-alendronate 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/08/fda-approves-nplatetm-for-longterm-treatment-of-adult-chronic-itp 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/250-amgen-scholars-from-10-premier-universities-convene-for-national-summer-symposium-to-explore-drug-discovery--development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgen-and-ortho-biotech-settle-antitrust-suit 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgen-announces-positive-top-line-results-for-denosumab-pivotal-postmenopausal-osteoporosis-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgen-announces-positive-top-line-results-for-denosumab-treatment-of-bone-loss-in-men-with-non-metastatic-prostate-cancer-undergoing-androgen-deprivation-therapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgen-announces-webcast-of-2008-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgen-commits-to-phrmas-enhanced-code-on-interactions-with-healthcare-professionals-as-part-of-the-companys-clearly-amgen-initiative 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgen-issues-statement-in-response-to-revised-esa-labeling-received-from-the-fda-today 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgen-licenses-molecule-for-the-treatment-of-chronic-and-neuropathic-pain-to-orthomcneiljanssen-pharmaceuticals-inc 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/amgens-second-quarter-2008-adjusted-earnings-per-share-increased-2-percent-to-114 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/07/study-showed-half-of-patients-treated-with-enbrelr-etanercept-plus-methotrexate-can-achieve-das-clinical-remission-and-80-percent-had-no-progression-of-joint-damage-in-active-early-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/2008-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/amgen-and-wyeth-statement-on-outcome-of-dermatologic-and-ophthalmic-drugs-advisory-committee-dodac-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/amgen-and-wyeth-statement-on-the-fda-early-communication-about-tumor-necrosis-factor-tnf-blockers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/amgen-names-anna-richo-senior-vice-president-of-worldwide-compliance 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/amgen-svp-of-north-american-commercial-operations-james-daly-to-present-at-the-goldman-sachs-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/enbrelr-etanercept-application-for-the-treatment-of-pediatric-psoriasis-to-be-discussed-at-fda-dermatologic-and-ophthalmic-drugs-advisory-committee-dodac-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/new-data-show-preemptive-treatment-may-significantly-reduce-skin-toxicities-in-patients-receiving-vectibixr-panitumumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/romiplostim-data-show-potential-long-term-efficacy-and-safety-in-adults-with-chronic-itp 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/06/updated-data-from-ongoing-phase-3-trials-support-the-continued-study-of-vectibixr-panitumumab-in-combination-with-standard-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-announces-webcast-to-discuss-results-of-denosumab-phase-3-head-to-head-study-versus-alendronate-at-the-upcoming-european-symposium-on-calcified-tissues-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-highlights-data-to-be-presented-at-asco 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-posts-medical-education-and-foundation-grants-and-donations-as-part-of-the-companys-clearly-amgen-initiative 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-presents-new-data-at-asco-on-four-investigational-molecules-from-oncology-pipeline 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-reports-positive-data-at-asco-from-three-studies-of-denosumab-in-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-to-participate-in-chmp-oncology-scientific-advisory-group-meeting-in-may 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-to-participate-in-dermatologic-and-ophthalmic-drugs-advisory-committee-meeting-in-june 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-clinical-oncology-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/amgen-vp-of-investor-relations-arvind-sood-to-present-at-the-baird-growth-stock-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/denosumab-achieved-superior-bone-mineral-density-gains-in-headtohead-trial-versus-weekly-alendronate-fosamaxr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/denosumab-osteoporosis-study-meets-primary-and-all-secondary-bone-mineral-density-endpoints-in-alendronate-fosamaxr-transition-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/05/interim-phase-2-results-of-open-label-clinical-trial-of-denosumab-in-giant-cell-tumor-of-bone-demonstrated-87-percent-response-rate 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgen-announces-webcast-of-2008-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgen-cfo-bob-bradway-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgen-presents-preclinical-and-clinical-data-from-oncology-programs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgen-scientist-visits-los-angeles-classroom-during-teach-for-america-week 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgens-first-quarter-2008-adjusted-earnings-per-share-increased-4-percent-to-112 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgens-oncology-pipeline-data-highlighted-at-upcoming-scientific-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgen-statement-on-romiplostim-pdufa-date 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/amgen-teach-for-america-summit-to-focus-on-strategies-for-advancing-math-and-science-education 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/early-data-on-amgens-antiangiogenesis-pipeline-molecules-suggest-biologic-activity-across-tumor-types 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/national-kidney-foundation-introduces-plan-to-track-patients-in-national-screening-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/04/pivotal-phase-3-data-show-denosumab-increased-bone-density-at-multiple-skeletal-sites-in-early-and-later-stage-postmenopausal-women 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/amgen-and-wyeth-announce-updates-to-us-prescribing-information-for-enbrelr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/amgen-announces-update-to-us-prescribing-information-for-aranespr-and-epogenr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/amgen-statement-on-successful-outcome-of-romiplostim-panel-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/amgen-to-discuss-benefits-and-risks-of-esa-treatment-for-cancer-patients-with-anemia-due-to-chemotherapy-at-fda-odac-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/amgen-to-discuss-romiplostim-application-at-fda-odac-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/amgen-to-present-at-the-28th-annual-cowen-healthcare-conference-and-the-11th-annual-lehman-brothers-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/eu-commission-approves-updated-prescribing-information-for-aranespr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/kras-biomarker-analysis-from-pivotal-vectibixtm-trial-published 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/kyowa-hakko-and-amgen-enter-licensing-agreement-for-anti-ccr4-humanized-monoclonal-antibody 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/03/the-colon-cancer-alliance-teams-up-with-joan-lunden-for-amgen-sponsored-workshop-series-designed-to-provide-support-to-patients-and-caregivers 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/02/amgen-and-takeda-announce-exclusive-collaboration-in-japan-on-up-to-13-amgen-clinical-candidates 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/02/new-findings-show-enbrelr-etanercept-significantly-reduced-levels-of-creactive-protein-a-marker-of-inflammation-in-patients-with-moderate-to-severe-plaque-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/amgen-announces-webcast-of-2007-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/amgen-commences-registered-exchange-offer-for-its-senior-floating-rate-notes-due-2008-585-percent-senior-notes-due-2017-and-6375-percent-senior-notes-due-2037 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/amgens-fourth-quarter-2007-adjusted-earnings-per-share-eps-increased-11-percent-to-100-full-year-2007-adjusted-eps-increased-10-percent-to-429 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/amgen-statement-on-aranesp-manuscript-in-the-journal-of-clinical-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/amgen-to-present-at-the-26th-annual-jp-morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/amgen-updates-2007-adjusted-eps-guidance-and-outlines-2008-expense-outlook-at-the-jp-morgan-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/breakaway-from-cancer-public-service-announcement-spreads-support-and-hope 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/denosumab-osteoporosis-study-met-primary-and-all-secondary-bone-mineral-density-endpoints-in-a-headtohead-comparison-with-weekly-alendronate-fosamaxr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/interim-safety-data-presented-on-vectibixtm-panitumumab-in-combination-with-standard-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/kras-gene-status-may-impact-vectibixtm-panitumumab-efficacy-and-patient-reported-outcomes-in-advanced-colorectal-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/new-study-reports-enbrelr-etanercept-significantly-improved-moderate-to-severe-plaque-psoriasis-in-children-and-adolescents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2008/01/pooled-phase-3-study-of-nplatetm-romiplostim-in-adult-patients-with-chronic-itp-published-in-the-lancet 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/12/amgen-foundation-and-leading-universities-invite-college-students-to-apply-for-amgen-scholars-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/12/amgen-in-discussions-with-fda-to-update-u-s--prescribing-information-for-esas 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/12/pivotal-phase-3-data-show-denosumab-increased-bone-density-throughout-skeleton-in-non-metastatic-breast-cancer-patients-on-adjuvant-aromatase-inhibitor-therapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/12/pivotal-phase-3-nplatetm-study-in-nonsplenectomized-patients-met-primary-endpoints 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/12/pivotal-phase-3-romiplostim-study-in-splenectomized-patients-meets-primary-endpoints 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/12/vectibixr-approved-in-the-european-union-for-the-treatment-of-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/11/amgen-announces-interim-results-of-aranespr-prepare-study-in-breast-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/11/amgen-announces-my-cancer-coach-contest-winners-at-the-college-hoops-classic 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/11/amgen-announces-updates-to-the-u-s--prescribing-information-for-esas 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/11/amgen-to-provide-new-evidence-as-part-of-a-formal-reconsideration-of-cms-national-coverage-determination-on-esas 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/11/call-for-applications-the-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/11/new-data-show-that-half-of-patients-with-active-early-rheumatoid-arthritis-achieved-clinical-remission-at-one-year-when-treated-with-enbrelr-etanercept-plus-methotrexate 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/10/amgen-and-dompe-biotec-to-combine-commercial-operations-in-italy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/10/amgen-announces-webcast-of-2007-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/10/amgen-appoints-vance-d-coffman-to-the-companys-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/10/amgen-foundation-donates-500000-to-aid-in-southern-california-wildfire-relief-efforts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/10/amgens-third-quarter-2007-adjusted-earnings-per-share-increased-4-percent-to-108 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/10/amgen-to-postpone-indefinitely-its-plans-for-a-manufacturing-facility-in-ireland 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/10/jury-rules-roche-infringes-amgens-epo-patents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/amgen-foundation-awards-grant-to-mentor-la-to-help-improve-public-high-school-education-in-los-angeles 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/amgen-oncology-highlights-upcoming-data-presentations-at-the-2007-european-conference-on-clinical-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/amgen-provides-update-on-late-stage-and-early-stage-pipeline-at-ubs-global-life-sciences-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/amgen-receives-proposal-for-amending-eu-prescribing-information-for-aranespr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/amgen-to-review-benefits-risks-of-esa-therapy-in-chronic-renal-failure-patients-at-fda-advisory-committee 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/aranespr-dahanca-10-study-results-presented-at-ecco-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/aranespr-darbepoetin-alfa-approved-for-use-in-all-european-paediatric-patients-with-chronic-renal-failure-anaemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/aranespr-study-showing-no-negative-impact-on-survival-in-sclc-presented-at-world-conference-on-lung-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/new-analysis-suggests-first-cycle-use-of-neulastar-reduces-febrile-neutropenia-hospitalizations-and-chemotherapy-dose-reductions-in-breast-cancer-patients-compared-to-current-practice 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/new-biomarker-data-links-kras-gene-to-vectibixtm-clinical-response 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/phase-2-study-suggests-that-extended-dosing-of-aranespr-is-as-efficacious-as-weekly-dosing 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/09/vectibixtm-panitumumab-receives-positive-opinion-for-marketing-authorization-in-the-european-union 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/08/amgen-responds-to-final-cms-national-coverage-determination-on-use-of-erythropoiesis-stimulating-agents-in-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/08/amgen-restructures-due-to-lower-aranespr-revenues-while-continuing-to-invest-in-innovation-and-future-growth 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/08/amgen-to-hold-conference-call-today-after-the-close-of-financial-markets 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/08/court-rules-that-roche-infringes-one-of-amgens-erythropoietin-patents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/08/dennis-fenton-executive-vice-president-of-operations-elects-to-retire-after-25-years-with-amgen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/08/first-year-amgen-scholars-and-leading-scientists-attend-symposium-to-explore-drug-discovery--development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/07/amgen-and-daiichi-sankyo-announce-agreement-for-denosumab-in-japan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/07/amgen-announces-webcast-of-2007-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/07/amgen-board-authorizes-$5-billion-increase-in-stock-repurchase-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/07/amgen-completes-acquisition-of-alantos 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/07/amgen-completes-acquisition-of-ilypsa 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/07/amgens-second-quarter-2007-adjusted-earnings-per-share-increased-7-percent-to-112 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/06/amgen-submits-comments-in-response-to-cms-proposed-national-coverage-decision 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/06/amgen-submits-testimony-to-house-ways--means-committee 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/06/amgen-to-acquire-alantos-pharmaceuticals-a-private-biotechnology-company-in-cambridge-massachusetts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/06/amgen-to-acquire-ilypsa-a-private-san-francisco-bay-area-biotechnology-company-focused-on-kidney-disease-care 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/06/enbrel-safety-data-for-up-to-eight-years-in-patients-with-juvenile-rheumatoid-arthritis-being-presented-at-eular 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/06/ralph-lauren-center-for-cancer-care-and-prevention-receives-$2-5-million-from-the-amgen-foundation-to-launch-national-patient-navigation-training-institute 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/05/amgen-names-david-lacey-md-senior-vice-president-head-of-research 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/05/amgen-oncology-highlights-upcoming-data-presentations-at-the-american-society-of-clinical-oncology-asco-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/05/amgen-prices-4-billion-of-senior-notes-in-three-series-company-to-purchase-approximately-3-billion-in-common-stock 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/05/amgen-recommends-rejection-of-mini-tender-offer-by-trc-capital-corporation 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/05/amgen-to-appeal-chmp-opinion-on-vectibixtm-panitumumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/05/amgen-to-offer-4-billion-in-three-series-of-senior-notes-company-to-purchase-approximately-3-billion-in-common-stock 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/04/2007-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/04/amgen-announces-webcast-of-2007-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/04/amgen-names-robert-bradway-executive-vice-president-and-chief-financial-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/04/amgens-first-quarter-2007-revenue-increased-15-percent-to-37-billion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/04/aranespr-145-study-shows-no-difference-in-survival-in-patients-with-smallcell-lung-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/04/aranespr-phase-3-study-in-patients-with-active-cancer-not-receiving-concurrent-chemotherapy-or-radiotherapy-presented-at-aacr-annual-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/04/final-vectibixtm-positive-pivotal-phase-3-trial-results-in-metastatic-colorectal-cancer-patients-published 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/03/amgen-announces-update-to-us-prescribing-information-for-aranespr-and-epogenr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/03/amgen-discontinues-vectibixtm-treatment-in-pacce-trial-evaluating-vectibixtm-as-part-of-triple-combination-regimen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/03/amgen-to-present-at-the-27th-annual-cowen--company-health-care-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/03/amgen-to-present-at-the-lehman-brothers-tenth-annual-global-healthcare-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/03/prime-minister-tony-blair-opens-major-amgen-development-centre-in-london 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/02/amgen-announces-proposals-to-declassify-board-to-be-presented-at-2007-annual-meeting-and-adopts-majority-vote-bylaw 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/02/amgen-ceo-kevin-sharer-to-present-at-the-merrill-lynch-global-pharmaceutical-biotechnology--medical-device-conference 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/02/amgen-to-hold-analyst-call-to-discuss-danish-head-and-neck-cancer-dahanca-10-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/02/amgen-to-participate-in-goldman-sachs-in-your-office-call 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/02/amgen-to-participate-in-oncologic-drugs-advisory-committee-in-may 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/02/survey-indicates-people-with-chronic-moderate-to-severe-plaque-psoriasis-may-be-under-treated 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/01/amgen-announces-put-option-for-liquid-yield-option-notes-due-2032-and-zero-coupon-convertible-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/01/amgen-announces-webcast-of-2006-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/01/amgen-launches-2007-breakaway-from-cancer-initiative 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/01/amgens-fourth-quarter-2006-revenue-increased-17-to-38-billion-full-year-2006-revenue-increased-15-to-143-billion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2007/01/cytokinetics-and-amgen-announce-strategic-alliance-in-heart-failure 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/amgen-announces-$5-billion-stock-repurchase-plan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/amgen-names-yuji-orihara-president-amgen-kk 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/amgen-responds-to-reports-about-use-and-safety-of-epogen-and-aranesp-in-ckd-anemia-therapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/amgen-submits-testimony-to-house-ways--means-committee 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/data-show-efficacy-of-extended-dosing-of-aranespr-in-the-treatment-of-chemotherapyinduced-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/final-phase-2-data-continue-to-show-promising-results-after-one-year-of-aranespr-treatment-for-anemia-in-patients-with-myelodysplastic-syndromes-mds 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/new-phase-2-data-show-promise-of-aranespr-treatment-for-anemia-of-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/12/updated-interim-long-term-follow-up-data-reported-amg-531-dosed-once-weekly-increased-and-sustained-platelet-counts-in-patients-with-immune-platelet-disorder 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/amg-706-shows-activity-in-phase-2-study-of-patients-with-advanced-imatinib-resistant-gastrointestinal-stromal-tumors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/amgen-launches-chemocoachcom-and-my-cancer-coach-contest-in-conjunction-with-sponsorship-of-college-hoops-classic-benefiting-coaches-vs-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/colorectal-patients-offered-new-resource-to-help-navigate-treatment-process 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/data-shows-enbrel-provides-sustained-clinical-improvements-for-people-with-ankylosing-spondylitis-for-up-to-three-years 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/district-court-judge-denies-preliminary-injunction-in-ortho-v--amgen-suit 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/enbrel-is-the-first-biologic-to-publish-data-showing-safety-and-sustained-efficacy-for-up-to-nine-years-in-patients-with-moderate-to-severe-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/fashion-designer-and-cancer-survivor-carmen-marc-valvo-offers-support 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/10/amgen-announces-webcast-of-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/10/amgen-completes-acquisition-of-avidia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/10/amgen-foundation-launches-$25-million-undergraduate-research-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/10/amgen-receives-complete-response-letter-for-extended-dosing-of-aranespr-for-patients-with-chronic-kidney-disease-and-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/10/amgens-third-quarter-2006-adjusted-earnings-per-share-excluding-stock-option-expense-increased-22-percent-to-104 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/10/u-s--district-court-denies-roche-motion-to-dismiss-amgen-patent-infringement-lawsuit 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/09/amgen-announces-license-agreement-with-yeda-research-and-development-company-ltd-license-agreement-accords-amgen-freedom-to-operate-under-866-patent 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/09/amgen-introduces-comprehensive-financial-assistance-programs-for-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/09/amgen-launches-aranespr-darbepoetin-alfa-prefilled-sureclicktm-autoinjector-for-treatment-of-anemia-associated-with-chemotherapy-and-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/09/amgen-names-thomas-flanagan-senior-vice-president-and-chief-information-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/09/amgen-presents-denosumab-and-sclerostin-antibody-data-at-american-society-for-bone-and-mineral-research-annual-meeting-data-suggest-the-potential-for-targeting-the-key-proteins-rank-ligand-and-sclerostin-for-bone-loss-conditions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/09/amgen-to-acquire-avidia-a-privately-held-biopharmaceutical-company-in-the-san-francisco-bay-area 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/09/fda-approves-vectibixtm-to-treat-patients-with-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/08/amgen-wins-tkt-appeal 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/07/amgen-announces-evolve-trialtm-to-investigate-impact-of-sensiparrmimparar-cinacalcet-hcl-on-mortality-and-cardiovascular-morbidity-in-secondary-hyperparathyroidism-patients-with-chronic-kidney-disease-receiving-dialysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/07/amgen-announces-termination-of-poison-pill-effective-july-31-2006 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/07/amgen-announces-webcast-of-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/07/amgens-second-quarter-2006-adjusted-earnings-per-share-excluding-stock-option-expense-increased-19-percent-to-105-gaap-earnings-per-share-of-1-cent-reflects-11-billion-onetime-writeoff-of-inprocess-rd-related-to-abgenix-acquisition 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/07/amgen-update-on-presentation-materials-for-webcast-of-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/07/itc-judge-grants-summary-determination-that-roches-activities-are-covered-by-clinical-trial-exemption 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/06/fda-grants-priority-review-of-panitumumab-for-treatment-of-patients-with-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/06/final-results-of-phase-2-clinical-trial-program-suggest-treatment-of-anemia-with-aranespr-darbepoetin-alfa-may-decrease-risk-of-hospitalization-and-allcause-mortality-in-heart-failure-patients-with-anemia-based-on-a-prespecified-pooled-analysis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/06/interim-data-suggest-potential-benefits-of-aranespr-dosed-every-three-weeks-with-intravenous-iron-for-chemotherapyinduced-anemia-94-percent-of-patients-achieved-target-hemoglobin-level 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/06/interim-phase-2-aranespr-data-suggest-major-response-after-2728-weeks-of-treatment-for-anemia-in-patients-with-myelodysplastic-syndromes-mds 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/06/new-interim-phase-2-data-suggest-the-antitumor-activity-of-panitumumab-in-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/06/phase-2-interim-data-show-denosumab-decreased-bone-turnover-in-advanced-cancer-patients-with-bone-metastases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/05/amgen-oncology-highlights-upcoming-data-presentations-at-the-american-society-of-clinical-oncology-annual-meeting-clinical-data-to-be-presented-on-four-investigational-targeted-cancer-therapies 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/05/itc-accepts-amgens-complaint-to-investigate-roches-importation-of-pegepo 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/05/large-headtohead-study-of-aranespr-dosed-every-two-weeks-versus-epoetin-alfa-dosed-weekly-published-in-the-journal-of-clinical-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/04/2006-recipients-of-amgen-award-for-science-teaching-excellence-announced-19-outstanding-science-teachers-and-their-schools-recognized-in-amgen-communities-across-the-us-and-puerto-rico 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/04/alcon-and-amgen-sign-collaboration-agreement-to-develop-and-commercialize-innovative-therapies-in-ophthalmology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/04/amgen-announces-webcast-of-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/04/amgen-completes-acquisition-of-abgenix-acquisition-provides-amgen-with-full-ownership-of-panitumumab-and-eliminates-a-denosumab-royalty 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/04/amgen-files-with-itc-against-roches-importation-of-pegepo 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/04/amgens-first-quarter-2006-adjusted-earnings-per-share-excluding-stock-option-expense-increased-26-percent-to-91-cents-first-quarter-2006-gaap-earnings-per-share-increased-22-percent-to-82-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/04/randomized-phase-3-trial-shows-panitumumab-significantly-improved-progression-free-survival-and-disease-control-in-metastatic-colorectal-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/03/amgen-and-abgenix-complete-biologics-license-application-for-fda-approval-of-panitumumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/03/fda-approves-extended-dosing-of-aranespr-to-treat-chemotherapyinduced-anemia-everythreeweek-dosing-can-provide-added-convenience-potentially-reducing-number-of-clinic-visits-and-injections-for-anemia-treatment 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/03/new-phase-2-data-suggest-treatment-of-anemia-with-aranespr-darbepoetin-alfa-may-provide-clinical-benefits-in-heart-failure-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/02/amgen-and-biovitrum-expand-existing-license-agreement-for-innovative-treatment-of-type-2-diabetes-and-other-metabolic-disorders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/02/amgen-continues-manufacturing-expansion-with-additional-$1-billion-investment-in-puerto-rico 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/02/amgen-donates-11-million-to-the-wellness-community-as-part-of--of--breakaway-from-cancer-initiative-and-title-sponsorship-of-amgen-tour-of-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/02/amgen-prices-50-billion-convertible-senior-notes-company-to-purchase-approximately-30-billion-in-common-stock 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/02/amgen-to-offer-40-billion-convertible-senior-notes-company-to-purchase-approximately-30-billion-in-common-stock 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/02/hundreds-of-local-residents-participate-in-breakaway-from-cancer-charity-ride-to-benefit-the-wellness-community-bruce-jenner-kicksoff-twentyfive-mile-ride-that-coincides-with-stage-six-of-amgen-tour-of-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/02/investigational-therapy-denosumab-increased-bone-mineral-density-with-twiceyearly-dosing-one-year-data-published-in-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/01/amgen-and-genentech-sign-license-agreements-for-antibody-patents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/01/amgen-announces-put-option-for-liquid-yield-option-notes-due-2032-and-zero-coupon-convertible-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/01/amgen-announces-webcast-of-2005-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/01/amgens-fourth-quarter-2005-adjusted-earnings-per-share-increased-29-percent-to-75-cents-full-year-2005-adjusted-earnings-per-share-increased-33-percent-to-320 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2006/01/amgen-to-make-significant-investment-in-manufacturing-rd-and-commercial-operations-expansion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/12/amgen-announces-$5-billion-stock-repurchase-plan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/12/amgen-to-acquire-abgenix-for-2250-per-share-provides-amgen-with-full-ownership-of-panitumumab-and-eliminates-a-denosumab-royalty 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/12/interim-longterm-followup-data-show-amg-531-increases-platelets-in-patients-with-immune-thrombocytopenic-purpura-results-suggest-onceweekly-dosing-of-amg-531-results-in-sustained-platelet-response 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/12/new-phase-3-data-show-potential-benefits-of-aranespr-dosed-every-three-weeks-for-chemotherapyinduced-anemia-aranesp-treatment-achieved-and-maintained-target-hemoglobin-levels-and-reduced-incidence-of-red-blood-cell-transfusions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/12/the-wellness-community-and-amgen-partner-with-professional-cyclist-george-hincapie-to-launch-breakaway-from-cancer-initiative 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/12/updated-interim-aranespr-phase-2-data-suggest-major-response-in-anemic-patients-with-myelodysplastic-syndrome-mds-patients-with-bone-marrow-disorder-also-showed-improvements-in-hemoglobin-levels-and-fatigue 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/amgen-announces-sponsorship-of-worldclass-cycling-event-company-to-join-with-the-wellness-community-to-raise-awareness-and-funds-to-help-people-fight-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/amgen-files-lawsuit-against-roche-for-patent-infringement 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/amgen-foundation-donates-500000-to-south-asia-earthquake-relief-efforts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/data-show-aranespr-darbepoetin-alfa-administered-once-monthly-maintains-hemoglobin-levels-in-chronic-kidney-disease-patients-with-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/media-notificationwebcast-notification--amgen-and-abgenix-to-conduct-conference-call-and-webcast-regarding-panitumumab-pivotal-study-results--november-3-2005-800-am-pt 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence-19-outstanding-teachers-will-be-recognized-in-communities-where-amgen-operates 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/panitumumab-significantly-improves-progression-free-survival-in-phase-3-randomized-metastatic-colorectal-cancer-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/treatment-has-demonstrated-improvement-in-physical-function-and-kept-joint-damage-from-progressing-at-three-years 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/11/twoyear-trial-results-of-amgen-investigational-therapy-for-bone-loss-denosumab-show-increased-bone-mineral-density-with-twiceyearly-dosing 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/10/amgen-announces-webcast-of-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/10/amgens-third-quarter-2005-adjusted-earnings-per-share-increased-33-percent-to-85-cents-third-quarter-2005-gaap-earnings-per-share-increased-to-77-cents-from-18-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/10/european-commission-approves-kepivancetm-palifermin-for-oral-mucositis-in-cancer-patients-undergoing-blood-and-bone-marrow-transplant 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/09/amgen-announces-fda-licensure-of-two-new-manufacturing-facilities-company-continues-to-meet-increased-demand-for-its-novel-therapeutics 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/09/amgen-announces-initiation-of-phase-3-trial-to-evaluate-the-impact-of-treating-anemia-with-darbepoetin-alfa-in-patients-with-heart-failure-to-reduce-mortality-and-hospitalization 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/09/amgen-donates-$2-5-million-to-hurricane-katrina-relief-efforts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/09/amgen-names-phyllis-piano-vice-president-corporate-communications-and-philanthropy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/09/fda-expands-neulastar-label-new-label-extends-firstcycle-protection-from-infection-to-cancer-patients-receiving-moderately-myelosuppressive-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/08/abgenix-and-amgen-announce-fda-grants-panitumumab-fast-track-designation-for-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/08/amgen-adopts-guiding-principles-for-directtoconsumer-advertising 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/08/amgen-names-michael-kelly-as-chief-accounting-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/08/amgen-strengthens-focus-on-oncology-pipeline-names-david-r-parkinson-to-new-role-in-research-and-development-organization 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/07/amgens-second-quarter-2005-adjusted-earnings-per-share-increased-42-percent-to-88-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/07/interim-data-suggest-major-response-with-aranespr-in-anemic-patients-with-myelodysplastic-syndromes-mds 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/07/kepivancetm-palifermin-receives-positive-regulatory-opinion-for-approval-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/06/amgen-announces-webcast-of-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/06/fda-expands-enbrel-psoriatic-arthritis-indication----enbrel-approved-as-first-and-only-treatment-to-improve-physical-function-in-these-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/2005-recipients-of-amgen-award-for-science-teaching-excellence-announced-19-outstanding-science-teachers-and-their-schools-recognized-in-communities-across-us-and-puerto-rico 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/amgen-announces-expiration-and-results-of-its-exchange-offer-for-its-outstanding-liquid-yield-option-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/amgen-announces-one-day-extension-of-its-exchange-offer-for-its-outstanding-liquid-yield-option-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/amgen-announces-plans-to-webcast-selected-management-presentations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/amgen-names-jim-daly-senior-vice-president-north-america-commercial-operations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/amgen-submits-supplemental-biologics-license-application-for-aranesp-extended-dosing-phase-3-study-evaluated-aranesp-dosed-once-every-three-weeks-in-patients-with-chemotherapyinduced-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/aranesp-dosed-every-three-weeks-achieved-and-maintained-target-hemoglobin-levels-in-patients-with-chemotherapy-induced-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/final-results-of-phase-3-head-to-head-study-demonstrate-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-weekly-in-cancer-patients-with-chemotherapy-induced-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/further-phase-2-data-confirm-panitumumab-single-agent-antitumor-activity-in-patients-with-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/05/large-community-based-clinical-trial-in-older-cancer-patients-suggests-benefits-of-neulasta-in-first-and-subsequent-cycles-of-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/04/amgen-announces-webcast-of-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/04/amgen-commences-exchange-offer-for-its-outstanding-liquid-yield-option-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/04/amgens-first-quarter-2005-adjusted-earnings-per-share-increased-26-percent-to-72-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/04/landmark-trial-to-link-reduction-in-cardiovascular-risk-with-treatment-of-anemia-in-diabetics-with-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/04/multimedia-available-landmark-trial-to-link-reduction-in-cardiovascular-risk-with-treatment-of-anemia-in-diabetics-with-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/04/phase-3-clinical-trial-initiated-to-evaluate-the-use-of-panitumumab-therapy-for-firstline-treatment-of-metastatic-colorectal-cancer-study-evaluates-panitumumab-administered-with-bevacizumab-and-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/03/amgen-announces-results-of-its-repurchase-of-tendered-liquid-yield-option-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/03/landmark-trial-will-evaluate-the-impact-of-treating-anemia-on-cardiovascular-outcomes-in-patients-with-chronic-kidney-disease-and-type-2-diabetes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/02/amgen-announces-one-time-cash-payment-and-additional-put-right-for-liquid-yield-option-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/02/following-complete-review-of-phase-2-trial-data-amgen-confirms-decision-to-halt-gdnf-study-comprehensive-review-of-scientific-findings-patient-safety-drove-decision 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/02/phase-3-study-published-in-the-journal-of-clinical-oncology-shows-first-cycle-administration-of-neulasta-significantly-lowers-incidence-of-neutropenia-with-related-fever-and-hospitalization 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/02/treatment-with-enbrel-had-a-positive-effect-on-activities-of-daily-living-for-patients-with-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/01/amgen-announces-put-option-notification-for-liquid-yield-option-notes-due-2032 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/01/amgen-announces-webcast-of-2004-fourth-quarter-and-full-year-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/01/amgen-donates-1-million-and-establishes-tsunami-relief-program-staff-donations-company-contributions-to-help-south-asia-victims 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/01/amgens-fourth-quarter-2004-adjusted-earnings-per-share-increased-26-percent-to-58-cents-full-year-2004-adjusted-earnings-per-share-increased-26-percent-to-240 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2005/01/amgen-significantly-expands-support-of-patient-assistance-programs-financial-support-to-help-ensure-patients-have-access-to-innovative-therapies-critical-to-care 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/12/amgen-announces-$5-billion-stock-repurchase-plan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/12/amgen-names-willard-dere-senior-vice-president-global-development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/12/fda-approves-kepivance-for-severe-oral-mucositis-in-cancer-patients-undergoing-bone-marrow-transplant-pivotal-phase-3-study-published-in-this-weeks-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/12/fda-grants-fast-track-designation-for-amgens-amg-531-and-amg-706-experimental-therapies-to-potentially-treat-lifethreatening-conditions 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/12/phase-3-study-shows-majority-of-neutropenia-with-related-fever-and-hospitalization-occurs-in-first-treatment-cycle-for-breast-cancer-patients-not-receiving-neulasta 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/12/randomized-head-to-head-trial-shows-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-once-a-week-in-breast-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/11/amgen-announces-offer-of-$2-billion-in-two-series-of-senior-notes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/11/amgen-announces-the-formation-of-amgen-ventures-venture-capital-fund-designed-to-provide-resources-to-help-advance-earlystage-biotechnology-companies-and-human-therapeutics 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/11/amgen-launches-landmark-trial-to-evaluate-the-impact-of-treating-anemia-on-cardiovascular-risks-in-patients-with-chronic-kidney-disease-and-type-2-diabetes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/11/interim-phase-2-data-suggest-activity-of-panitumumab-with-chemotherapy-in-first-line-treatment-of-metastatic-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence-19-outstanding-teachers-will-be-recognized-in-communities-where-amgen-operates 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/11/published-head-to-head-data-show-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-once-a-week 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/10/amgen-announces-webcast-of-third-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/10/amgen-investigational-therapy-for-bone-loss-amg-162-increased-bone-mineral-density-with-twice-yearly-injection 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/10/amgen-names-rolf-hoffmann-senior-vice-president-european-operations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/10/amgens-third-quarter-2004-adjusted-earnings-per-share-increased-21-percent-to-64-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/10/court-rules-in-amgens-favor-in-tkt-litigation-affirms-validity-of-epo-patents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/10/european-commission-approves-innovative-first-in-class-treatment-for-a-serious-complication-of-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/10/new-two-year-data-show-that-most-rheumatoid-arthritis-patients-treated-with-enbrel-plus-methotrexate-had-no-progression-of-joint-damage 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/09/amgen-announces-plans-to-webcast-selected-management-presentations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/09/amgen-names-arvind-sood-vice-president-investor-relations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/09/aranesp-approved-for-extended-dosing-by-european-commission 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/09/fda-approves-enbrel-to-induce-major-clinical-response-in-patients-with-rheumatoid-arthritis-additional-data-demonstrates-increased-levels-of-sustained-disease-control 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/09/fda-approves-new-and-easy-way-to-take-enbrel-benefits-of-enbrel-delivered-in-convenient-onceweekly-50-mgml-prefilled-syringe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/08/amgen-completes-acquisition-of-tularik-acquisition-enhances-amgens-strong-research-organization-and-establishes-amgen-in-the-san-francisco-bay-area 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/08/aranesp-receives-positive-regulatory-opinion-for-extended-dosing-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/08/first-patients-dosed-with-amgens-amg-162-in-phase-3-studies-for-postmenopausal-osteoporosis-and-treatmentinduced-bone-loss 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/07/amgen-announces-webcast-of-second-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/07/amgen-names-brian-kotzin-vice-president-inflammation-clinical-development-and-willard-dere-vice-president-general-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/07/amgen-names-joshua-ofman-vice-president-reimbursement-and-payment-policy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/07/amgens-second-quarter-2004-total-product-sales-adjusted-earnings-and-gaap-earnings-per-share-increased-27-percent 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/07/lifestyle-coaching-program-launched-today-helps-people-with-rheumatoid-arthritis-remain-active 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/07/mimpara----cinacalcet-hcl----receives-positive-regulatory-opinion-for-approval-in-europe 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/amgens-phase-2-study-of-gdnf-for-advanced-parkinsons-disease-fails-to-meet-primary-endpoint-six-months-of-treatment-showed-biological-effect-but-no-clinical-improvement 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/amgen-submits-biologics-license-application-for-fda-approval-of-palifermin 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/head-to-head-studies-show-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-once-a-week 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/interim-phase-2-data-show-panitumumab-has-singleagent-antitumor-activity-in-metastatic-colorectal-cancer-response-appears-independent-of-prior-chemotherapy-regimen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/new-two-year-data-demonstrate-that-enbrel-therapy-allowed-significantly-more-rheumatoid-arthritis-patients-to-achieve-clinical-remission 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/phase-3-study-shows-first-cycle-administration-of-neulasta-significantly-lowers-incidence-of-infection-and-hospitalization 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/study-results-demonstrate-aranesp-dosed-once-every-three-weeks-achieves-treatment-goals-in-managing-anemia-in-cancer-patients-receiving-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/06/study-results-demonstrate-the-activity-of-aranesp-in-treating-anemia-in-cancer-patients-not-receiving-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/05/catwalk-beauty-vendela-to-help-educate-public-about-effects-of-psoriasis-through-making-connections-health-education-campaign 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/2004-california-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/2004-cambridge-boston-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/2004-colorado-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/2004-kentucky-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/2004-puerto-rico-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/2004-rhode-island-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/2004-washington-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/amgen-announces-webcast-of-first-quarter-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/amgens-first-quarter-2004-adjusted-earnings-per-share-increased-36-percent-to-57-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/fda-approves-enbrel-to-treat-psoriasis-new-convenient-treatment-provides-rapid-and-significant-relief-of-symptoms 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/immunomedics-regains-north-american-development-rights-from-amgen-for-epratuzumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/04/sensipar-pivotal-studies-in-over-700-patients-published-in-new-england-journal-of-medicine 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/03/amgen-names-rodger-currie-vice-president-government-affairs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/03/amgens-first-research-and-development-day-highlighted-24-of-the-approximately-40-programs-in-its-pipeline 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/03/amgen-to-acquire-tularik-for-$1-3-billion 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/03/fda-approves-innovative-firstinclass-treatment-for-a-serious-complication-of-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/03/frank-herringer-nominated-for-amgen-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/03/leonard-schaeffer-joins-amgens-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/02/amgen-announces-webcast-of-rd-day-with-the-investment-community 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/02/amgen-opens-state-of-the-art-biotechnology-research-campus 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/02/new-phase-3-enbrel-data-show-psoriasis-patients-achieved-a-therapeutic-response-from-step-down-dosing-regimen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-colorado 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-puerto-rico 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-rhode-island 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-announces-webcast-of-fourth-quarter-and-full-year-2003-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgen-names-david-j-scott-senior-vice-president-general-counsel-and-secretary 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2004/01/amgens-fourth-quarter-2003-adjusted-earnings-per-share-increased-31-percent-to-46-cents-full-year-2003-adjusted-earnings-per-share-increased-37-percent-to-190 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/12/amgen-announces-webcast-of-conference-call-to-provide-financial-guidance-for-2004 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/12/amgen-forecasts-strong-2004-financial-performance 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/12/amgen-named-one-of-fortune-magazines-100-best-companies-to-work-for 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/12/amgen-names-david-beier-senior-vice-president-global-government-affairs 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/12/analysis-of-headtohead-studies-shows-that-aranespr-dosed-every-two-weeks-offers-similar-results-with-less-frequent-administration-compared-to-epoetin-alfa 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/12/new-data-suggest-aranespr-benefits-patients-suffering-from-anemia-of-cancer-who-are-not-receiving-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/12/phase-3-data-show-palifermin-improves-patient-reported-outcomes-in-cancer-patients-and-helps-reduce-hospitalizations-and-healthcare-resources 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/11/amgen-announces-plans-for-epratuzumab 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/11/aranespr-administered-once-monthly-maintains-hemoglobin-levels-in-patients-with-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/11/cinacalcet-hcl-phase-3-results-demonstrate-improvement-in-the-management-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/abgenix-and-amgen-clarify-responsibilities-for-abx-egf 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/amgen-announces-webcast-of-third-quarter-2003-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/amgen-names-h-christian-fibiger-phd-and-paul-g-pearson-phd-as-vice-presidents-to-lead-research-efforts 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/amgens-third-quarter-2003-adjusted-earnings-per-share-increases-56-to-53-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/fda-approves-enbrel-for-once-weekly-dosing 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/longterm-data-support-sustained-efficacy-tolerability-and-increased-vitality-for-psoriatic-arthritis-patients-treated-with-enbrel-and-landmark-phase-3-data-show-ankylosing-spondylitis-patients-experienced-partial-clinical-remission-improved-pain-relief 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/new-data-show-many-rheumatoid-arthritis-patients-treated-with-enbrel-plus-methotrexate-have-experienced-clinical-remission-and-most-had-no-progression-of-joint-damage 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/10/science-recognizes-amgen-as-a-top-employer-in-annual-survey 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/09/amgen-and-biovitrum-sign-license-agreement-for-innovative-treatment-of-type-2-diabetes-and-other-metabolic-disorders 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/09/amgen-foundation-gives-$8-million-in-grants-in-2002 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/09/amgen-submitted-new-drug-applicatioin-for-cinacalcet-hci 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/08/amgen-and-genentech-settle-patent-dispute 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/08/fda-approves-enbrel-as-first-therapy-to-inhibit-bone-and-joint-damage-in-psoriatic-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/07/amgen-announces-webcast-of-second-quarter-2003 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/07/amgen-names-dr-willard-dere-vice-president-global-inflammation-clinical-development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/07/enbrel-is-first-anti-tnf-therapy-submitted-to-the-fda-for-approval-to-treat-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/07/enbrel-is-first-biologic-to-receive-fda-approval-for-the--treatment-of-ankylosing-spondylitis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/07/fda-approves-enbrelr-as-treatment-to-improve-physical-function-in-rheumatoid-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/07/ten-thousand-patients-enrolled-in-landmark-rheumatoid-arthritis-study-program 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/amgen-announces-first-annual-recipient-of-the-amgen-prize-for-therapeutic-advances-in-nephrology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/aranesp-dosed-once-every-two-weeks-increases-hemoglobin-levels-improves-fatigue-and-reduces-need-for-transfusions-in-patients-with-chemotherapyinduced-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/enbrel-combination-therapy-inhibited-progression-of-joint-damage-and-offered-significant-rheumatoid-arthritis-symptom-relief-in-new-clinical-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/enbrel-is-first-biologic-recommended-by-fda-panel-for-approval-to-treat-ankylosing-spondylitis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/enbrel-provided-rapid-and-significant-relief-for-psoriasis-patients-in-second-pivotal-study 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/enbrel-rapidly-and-significantly-improved-back-pain-mobility-and-physical-function-in-patients-with-ankylosing-spondylitis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/in-a-new-clinical-study-enbrel-taken-once-weekly-significantly-reduced-pain-and-inflammation-and-improved-function-in-rheumatoid-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/new-data-highlight-aranesp-efficacy-in-anemic-patients-with-lymphoid-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/new-data-suggest-risk-of-infection-doubles-with-reduced-neupogen-administration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/new-study-demonstrates-combination-therapy-with-enbrel-inhibited-progression-of-joint-damage-and-offered-significant-symptom-relief-for-rheumatoid-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/06/phase-3-data-suggest-palifermin-significantly-reduces-the-duration-and-incidence-of-oral-mucositis-in-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/2003-california-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/2003-colorado-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/2003-jefferson-county-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/2003-puerto-rico-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/2003-rhode-island-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/2003-seattle-area-recipients-of-amgen-award-for-science-teaching-excellence-announced 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/amgen-appoints-industry-veteran-dr--david-r--parkinson-to-head-oncology-clinical-development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/amgen-launches-the-amgen-oncology-institute-to-support-cancer-education 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/deborah-norville-launches-national-hope-relay-in-celebration-of-people-leading-active-lives-despite-their-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/05/interim-phase-2-data-demonstrate-single-agent-antitumor-activity-with-abx-egf-in-advanced-colorectal-cancer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/04/amgen-announces-webcast-of-first-quarter-2003-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/03/amgen-announces-800-million-investment-in-juncos-puerto-rico-for-biotech-manufacturing-center 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/03/rob-lowe-launches-town-meetings-to-help-cancer-patients-and-their-loved-ones-understand-chemotherapy-and-its-side-effects 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/02/amgen-announces-webcast-of-business-review-meeting 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/02/amgen-provides-business-overview-through-2005 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-and-immunomedics-announce-emphasis-on-development-of-amg-412-epratuzumab-as-combination-therapy-while-closing-single-agent-trial 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-award-for-science-teaching-excellence 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-colorado 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-king-and-snohomish-counties 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-rhode-island 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-positive-results-of-phase-3-enbrel-study-in-psoriasis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-positive-results-of-phase-3-study-for-rhu-kgf 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/amgen-announces-webcast-of-fourth-quarter-and-full-year-2002-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/epogen---important-prescribing-information 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/federal-appeals-court-affirms-tkt-infringement-remands-certain-validity-issues-to-lower-court 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/jj-ordered-to-pay-amgens-costs-and-attorneys-fees-in-recent-arbitration 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2003/01/on-an-adjusted-basis-amgen-reports-fourth-quarter-earnings-per-share-increase-17-percent-to-35-cents-full-year-2002-increase-18-percent-to-139 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/12/amgen-announces-results-of-phase-3-study-of-enbrel-dosed-once-weekly 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/12/amgen-announces-webcast-of-conference-call-to-provide-financial-guidance-for-2003 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/12/amgen-submits-data-to-fda-supporting-once-weekly-dosing-of-enbrel 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/12/court-dismisses-amgen-reimbursement-challenge 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/12/data-from-study-shows-aranesp-dosed-every-other-week-more-cost-effective-than-epoetin-alfa-for-treating-anemia-in-chemotherapy-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/12/enbrel-offered-to-additional-40000-rheumatoid-arthritis-juvenile-rheumatoid-arthritis-and-psoriatic-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/12/fda-approves-enbrel-manufacturing-facility-supply-for-patients-dramatically-increases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/11/amgen-business-review-meeting-resheduled-to-february-25-2003 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/11/amgen-files-suit-seeking-relief-from-reimbursement-ruling 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/11/first-in-class-oral-calcimimetic-shown-to-reduce-parathyroid-hormone-levels-in-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/11/first-in-class-oral-calcimimetic-shown-to-reduce-parathyroid-hormone-levels-in-chronic-kidney-disease 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/11/new-data-on-aranespr-dosed-every-other-week-in-anemic-chronic-kidney-disease-patients-presented-at-35th-annual-meeting-of-the-american-society-of-nephrology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/11/serono-and-amgen-sign-license-agreement-for-multiple-sclerosis-product 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/amgen-and-wyeth-pharmaceuticals-announce-initiation-of-landmark-study-in-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/amgen-announces-positive-study-results-of-kineretr--in-rheumatoid-arthritis-disease-progression-and-in-the-treatment-of-juvenile-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/amgen-announces-webcast-of-third-quarter-2002-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/amgen-comment-on-new-opps-rule 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/amgen-files-with-fda-for-use-of-kineretr-to-inhibit-bone-and-joint-damage-due-to-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/amgens-third-quarter-2002-adjusted-earnings-per-share-increase-13-to-34-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/amgen-wins-arbitration-and-awarded-150-million-against-johnson--johnson 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/enbrelr-first-therapy-submitted-to-fda-showing-inhibition-of-bone-and-joint-damage-in-psoriatic-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/enbrelr-is-first-therapy-shown-to-inhibit-bone-and-joint-damage-in-psoriatic-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/10/enbrelr-only-tnf-receptor-with-five-years-sustained-data-in-treatment-of-rheumatoid-arthritis 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/09/amgen-submits-data-to-fda-supporting-use-of-enbrel-to-improve-physical-function-in-rheumatoid-arthritis-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/08/amgen-announces-filing-with-fda-for-licensure-of-enbrel-production-facility-in-rhode-island 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/08/rob-lowe-introduces-one-to-one-support-network-for-new-cancer-patients 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/07/amgen-announces-webcast-of-second-quarter-2002-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/07/amgen-completes-acquisition-of-immunex 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/07/fda-approves-amgens-aranesp-for-anemia-associated-with-chemotherapy 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/07/second-quarter-2002-earnings-per-share-increase-27-percent-to-38-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/06/amgen-announces-$2-billion-stock-repurchase-plan 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/06/amgen-receives-cpmp-positive-recommendation-for-european-union-regulatory-approval-of-aranesprn-oncology 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/06/amgen-receives-cpmp-recommendation-for-european-union-marketing-approval-of-neulasta-for-the-reduction-of-chemotherapy---induced-neutropenia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/05/amgen-announces-its-registration-statement-on-form-s-3-has-been-declared-effective 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/05/amgen-files-registration-statement-in-connection-with-its-zero-coupon-convertible-notes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/05/amgen-stockholders-approve-issuance-of-shares-in-connection-with-immunex-acquisition 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/05/amgen-to-acquire-filgrastim-and-pegfilgrastim-in-europe-from-roche 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/05/aranesp-studies-explore-potential-of-new-anemia-treatment-paradigms 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/05/hassan-dayem-will-join-amgen-as-senior-vice-president-and-chief-information-officer 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/05/important-drug-warning-counterfeiting-of-epogenr 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/04/2002-recipients-of-amgen-award-for-science-teaching-excellence-announced-boulder-county-colorado 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/04/2002-recipients-of-amgen-award-for-science-teaching-excellence-announced-california 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/04/2002-recipients-of-amgen-award-for-science-teaching-excellence-announced-jefferson-county-kentucky 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/04/amgen-announces-webcast-of-first-quarter-2002-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/04/amgen-reports-first-quarter-2002-earnings-per-share-increased-14-percent-to-32-cents 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/04/rob-lowe-launches-awareness-campaign-about-one-of-the-most-dangerous-and-unrecognized-side-effects-of-chemotherapy----infections 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/03/amgen-signs-multiyear-agreement-with-international-oncology-network-for-aranesp-neulasta-and-neupogen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/03/amgen-signs-multiyear-agreement-with-us-oncology-for-aranesp-neulasta-and-neupogen 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/03/european-commission-approves-amgens-kineret-for-the-treatment-of-rheumatoid-arthritis-first-interleukin1-receptor-antagonist-represents-new-way-to-treat-ra 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/actor-danny-glover-joins-anemia-lifelinetm-to-help-millions-of-americans-who-suffer-from-anemia-associated-with-serious-diseases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/amgen-and-immunex-receive-request-for-additional-information-from-the-federal-trade-commission 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/amgen-to-raise-$2-5-billion-from-offering-of-zero-coupon-senior-convertible-notes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/amgen-to-receive-$2-5-billion-from-offering-of-zero-coupon-senior-convertible-notes 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/fda-approves-amgens-neulasta-for-serious-and-frequent-chemotherapy-side-effect 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/multimedia-available-actor-danny-glover-joins-anemia-lifeline-to-help-millions-of-americans-who-suffer-from-anemia-associated-with-serious-diseases 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/multimedia-available-fda-approves-amgens-neulasta-for-serious--frequent-chemotherapy-side-effect 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/multimedia-available-whats-your-aq--anemia-quotient 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/the-united-states-pharmacopeia-accepts-amgens-aranesp-for-treatment-of-chemotherapyassociated-anemia 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/02/update-fda-approves-amgens-neulasta-for-serious-and-frequent-chemotherapy-side-effect 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/01/amgen-announces-award-for-science-teaching-excellence-first-year-focusing-on-science-teaching 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/01/amgen-announces-award-for-science-teaching-excellence-in-california-first-year-focusing-on-science-teaching-a-statewide-call-for-nominations 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/01/amgen-announces-webcast-of-fourth-quarter-and-full-year-2001-financial-results 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/01/amgen-appoints-beth-seidenberg-as-senior-vice-president----development 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/01/amgen-reports-fourth-quarter-and-full-year-2001-financial-results-in-line-with-guidance 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/01/frank-biondi-joins-amgens-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/press-releases/2002/01/patricia-sueltz-elected-to-amgens-board-of-directors 2020-12-07 monthly 1.0 https://www.amgen.com/newsroom/company-statements/archives/opinion-pieces/aug-25-2016---submitted-to-the-jama-editor 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/opinion-pieces/feb-12-2013---submitted-to-the-editor---new-york-times 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/opinion-pieces/feb-13-2013---submitted-to-the-editor---denver-post 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/opinion-pieces/jan-28-2013---submitted-to-the-editor---new-york-times 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/opinion-pieces/jan-29--2013---submitted-to-the-editor---new-york-times 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/opinion-pieces/mar-18-2013---submitted-to-the-editor---los-angeles-times 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-response-to-recent-new-york-times-stories-and-an-editorial 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-response-to-recent-new-york-times-story-biotech-firms-billions 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-response-to-the-new-england-journal-of-medicine-study 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-response-to-the-proposed-icer-review-of-treatments-for-ra-and-psa 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-response-to-usa-today-article-on-restructuring 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgens-response-to-icers-draft-report-treatment-options-for-relapsed-or-refractory-multiple-myeloma 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgens-response-to-technology-assessments-for-kyprolis-carfilzomib-in-multiple-myeloma 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-additional-biomarker-analysis-beyond-kras-from-completed-phase-3-study 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-ema-review-of-ivabradine 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-evolocumab-proactive-monitoring 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-fda-fast-track-designation-for-investigational-ivabradine 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-gpha-citizen-petition-on-naming-for-biologics 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-jan-27-2014-fda-warning-letter 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-stroke-research 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-support-for-sound-science-based-biosimilar-policies 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-on-veto-for-california-biosimilars-bill 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-regarding-pcsk9-economic-analysis-published-in-jama 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-submits-comments-to-fda-on-biosimilars-naming-citizen-petitions 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-supports-distinguishable-naming-policy-for-biosimilars 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-supports-world-health-organizations-proposed-distinguishable-naming-policy-for-biosimilars 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-welcomes-european-commission-report-on-eu-biosimilars-uptake 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/commercialize-prolia-on-its-own-in-the-european-union-switzerland-norway-russia-and-mexico 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/neulasta-and-the-340b-drug-discount-program 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/response-to-icers-background-and-draft-scoping-document-disease-modifying-anti-rheumatic-drugs 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/response-to-icers-background-and-draft-scoping-document-treatment-options-for-plaque-psoriasis 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/response-to-the-editorial-building-a-wall-against-biosimilars-nature-biotechnology 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct/quality 2021-05-19 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct/protection-of-personal-information 2021-05-20 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct/insider-trading 2021-05-20 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct/conflicts-of-interest 2021-05-20 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct/antitrust-and-unfair-competition 2021-05-20 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct/political-activities 2021-05-20 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/business-conduct/anti-bribery-and-anti-corruption 2023-02-23 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/global-code-of-ethics-for-clinical-trials 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/clinical-data-transparency-practices 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/amgen-guidelines-for-publications 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/amgen-position-statement-on-stem-cell-research 2021-01-30 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/biobanking-of-human-samples 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/adverse-event-reporting 2022-10-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/amgen-statement-on-compendia 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/commitment-to-the-ethical-use-of-animals-in-research 2024-12-17 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/r-and-d-gifts-policy 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/statement-on-efforts-to-reduce-use-of-animal-derived-endotoxin-testing-assays 2024-12-06 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/international-trade/economic-sanctions-embargoes-and-boycotts 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/international-trade/export-and-import-control-laws 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/our-approach-to-responsible-marketing 2023-08-01 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/direct-to-consumer-dtc-advertising 2023-08-01 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/interactions-with-healthcare-providers 2023-08-01 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/post-marketing-commitments-post-marketing-requirements 2023-08-01 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/driving-a-compliant-workforce 2023-08-01 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/interactions-with-patient-groups 2023-08-01 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/third-party-sales 2023-08-01 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/responsible-marketing-and-product-information/interactions-with-the-public 2023-08-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/political-contributions 2024-07-25 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/physician-payment-disclosures 2024-07-25 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/efpia-disclosures 2023-11-21 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/work-environment/safe-and-healthy-workplace 2023-06-08 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/work-environment/environment-health-and-safety 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/work-environment/equal-employment-opportunity 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/work-environment/non-discrimination-and-harassment-free-workplace 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/work-environment/compliance-reporting-and-non-retaliation 2020-12-07 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/amgen-foundation/amgen-foundation-grants 2023-01-10 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/us-healthcare-donations/eligibility-criteria 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/us-healthcare-donations/healthcare-donations-frequently-asked-questions 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/us-healthcare-donations/contact-us 2023-01-23 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/independent-medical-education-funding/independent-medical-education-frequently-asked-questions 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/independent-medical-education-funding/budget-instructions 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/independent-medical-education-funding/contact-us 2022-04-25 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/amgen-patient-advocacy-and-strategic-alliances/amgen-supported-initiatives 2023-08-21 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/community-investment/amgen-patient-advocacy-and-strategic-alliances/every-patient-counts-every-story-matters 2024-09-12 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines/access--to-healthcare-programs-and-partnerships-in-low--and-middle-income-countries/pricing-and-patient-support 2024-07-31 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines/access--to-healthcare-programs-and-partnerships-in-low--and-middle-income-countries/product-donations 2023-04-27 monthly 0.5 https://www.amgen.com/responsibility/healthy-people/access-to-medicines/access--to-healthcare-programs-and-partnerships-in-low--and-middle-income-countries/r-and-d-manufacturing-and-distribution 2023-04-27 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/our-workforce/diversity-and-inclusion/commitment-to-diversity-inclusion-and-belonging 2025-04-17 monthly 0.5 https://www.amgen.com/responsibility/a-healthy-amgen/our-workforce/human-capital-management/safety 2024-08-21 monthly 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/access-to-medicine 2021-05-19 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/business-ethics 2021-05-19 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/community 2021-05-19 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/environment 2022-04-27 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/forward-looking-statements 2021-05-19 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/letter-from-bob-bradway 2022-04-27 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/our-response-to-covid-19 2021-05-19 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/reporting-and-metrics 2021-12-17 daily 0.5 https://www.amgen.com/responsibility/reporting-and-metrics/archived-reports/2019-responsibility-highlights-report/workplace 2021-05-19 daily 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-regarding-pcsk9-economic-analysis-published-in-jama/letters-to-the-editors 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/ethical-research/clinical-data-transparency-practices/clinical-trial-data-sharing-request 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/independent-medical-education-and-healthcare-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/amgen-foundation-grants 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups 2022-08-03 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/donations-and-grant-disclosures-faqs 2023-03-08 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-regarding-pcsk9-economic-analysis-published-in-jama/letters-to-the-editors/cost-effectiveness-model-greatly-exaggerates-costs-of-pcsk9-inhibitors 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-regarding-pcsk9-economic-analysis-published-in-jama/letters-to-the-editors/flawed-jama-study-misrepresents-costs-and-benefits-of-new-cholesterol-drugs 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-regarding-pcsk9-economic-analysis-published-in-jama/letters-to-the-editors/jama-report-on-cholesterol-drugs-fails-reliability-test-by-raymond-c--jordan 2020-12-07 monthly 0.5 https://www.amgen.com/newsroom/company-statements/archives/statements-and-responses/amgen-statement-regarding-pcsk9-economic-analysis-published-in-jama/letters-to-the-editors/usa-today-new-cholesterol-drugs-could-add-$120-billion-to-annual-u-s--health-costs 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2024---amgen-europe-gmbh-and-affiliates-patient-donations 2025-06-05 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2023---amgen-europe-gmbh-and-affiliates-patient-donations 2024-06-11 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2022---amgen-europe-gmbh-and-affiliates-patient-donations 2024-06-11 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2021---amgen-europe-gmbh-and-affiliates-patient-donations 2022-06-06 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2020---amgen-europe-gmbh-and-affiliates-patient-donations 2021-05-28 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2019---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-22 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2018---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2017---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2016---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2015---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2014---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2013---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2012---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2011---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2010---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2009---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5 https://www.amgen.com/about/how-we-operate/policies-practices-and-disclosures/transparency-disclosures/donation-and-grant-recipients/european-donations-to-patient-groups/2008---amgen-europe-gmbh-and-affiliates-patient-donations 2020-12-07 monthly 0.5